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Preface
Most of the work presented in this thesis was supported by a Department of 
Defense (DoD) Congressionally Directed Medical Research Program (CDMRP) award 
(GW080094) to Dr. Fiona Crawford. A small portion of this work was also supported by a 
DoD CDMRP award (GW100076) to Dr. Ghania Ait-Ghezala.
The main focus of this work was to develop and characterize mouse models of Gulf 
War Illness (GWI), a multisymptom condition associated with service in the 1990-1991 
Persian Gulf War (GW). It is estimated that GWI affects approximately 200,000 of 
700,000 U.S. veterans and 6,000 of the 50,000 UK veterans who were deployed to the 
1990-1991 Gulf War. This work provides a novel insight into the putative pathological 
mechanisms that might be associated with GWI. It is anticipated that the work described 
here will be helpful to future studies aimed at identifying potential therapies for treating 
GWI and at discovering objective biomarkers for diagnosing GWI.
3
Collaborators:
Michael Mullan, Jon M. Reed, Gogce Crynen, Alex Bishop, Benoit Mouzon, Scott 
Ferguson, John Phillips, Myles Mullan, Austin Ferro, Robert Pelot, Ariel Gonzalez, Chris 
Mullan and Venkatarajan Mathura.
Roskamp Institute 
2040 Whitfield Ave 
Sarasota, FL, 34234 
Peer-reviewed publications:
Abdullah L, Crynen G, Reed J, Bishop A, Phillips J, Ferguson S, Mouzon B, Mullan MA, 
Mathura V, Mullan M, Ait-Ghezala G, Crawford F. Proteomic CNS profile of delayed 
cognitive impairment in mice exposed to Gulf War agents. Neuromolecular Med. 2011 
Dec;13(4):275-88.
Abdullah L, Evans JE, Bishop A, Reed JM, Crynen G, Phillips J, Pelot R, Mullan MA, 
Ferro A, Mullan CJ, Mullan MJ, Ait-Ghezala G, Crawford FC (2012). Lipidomic profiling 
of phosphocholine containing brain lipids in mice with sensorimotor deficits and anxiety­
like features after exposure to Gulf War agents. Neuromolecular Medicine July 14 [epub 
ahead of print].
Scienti fic presentations:
Abdullah L, Bishop A, Phillips J, Mouzon B, Ferguson S, Ganapathi V, Mullan MA, Ait- 
Ghezala G, Mullan M and Crawford F (2010). Delayed memory impairment in a new 
mouse model of Gulf War Illness. 40th Annual Meeting of Society for Neuroscience. 
November, San Diego, California (published).
4
Abdullah L, Bishop A, Phillips J, Mouzon B, Ferguson S, Ganapathi V, Mullan MA, Ait- 
Ghezala G, Mullan M and Crawford F (2010). Mice exposed to pyridostigmine bromide 
and pesticide/insect repellent model CNS symptoms associated with Gulf War Illness. 27th 
Army Conference Proceedings. December, Orlando, Florida (published).
Abdullah L, Bishop A, Phillips J, Mouzon B, Ferguson S, Ganapathi V, Mullan MA, Ait- 
Ghezala G, Mullan M and Crawford F (2010). Delayed memory impairment in a new 
mouse model of Gulf War Illness. 40th Annual Meeting of Society for Neuroscience. 
November, San Diego, California (published).
Abdullah L, Bishop A, Phillips J, Mouzon B, Ferguson S, Ganapathi V, Mullan MA, Ait- 
Ghezala G, Mullan M and Crawford F (2011). Proteomic-based identification of a CNS 
biological profile of delayed cognitive impairment in mice exposed to gulf war agents. 41st 
Annual Meeting of Society for Neuroscience, November, Washington, D.C (published).
Abdullah L, Bishop A, Crynen G, Reed J, Phillips J, Mouzon B, Ferguson S, Mullan MA, 
Ait-Ghezala G, Mullan M and Crawford F (2011). Proteomic-based identification of a CNS 
biological profile of delayed cognitive impairment in mice exposed to gulf war agents. 
Veterans Administration Research Day. April, Tampa, Florida (published).
Abdullah L, Evans J, Reed J, Crynen G, Bishop A, Phillips J, Mouzon B, Ferguson S, 
Mullan MA, Pelot R, Moser A, Mullan C, Mathura V, Mullan M, Ait-Ghezala G, Crawford 
F (2011). Proteomic and lipidomic-based CNS profile of delayed cognitive impairment in 
mice exposed to Gulf War agents. Bioactive lipid conference meeting. September, Seattle, 
Washington (published).
Gonzalez A, Abdullah L, Bishop A, Crynen G, Reed J, Phillips J, Mouzon B, Ferguson S, 
Mullan MA, Ait-Ghezala G, Mullan M and Crawford F (2012). Proteomic-based 
identification of a CNS biological profile of delayed cognitive impairment in mice exposed 
to gulf war agents. Veterans Administration Research Day. April, Tampa, Florida 
(published).
Abdullah L, Evans JE, Reed J, Pelot R, Bishop A, Pelot R, Reed J, Evans JE, Bishop A, 
Crynen G, Mullan MA, Ferro A, Mullan C, Mullan M, Ait-Ghezala G and Crawford F 
(2012). Lipidomic profiles of motor and anxiety like features of GWI in mice exposed to 
pyridostigmine bromide, N,N-Diethyl-meta-toluamide, permethrin and stress. The 
American Society for Mass Spectrometry Meeting, Vancouver, British Columbia 
(published).
Evans JE, Abdullah L, Reed J, Pelot R, Bishop A, Pelot R, Reed J, Evans JE, Bishop A, 
Crynen G, Mullan MA, Mullan M, Crawford F (2012). Normal phase LCMS with SCID 
phospholipidomic Analysis of Plasma and Brain from a mouse model of Traumatic Brain 
Injury. The American Society for Mass Spectrometry Meeting, Vancouver, British 
Columbia (published). ^
Abdullah L, Evans JE, Gonzalez A, Bishop A, Reed JM, Crynen G, Mouzon B, Ferguson 
S, Mullan C, Pelot R, Mullan M, Ait-Ghezala G, Crawford F (2012). Distinct brain 
phospholipidomic profiles in different mouse models of neurocognitive dysfunction. 42nd 
Annual Meeting of Society for Neuroscience, New Orleans, Louisiana (published).
6
List of abbreviations
AA Arachidonic acid
ACh Acetylcholine
AChE Acetylcholinesterase
ACN Acetonitrile
ACTH Adrenocorticotropic hormone
2AG 2-arachidonylglycerol
APP Amyloid Precursor Protein
ANOVA Analysis of Variance
BACE (3-secretase APP converting enzyme
BBB Blood brain barrier
CE Collision energy
CCI Controlled cortical impact
CHI Closed head injury
CNS Central nervous systems
COX Cyclooxygenase
GFAP Glial Fibrillary Acid Protein
GH Growth hormone
DDA Data-dependent acquisition
DEET N,N-Diethyl-meta-toluamide
DHA Docosahexaenoic acid
DHP-CCB Dihydropyridine calcium channel blocker
2DGE Two dimensional gel electrophoresis
DoD Department of Defense
FDR False discovery rate
FFA Free fatty acids
GWI Gulf War Illness
H&E Hematoxylin and Eosin
ICAT Isotopic Coded Affinity Tags
IgE Immunoglobulin E
IFN-y Interferon-gamma
IPA Ingenuity Pathways Analysis
iTRAQ Isobaric Tagging for Relative and Absolute Quantification
LCFA Long chain fatty acids
LC/MS Liquid chromatography with mass spectrometry
LPC Lysophosphatidylcholine
LOX Lipooxygenase
mAChR Muscarinic AChR
MAG Monoacylglycerol
MAGL Monoacylglycerol lipase
MeOH Methanol
MLM Mixed linear model
MRI Magnetic Resonance Imaging
MS Mass spectrometry
mTBI mild TBI
MUFA Monounsaturated fatty acids
MWM Morris Water Maze
nAChR Nicotinic AChR
NH4OAc Ammonium acetate
OFT Open Field Test
OP Organopho sphate
8
PA Phosphatidic acid
PAF Platelet-activating factor
PB Pyridostigmine bromide
PC Phosphatidylcholine
PCA Principal component analysis
PE Phosphatidylethanolamine
PER Permethrin
PG Phosphatidylglycerol
PI Phosphatidylinositol
PL Phospholipids
PLA2 Phospholipase A2
PNS Peripheral nervous system
PQD Pulsed-Q Dissociation
PS Phosphatidylserine
PUFA Polyunsaturated fatty acids
PVDF Polyvinylidene fluoride
rCBF Regional cerebral blood flow
RPLC/MS Reverse phase LC /MS
RT Retention time
TBI Traumatic Brain Injury
TNF Tumor necrosis factor
SCID In-source collision induced dissociation
SFA Saturated fatty acids
SILAC Stable Isotope Labeling by Amino Acids in Cell Culture
SILAM Stable Isotope Labeling by Amino Acids in Mammals
SPECT Single Photon Emission Computed Tomography
SM Sphingomyelin
VGSC Voltage gated sodium channels
VLCFA Very long chain fatty acids
10
Abstract:
The clinical profile of GWI is characterized by the presence the central nervous 
systems (CNS) symptoms which include memory impairment, anxiety, widespread pain 
and motor problems. Now, even twenty years later, veterans with GWI continue to suffer 
from these persistent symptoms. Currently, there is no treatment available for treating 
GWI, which is largely due to the complexity of the clinical presentation of this illness and 
the heterogeneity of GW exposures. The main goals of this thesis were to develop and 
characterize GW agent exposure mouse models that recapitulate the CNS symptoms of 
GWI and to identify the underlying aberrant biological pathways. Three major objectives 
were undertaken to accomplish these goals: (1) Two mouse models of GW-agent exposure 
were developed using combination of the anti-nerve gas treatment pyridostigmine bromide 
(PB), pesticides (permethrin), an insect repellent (N,N-Diethyl-meta-toluamide) and stress. 
Neurobehavioral studies show that combined exposure to GW agents produced anxiety and 
sensorimotor deficits in one mouse model and anxiety and cognitive impairment in the 
other. Neuropathological studies showed a presence of astrogliosis in both models. (2) 
Exploratory proteomic studies suggested that lipid-metabolism and immune/inflammation 
were associated with GW-agent exposure. (3) As lipid dysfunction is upstream of the 
inflammatory pathways, a lipidomics approach was used to identify the GW-agent 
exposure dependent lipid profiles. Lipid profiles of mouse models of GW-agent exposure 
were compared with those of other neurological conditions to identify profiles that were 
unique to GW-agent exposure. Lipid profiles were interrogated to identify lipid- 
metabolism pathways that may be amenable to therapeutic targeting. Studies described in 
this thesis provide novel insight into the pathobiology of GWI and suggest that pathways 
involved in phosphatidylcholine metabolism might be of therapeutic value in treating the 
CNS symptoms of GWI.
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1.0. CHAPTER 1: Introduction to Gulf War Illness
1.1. Background
Gulf War Illness (GWI) represents a significant military health problem that affects 
approximately 25% of the 700,000 veterans from the 1990-1991 Persian Gulf War (GW). 
This illness has a complex multisymptom clinical presentation consisting of 
gastrointestinal problems, pain and neurological symptoms. While a number of other 
illnesses, such as brain cancer and amyotrophic lateral sclerosis (ALS) afflict GW veterans 
at a higher rate than veterans from other wars, GWI continues to be the most prevalent 
disorder among these veterans (Binns et al 2008). Recent longitudinal studies suggest that 
compared to non-deployed veterans, deployed GW veterans continue to report persistence 
of this multisymptom illness as well as the new onset of seemingly unrelated chronic 
diseases, such as hypertension and cardiovascular disease (Li et al 2011a). The severity of 
GWI ranges from moderate, which does not interfere with a normal daily life, to highly 
debilitating that disrupts the activities of daily living. To date, there have been only two 
major federally funded randomized clinical trials for treating symptoms of GWI which 
include fatigue, pain, distress, cognitive problems and mental health functioning. The 
doxycycline intervention trial was based on a hypothesis that symptoms of GWI were due 
to a systemic bacterial infection in these veterans. Another randomized trial using 
cognitive behavioral therapy was conducted as it had provided relief to patients with 
fibromyalgia (an illness that has some of the symptoms that overlap with GWI). However, 
neither trial significantly improved symptoms of veterans with GWI, so thus far GWI 
remains an untreatable condition (Donta et al 2003; Donta et al 2004).
Over twenty years have now elapsed since the original exposure, and therefore, 
characterizing the long-term sequelae of this illness is critical to understanding the 
pathology of GWI. To date, there has been a lack of focused and effective preclinical
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research on the CNS symptoms of GWI in well-characterized animal models, an approach 
which is likely to be extremely valuable in successfully translating therapies for treating 
GWI. The main objective of this thesis was to develop and characterize mouse models of 
GWI and to identify the underlying pathobiology of this illness. In these mouse models, 
neurobehavioral outcomes were examined and were found to be similar to symptoms 
observed in veterans with GWI. Chronic neuropathological consequences were also 
examined in the brains, and accompanying biological and molecular changes were 
identified in the brain and blood of exposed mice compared to controls. It is anticipated 
that these studies will provide novel avenues for finding therapies against GWI as well as 
for developing biomarker panels that could aid in providing an objective diagnosis of GWI.
1.2. Central Nervous System component of GWI
Evidence of a CNS component to this illness comes from brain imaging studies, 
which show a smaller hippocampal volume in deployed and reservist GW veterans 
compared to healthy civilians, and hypometabolism in the hippocampi of veterans with 
GWI compared to asymptomatic veterans who served in the GW (Menon et al 2004; 
Vythilingam et al 2005). In addition, 32% of deployed Gulf War veterans self-reported 
memory problems compared to 8% of non-Gulf War veterans (Steele 2000). This is 
supported by neuropsychological studies demonstrating cognitive impairment in deployed 
GW veterans compared to non-deployed GW military personnel or GW veterans who were 
deployed elsewhere (David et al 2002; Toomey et al 2009; White et al 2001). Furthermore, 
even decades later, deployed GW veterans continue to experience deficits in working 
memory (Toomey et al 2009). Lange and colleagues demonstrated that compared to 
healthy GW veterans, those with GWI had significant difficulty with information 
processing and the use of abstract concepts, particularly within the cognitive domains that
17
require attention and concentration (Lange et al 2001). Among the UK veterans, 
deployment to the 1990-1991 GW was associated with subjective memory failure and 
general cognitive and constructional impairment on neuropsychological testing, which 
remained significant even after adjusting for depression (David et al 2002). While 
cognitive problems remain one of the top four complaints among veterans with GWI, other 
neuropsychological problems, such as anxiety, attention deficits and impairment in motor 
speed are also experienced by these veterans (Toomey et al 2009; Gray et al 1999).
In an attempt to comprehensively evaluate the neurobehavioral symptoms of GWI, 
an initial survey of 249 members of a naval reserve construction battalion showed that 
there were six symptom clusters, and, of these, three were categorized as major syndromes 
(Kurt 1998; Haley et al 1997). All of the participants in this study were noted to have 
taken the anti-nerve gas treatment pyridostigmine bromide (PB) and therefore exposure to 
PB was considered to have been associated with all three syndromes. Pesticide application 
was correlated with Syndrome 1, which was characterized by cognitive impairment. 
Syndrome 2, consisting of confusion-ataxia, was correlated with the reports of chemical 
weapons attacks. Syndrome 3 was characterized by an arthro-myo-neuropathy component 
consisting of symptoms such as muscle pain, fatigue and numbness of hands and feet, 
which was correlated with a heavy use of the insect repellent N,N-Diethyl-meta-toluamide 
(DEET) (Kurt 1998; Haley et al 1997). These observations suggest that there are several 
distinct CNS symptom profiles of GWI, which may be associated with different 
combinations of chemical exposures. This would be consistent with the complexity of the 
clinical presentation of this illness, which remains a central challenge in dissecting the 
CNS pathophysiology of GWI and in identifying appropriate therapeutic approaches for 
treating this illness.
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1.3. Key etiological factors in GWI
In 2008, the Research Advisory Committee on GWI prepared a comprehensive 
report which concluded that there is now considerable scientific evidence that exposure to 
pesticides, insect repellents and the use of PB as a pretreatment against neurotoxins, are 
some of the main contributory factors to GWI (Binns et al 2008). Although a number of 
other factors (e.g., oil well fires, accidental release of sarin gas) have been identified as 
potential GW exposures that are also unique to this deployment, epidemiological data are 
weak and provide limited support for their role as causative factors of GWI. For instance, 
exposure to Kuwaiti oil well fires was a unique exposure for the deployed service members 
from the 1990-1991 GW but largely affected only the ground troops stationed in Kuwait. 
Therefore this exposure does not explain a presence of GWI among veterans stationed 
elsewhere, such as those in support areas on land and those onboard ships during 
deployment (Binns et al 2008). Epidemiological studies aimed at determining an 
association between risk of GWI and oil well fires have provided discrepant results, most 
showing a lack of such an association (Smith et al 2002; Cowan et al 2002; Lange et al 
2002). Similarly, there is a lack of consistent clinical data on a possible association of 
other GW exposures (e.g., an accidental release of sarin gas, depleted uranium, vaccines) 
and the risk of GWI (Binns et al 2008). These limitations preclude their further evaluation 
as potential causative factors of GWI, unless relevant indicative clinical data become 
available. On the other hand, a recent case-controlled study conducted by Steele and 
colleagues showed that a nearly 3-fold elevated risk of GWI was associated with PB 
consumption and about 13-fold increased risk with the use of pesticide treated uniforms as 
well as pesticide application to the skin (Steele et al 2012). Furthermore, there are 
considerable clinical data from other sources supporting an individual and a collective role 
of these chemicals in the manifestation of GWI. These are described in more detail below.
1.3.1 Pyridostigmine bromide exposure
Physostigmine, a pure alkaloid, isolated from Calabar beans by Jobst and Hesse in 
the 19th century, was later shown to contract pupils and was subsequently shown to have 
therapeutic properties in treating glaucoma (Pope et al 2005). A series of such compounds 
are now available and include PB, which was used as a prophylactic agent against 
organophosphate (OP) nerve agent exposures in the 1990-1991 GW to avoid cholinergic 
toxicity (Pope et al 2005). Pyridostigmine bromide is a reversible carbamate 
acetylcholinesterase (AChE) inhibitor, which binds to a serine residue on the active site of 
AChE and is considered to have an excellent safety profile in treatment of myasthenia 
gravis (patients generally given 30 mg oral dose every 8 hrs), an autoimmune disorder in 
which acetylcholine (ACh) receptors are blocked by autoantibodies (Aquilonius et al 
1983). Epidemiological studies using retrospective data collection on exposure have 
consistently reported PB to be associated with GWI (Golomb 2008). In fact, a higher risk 
of GWI and more severe illness was observed in those veterans who consumed a larger 
quantity of PB pills ( > 22 pills of 30 mg) than those taking fewer pills, which suggests the 
presence of a biological gradient (Haley 1997; Golomb 2008).
1.3.2. Pesticide exposure
With respect to pesticide exposure among GW personnel, 62% of the ground troops 
reported using pesticides, and of those, 44% reported using pesticide sprays, which 
contained permethrin (PER) or other pyrethroids. The Department of Defense (DoD) 
estimates that the US service members from the 1990-1991 GW may have been exposed to 
at least 64 different pesticides and insect repellents containing 37 active ingredients, 
including DEET and pyrethroids, such as PER (Binns et al 2008). A RAND Corporation 
survey indicated that among GW veterans, overuse of pesticides primarily involved 
pyrethroids, such as PER and d-phenothrin (Hilbome et al 2005). Veterans with high
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pesticide use were at a greater risk of GWI than those with limited use, suggesting a dose- 
response relationship (Binns et al 2008).
During the GW, military personnel were issued PER imbedded uniforms as well as
0.5% PER containing spray. Surveys conducted by the DoD report that PER was used on 
average 30 times over a period of one month despite the guidance issued by the military to 
Army personnel asking that a light-coat of PER should be applied every 4 to 5 days. This is 
a potential cause of concern since the PER manufacturer’s label indication suggested that 
uniforms should have been sprayed only once every six weeks, or after six launderings. 
Permethrin is a type I synthetic pyrethroid, which works by prolonging activation of the 
voltage gated sodium channels (VGSC). Due to its high lipophilicity, once displaced from 
the binding site, PER can transfer to the adjacent membrane lipids and then rebind to the 
VGSC (Ray, & Fry 2006).
N,N-diethyl-meta-toluamide, an amide, is used by approximately 30% of both 
adults and children in the US annually (Boomsma, & Parthasarthy 1990) and generally has 
a good safety profile in a 10-25% formulation. However, military personnel were issued 
33% and 75% formulations of DEET for topical application, much higher concentrations 
than those used in the civilian population. The primary mode of action for DEET is to 
modulate the odor-gated ion channels within the insect odor-receptor complex (Pellegrino 
et al 2011). More recently, DEET was also shown to be a weak AChE inhibitor (Corbel et 
al 2009). Overexposure to DEET can cause seizures, encephalopathies, tremors and 
hyperactivity, which are characteristic of cholinergic toxicity (Binns et al 2008). Table 1.1 
below provides a summary of pharmacokinetics and adverse effects on human health at 
high level exposure (Goodyer and Behrens 1998; Baker et al 1978; Vogel et al 2002; Qiu et 
al 1997).
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Table 1.1: Pharmacokinetics and general information on GW agents
GW agent
Mechanism of 
Action
LD50
dose Route Species
Plasma
half-life
Side effects in 
human
Pyridostigmine
bromide
AChE inhibitor 4mg/kg i.p. mice 1.5- 2hrs*
Severe allergic 
reactions, diarrhea, 
increased production 
of saliva, small pupils, 
trouble breathing, 
vision changes, 
vomiting and 
weakness.
Permethrin
Voltage gated 
sodium channel 
blocker
429mg/kg i.p. mice 24hrs*
Skin sensations, 
paraesthesia, 
numbness, itching and 
tingling,
N,N-diethyl-m-
toluamide
AChE inhibitor 2-4g/kg oral rats 3hrs*
Dermititis, 
encephalopahty, 
seizures, tremors and 
hyperactivity.
Note: ^Based on PB drug insert and pharmacokinetic studies in dogs (Baker et al 1978). *Based on 
studies by Vogel and colleagues (Vogel et al 2002. *Based on studies on dogs (Goodyer and Behrens 
1998, Qiu et al 1997).
1.4. Combined exposure to PB, PER and DEET as a causative factor in 
GWI
Epidemiological studies have shown a consistent association between GWI and 
exposure to PB and pesticides and accumulating literature suggests that the combined 
exposure is one of the key contributory factors to the pathobiology of GWI. For instance, a 
RAND survey indicated that high exposure to pesticides was associated with high PB use, 
as nearly one in four GW veterans reported using several pesticides ranging from 51 to 120 
times in a month while taking 15-19 PB pills (30 mg each) during the same timeframe 
(Hilbome et al 2005).
Government sponsored and independent surveys indicate that GW veterans were 
exposed to a unique mixture of these potentially neurotoxic chemicals which include PB 
and pesticides/insect repellent. However, very limited information is available on the short 
or long-term adverse health effects of combined exposure to these neurotoxic chemicals. 
As a consequence, laboratory animal work has been undertaken to understand the
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neurobehavioral and biological effects of combined exposure to these chemicals. Much of 
the supporting data on combined exposure comes from animal models of GW agent 
exposure which suggest mediation of adverse effects through the periphery or due to a 
possible compromise of the blood brain barrier (BBB). Work by Friedman and colleagues 
showed that at low doses PB alone (0.1-0.5mg/kg) had no effect on brain AChE activity. 
However, at higher doses (2mg/kg) or when combined with stress, PB was able to inhibit 
brain AChE activity and induce changes in expression of genes (BDNF, TrkB and 
CamKIIa) that are involved in learning and memory (Friedman et al 1996; Barbier et al 
2009). The authors suggested that, under stress or in high concentration, PB was able to 
cross the BBB (Friedman et al 1996; Barbier et al 2009). However, accompanying work 
conducted by Amourette et al, using radiolabeled PB, revealed that even under stress, PB 
was unable to enter the brain (Amourette et al 2009). Perhaps the neurotoxic effects of PB 
may be mediated by its interactions with the peripheral system, particularly those that are 
intimately linked with ACh. Despite this apparent inability of PB to cross the BBB, 
biochemical analyses continue to show an inhibition of AChE activity in the brain and 
neurobehavioral tests have shown delayed presentation of cognitive impairment in rats 
exposed to PB and stress (Barbier et al 2009; Lamproglou et al 2009; Amourette et al 
2009).
Studies have shown that combined exposure to PB, DEET, PER and stress (GW
agents) for up to 28 days of exposure can disrupt the BBB in several different brain regions
which include the cortices and the hippocampi of exposed rats compared to controls
(Abdel-Rahman et al 2002). Accompanying work from these studies also showed other
neuropathological abnormalities, which included neuronal death and an increase in
astrogliosis by nearly 50% in rats at acute post-exposure timepoints after GW agent
exposure (Abdel-Rahman et al 2004). Chaney and colleagues demonstrated that
immediately after a single combined exposure to high doses of PB and DEET, brain AChE
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activity was reduced by 40% in exposed rats compared to controls (Chaney et al 2000). 
The neurobehavioral consequences of combined exposure to these GW agents include an 
increase in anxiety and sensorimotor deficits in exposed rodents compared to controls at 
varying acute post-exposure timepoints (Abou-Donia et al 2004; Hoy et al 2000). 
Together, these studies provide a compelling argument for an adverse effect of combined 
exposure to PB, PER, DEET and/or stress on the brain’s structural, cellular and molecular 
integrity, which could be responsible for the symptoms observed in veterans with GWI. 
These studies support the current contention that combined exposure to PB and pesticides 
is one of the main causative factors in GWI pathogenesis. These studies also highlight that 
the heterogeneity of GW agents could further complicate the clinical presentation and that 
animal modeling work focused on combined exposure to GW agents is likely to produce 
neurobehavioral features that most closely recapitulate the symptoms observed in veterans 
with GWI. Development and characterization of such animal models of GW agent 
exposure will be invaluable in identifying the underlying pathobiological changes 
associated with GWI.
1.5. Biological mechanism for a role of combined PB, PER and DEET in 
GWI
Based on the mechanisms of action of these GW agents at acute post-exposure 
time-points (immediately following the exposure), the biological pathways implicated in 
GWI may involve both the peripheral and the central cholinergic systems. The literature 
review below provides biological rationale to assist with dissecting the pathobiology of 
GWI. Understanding the immediate biological effects of PB, PER, DEET and stress will 
be useful in conducting further investigation to assess the biological changes several 
months (chronic) after exposure.
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1.5.1. Cholinergic receptor system and GW agents
The studies described in this section provide supporting data for a potential 
dysfunction of the cholinergic system in GWI, particularly as the chemicals utilized in 
these studies most likely modulate synaptic ACh levels. Synthesis of ACh occurs in 
cholinergic neurons by choline acetyltransferase using choline and acetyl coenzyme A as 
substrates. It is then packaged into synaptic vesicles (Pope et al 2005) and upon terminal 
depolarization, ACh is transported out of the neurons by the vesicular ACh transporter into 
the synaptic cleft where it binds to cholinergic receptors and activates a number of 
intracellular signaling pathways. Under normal conditions, ACh is rapidly hydrolyzed by 
AChE. However, use of synthetic AChE inhibitors leads to prolonged accumulation of 
ACh at the synapse and causes an abnormal alteration of the cholinergic receptor-mediated 
signaling pathways. Studies on combined exposure to a pyrethroid and a carbamate AChE 
inhibitor have shown to result in a synergistic increase in membrane depolarization 
accompanied by an increase in ACh release into synapse (Corbel et al 2006). Studies also 
suggest that excessive synaptic ACh can self-regulate by binding to presynaptic muscarinic 
AChR (mAChR), promoting negative feedback that inhibits its further release (Zhang et al 
2002). It is therefore plausible to suggest that combined exposure to PB, a carbamate 
AChE inhibitor, and PER, a pyrethroid, may synergistically enhance synaptic ACh levels 
in the short-term but may result in depletion of synaptic ACh via negative feedback in the 
long-term (see Figure 1.1).
Additional support for modulation of AChR properties as a consequence of GW 
agent exposure comes from studies using animal models. For instance, enhanced ligand 
binding of the muscarinic 2 (M2) AChR subtype in the cortex was observed in a rat model 
of GWI treated with either PB alone or in combination with PER and DEET (Abou-Donia 
et al 2004). Combined exposure to these GW agents also increased the ligand binding of
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Figure 1.1. Hypothesized synergistic effect of PB and PER on neuronal ACh release:
This image, readapted from the original article (Corbel et al 2006), shows that exposure to 
PB increases synaptic ACh levels (step 1). Binding of PER to VGSC further increases the 
release of ACh (step 1) within the synaptic cleft (+ sign denotes increase ACh release/ 
accumulation). The excess of non-hydrolyzed ACh in the synaptic cleft may activate 
presynaptic mAChR (step 2) involved in the negative feedback mechanism (- sign denotes 
blocking further ACh release).
nicotinic AChR (nAChR) in the cortex of rodents. However, combined exposure to these 
chemicals and stress resulted in a decrease in mAChR ligand binding in the midbrain and 
the cerebellum, although cortical mAChR binding was not examined (Abdel-Rahman et al 
2004). A long-term consequence of such an enhanced cholinergic transmission may 
include a compensatory increase in AChE production which is suggested by studies 
performed by Bansal and colleagues showing that after 30 days of AChE inhibitor 
exposure, there is an increase in AChE mRNA levels in the cortex (Bansal et al 2009).
In addition to the animal studies described above, a number of human studies also 
provide support for a dysfunctional cholinergic system in veterans with GWI. For 
instance, recent imaging studies have shown an abnormal cholinergic response in veterans
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with GWI compared to controls (Liu et al 2011). Using atrial spin labeling Magnetic 
Resonance Imaging (MRI), Li and colleagues recently demonstrated that upon cholinergic 
challenge (intravenous infusion with 0.3 mg of physostigmine prior to imaging) veterans 
with GWI exhibit an abnormal increase of regional cerebral blood flow (rCBF) in the 
hippocampus compared to control veterans (Li et al 2011b). This work is supported by an 
earlier study which used Single Photon Emission Computed Tomography (SPECT) to 
show a similar increase in CBF in response to the cholinergic challenge with 
physostigmine among veterans with GWI (Haley et al 2009). Although based on a small 
sample size, these studies do suggest a dysfunctional cholinergic response in veterans with 
GWI.
1.5.2. Cholinergic system and immune/inflammatory changes in relation to GW 
agents
In addition to the symptoms described above, the clinical profile associated with 
GWI also includes gastrointestinal problems, heart rate variability and an increased 
occurrence of gall bladder disease (Binns et al 2008). These peripheral symptoms, coupled 
with the CNS symptoms described above, suggest insults to both the CNS and the 
peripheral nervous system (PNS), possibly mediated through the periphery (Binns et al 
2008).
Recently, it was shown that afferent fibers of the vagus nerve provide information 
to the brain regarding the peripheral inflammatory changes (Tracey 2007). Impaired 
peripheral immune and inflammatory responses are prominent features of GWI. Studies 
report a persistent immune imbalance that is accompanied by an increased expression of 
pro-inflammatory (Interferon-gamma [IFN-y]) and anti-inflammatory (Interleukin-5 
[IL-5]) cytokines in CD4 T-cells from veterans with GWI compared to healthy GW 
veterans (Skowera et al 2004; Broderick et al 2011).
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Studies show that PB and PER can modulate several aspects of both cell-mediated 
and humoral immunity. For instance, Peden-Adams and colleagues (2004) demonstrated 
that exposure to PB results in a decreased IgM response to a T-cell dependent antigen, 
which suggests suppression of the humoral immune response. In this study, exposure to 
PB resulted in a decrease in both CD4+/CD8+ and CD4-/CD8- cell types (Peden-Adams et 
al 2004). Studies report that PER can activate the systemic immune responses, which 
include inhibition of lymphocyte responses and T-cell proliferation (Prater et al 2005; 
Punareewattana et al 2000). An animal study showed elevation of IL-ip, IFN-y and IL-10 
in PER exposed rats compared to control rats (Vadhana et al 2011). Collectively, these 
studies support a prominent peripheral immune and inflammatory component to GWI.
The cross-talk between the brain and the immune system is through the “cholinergic 
anti-inflammatory pathway”, which is composed of the afferent and efferent vagus nerve 
connections, ACh, the a7 nAChR on macrophages in the periphery and the muscarinic 
receptor subtype 1/subtype 2 (M1/M2) within the CNS. See Figure 1.2 for additional 
explanation of the cholinergic anti-inflammatory pathway.
Once inflammation is detected in the periphery, information is relayed to the brain 
through afferent pathways, which consequently leads to stimulation of Ml receptors and a 
further release of ACh into the periphery via efferent fibers of the vagus nerve. In the 
periphery, ACh binds to the a l  nAChR on macrophages resulting in activation of cellular 
cascades that inhibit production of tumor necrosis factor (TNF) and other pro- 
inflammatory cytokines. Loss of the a l  nAChR on macrophages has been shown to result 
in increased TNF levels, despite a presence of preserved vagal nerve function. This 
suggests that the a l nAChR are a key component of the cholinergic anti-inflammatory 
pathway (Tracey 2007). As such, a possible explanation of the observed peripheral 
immune/inflammatory dysfunction in veterans with GWI could include a disruption of the 
cholinergic anti-inflammatory pathway.
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Figure 1.2. ACh anti-inflammatory pathway: Permission to reuse this published image 
was obtained from Dr. Tracey (Tracey 2007). This image shows that peripheral tissue 
injury results in cytokine production. However, an imbalance in the cytokine response 
further exacerbates the injury. Under this abnormal situation, afferent neuronal connections 
in the vagus nerve send a signal to the brain (involving Ml ACh receptors), which then 
activates an efferent response to inhibit cytokine release. Efferent signals from the vagus 
nerve are controlled by brain networks which inhibit cytokine production via ACh 
pathways that involve the a7 subunit of the AChR on macrophages and other immune cells.
1.5.3. Relevance of lipid metabolism and lipid-mediated pathways to GWI
Although lipid dysfunction has not been examined in veterans with GWI, studies do 
provide support that exposure to GW agents, such as PER, could affect membrane lipids. 
For instance, exposure to PER in rats was associated with a decrease in cellular cholesterol 
and a decrease in membrane fluidity (Vadhana et al 2011). Phospholipids (PLs), 
particularly those that contain choline, can be metabolized to replenish ACh (Amenta, & 
Tayebati 2008). Furthermore, PLs and their metabolites are upstream of the inflammatory 
cascades and contribute to immune and inflammatory balance within the CNS and the 
periphery. For example, docosahexaenoic acid (DHA) and arachidonic acid (AA) are the 
most abundant ©-3 and ©-6 polyunsaturated fatty acids (PUFA), respectively, in the brain. 
Arachidonic acid is a precursor of pro-inflammatory lipid mediators, such as
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prostaglandins and leukotrienes and DHA is a precursor of the anti-inflammatory 
mediators, neuroprotectins and resolvins (Serhan et al 2008; Fredman, & Serhan 2011). A 
number of other lipid metabolites, such as lysophosphatidylcholine (LPC) and platelet- 
activating factor (PAF) also have important roles in regulating immune/inflammatory 
changes (Hasegawa et al 2011). These studies suggest that examination of PL and their 
metabolites may be useful in providing novel insight into the pathobiology of GWI.
1.6. Hypothesis
Long-term outcomes of GW agent exposure may include chronic ACh depletion, and 
consequently activation of the biological pathways which break down PLs in cell 
membranes to replenish synaptic ACh to normal levels (Amenta, & Tayebati 2008). 
Acetylcholine receptors can modulate cascades of lipid-mediated intracellular biological 
events that are implicated in a number of neurocognitive disorders (Isacson et al 2002; 
Gallegos et al 2008). As described above, ligand binding of both mAChR and nAChR is 
increased in several different brain regions of rodents exposed to GW agents. It can then 
be assumed that combined exposure to GW agents may produce cumulative adverse effects 
on the cholinergic signaling pathways given their ability to affect the ACh turnover and 
ACh receptor activation that are described above. Hence, the central hypothesis of this 
thesis is that exposure to GW agents disrupt biological pathways that are downstream of 
ACh receptors which include inflammation related lipid metabolism pathways.
1.7. Objectives of this thesis
1. The first objective was to develop mouse models that recapitulate CNS symptoms of 
GWI. Neurobehavioral studies were conducted to characterize changes at a range of 
timepoints (both acute and chronic). Neuropathological studies were conducted at 
chronic post-exposure timepoints.
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2. Exploratory studies using targeted protein and proteomics analyses were conducted 
at chronic post-exposure timepoints to identify biomolecular pathways using brain 
and plasma samples from the two mouse models of GW agent exposure.
3. As proteomic findings suggested an involvement of lipid metabolism related 
pathways, lipidomic profiling was performed on brain and plasma samples from 
these mouse models of GW agent exposure.
4. Lipidomic profiles of GWI mouse models were compared with mouse models of 
other neurological illnesses in order to identify lipid profiles that were unique to GW 
agent exposure in mice.
5. Lipidomic profiles were interrogated to identify potential biological pathways which 
may be implicated GWI.
1.8. A summary of the upcoming Chapters
The chapters below provide a detailed account of the development of two mouse 
models of GW agent exposure and characterization of the neurobehavioral and 
neuropathological consequences of GW agent exposure over time (Objective 1). This is 
followed by a summary of exploratory studies that are aimed at identifying the biological 
pathways perturbed in response to GW agent exposure (Objective 2). The fourth chapter 
will highlight lipidomic studies performed using plasma and brain samples from GWI 
mouse models as well as other mouse models of neurodegenerative illnesses (Objectives 3 
and 4) in order to determine lipidomic changes that are specific to GW agent exposure in 
these mouse models (Objective 5).
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2.0. Chapter 2: Development of mouse models that recapitulate CNS 
symptoms of GWI
This chapter details the neurobehavioral and neuropathological work performed for 
the development of mouse models of GW agent exposure. Mouse model A was based on 
previously published work by Abdel-Rahman and colleagues, which at the time of 
development of this model was the only combined GW agent exposure that included PB in 
combination with pesticide/insect repellent. The main goal was to translate this GW agent 
exposure paradigm from rats to mice. Mouse model B was subsequently developed using 
high doses of PB and PER and the main goal was to examine if there is an adverse 
cognitive outcome associated with this exposure.
2.1. GW agent exposure model consisting o f  PB, PER, DEET and stress - 
model A
2.1.1. Introduction
To date, the most well-characterized GW agent exposure paradigm consists of 
combined exposure to PB, PER, and DEET with or without stress in rats and was 
previously employed by Abou-Donia et al (Abou-Donia et al 2001) and Abdel-Rahman and 
colleagues (Abdel-Rahman et al 2004). GW agent exposure consisting of PB, PER, and 
DEET was shown to produce sensorimotor deficits in exposed rats compared to controls 
(Abou-Donia et al 2001). An increased anxiety in rats exposed to PER and DEET 
compared to unexposed rats has been previously reported (Hoy et al 2000). However, 
effects of combined exposure to PB, PER, DEET and stress on anxiety-related outcomes 
have not been examined. Furthermore, there are no published reports suggesting that 
exposure to this particular GW agent combination results in cognitive impairment. In rats 
exposed to this particular GW agent combination, Abdel-Rahman and colleagues
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characterized neuronal loss using Hematoxylin and Eosin (H&E) staining. However, there 
have been some concerns over whether neuronal death characterized as a presence of dark 
neurons (basophilic and having a dark blue color of the perikaryal and dendritic cytoplasm 
detected using H&E staining) in studies by Abdel-Rahman and colleagues may have been 
an histopathological artifact (Jortner 2006). Jortner suggested that these findings are 
possibly a consequence of inadequate brain perfusion-fixation during tissue extraction 
(Jortner 2006). Other neuropathological findings included an observed increase of 
astrogliosis using Glial Fibrillary Acid Protein (GFAP) in exposed rats compared to 
controls but microglia activation was not evaluated (Abdel-Rahman et al 2004). Generally, 
microglia activation is considered to precede neuronal loss, and thus it might be an 
important marker of the CNS immune/inflammation status. Despite some limitations of 
this GW agent exposure paradigm, an extensive neuropathological characterization and 
some neurobehavioral studies presented by the original investigators provided a good 
starting point for development of a mouse model of GW agent exposure. Therefore, PB, 
PER, DEET and stress were utilized to develop mouse model A, which would help address 
the limitations described above and fill current gaps in knowledge regarding the cognitive 
consequences with this particular combination of GW agent exposures.
2.1.2. Materials and methods
2.1.2.1 Chemicals
Pyridostigmine bromide was purchased from Fisher Scientific (USA), PER (an 
analytical standard containing a mixture of 26.4% cis and 71.7% trans isomers) and DEET 
(97% purity) were both purchased from Sigma Aldrich (USA). In the absence of 
information on the cis/trans ratio of PER used in the 1990-1991 Gulf War, the above ratio 
was chosen since it was similar to that recommended by the World Health Organization 
(25% cis and 75% trans).
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2.1.2.2 Animals
Animal experiments described here were approved by the Roskamp Institute’s 
Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with 
the Office of Laboratory Animal Welfare and the Association for the Assessment and 
Accreditation of Laboratory Animal Care guidelines. Each mouse was individually caged 
in a controlled environment (regulated 14 hr day/10 hr night cycle) and maintained on a 
standard diet. Mice were randomized to either the exposure or the control group using an 
Excel-based random number generator.
This exposure paradigm was administered as previously utilized by Abdel-Rahman 
and colleagues in rats (Abdel-Rahman et al 2004). Twenty C57BL6 mice (age 15-17 
weeks, and mean weight 23.5 g ± 3.01 SD) were randomized within each gender to either 
the exposure or the control group using an Excel-based random number generator (n = 10; 
6F, 4M in exposed and n = 10, 6F, 4M in control). The exposure consisted of 1.3mg/kg PB 
orally in water, 0.13mg/kg PER and 40mg/kg DEET in 50pl of 70% ethanol, both as 
dermal applications on an approximately 2 cm2 pre-clipped area (at the back of the neck), 
and 5 minutes (min) of restraint stress in a plexiglass rodent restrainer. The authors had 
suggested that these doses represented the low level chronic exposure to which GW 
veterans were exposed (Abdel-Rahman et al 2004) (Abou-Donia et al 2001). The exposure 
was administered daily over a period of 28 days. The control group was given water and 
topical application of 70% ethanol throughout the same time-period.
2.1.2.3. Neurobehavioral testing
All behavior testing was performed during the light phase of the circadian cycle 
with operators blinded to the exposure assignment. The rotarod, open field test (OFT) and 
Morris water maze (MWM) tests were performed as briefly described below (see Figure 
2.1 for a timeline of behavior experiments).
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Figure 2.1
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Figure 2.1. Timeline of neurobehavioral experiments for mouse model A of GW agent 
exposure. Only the open field test was performed during the exposure period. All other 
tests were performed on post-exposure days.
2.1.2.3.1. The open field test
The OFT was conducted using a im  diameter arena on the last day of the exposure 
and a single trial lasting 15 min was conducted for each mouse. The test was conducted in 
a brightly lit room. The total distance traveled by each mouse within the arena was 
recorded to determine motor function and the amount of time spent in the periphery 
(perimeter activity) was used to quantify anxiety-related behavior. This measure has 
consistently been shown to reflect the anxiolytic state in animals (Blanchard et al 2001; 
Stanford 2007). The Ethovision tracking software (Noldus) was used for recording these 
experiments.
2.1.2.3.2. Rotarod
Baseline performance for each mouse was determined prior to the exposure period. 
Mice were allowed to acclimate to the experimental paradigm using 1 trial at 5 rpm fixed 
speed over 5 min. The baseline was established using 3 trials of 5 min each, conducted 
daily for 3 consecutive days (prior to initiating the exposure paradigm), during which the 
speed was accelerated from 5 to 60 rpm within each trial (with a 3 minute inter-trial 
interval). The average value for latency to fall on all 3 trials of the last day was used as
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baseline. Main testing occurred every other day from post-exposure days 1 to 7 using the 
same speed as above. The latency to fall on each day was averaged from three consecutive 
trials and the percent change from baseline was calculated to determine the exposure 
effect.
2.1.2.33. Morris Water Maze
The MWM test was conducted using a 2.5m2 diameter pool filled with cloudy 
water (addition of white non-toxic powdered paint), situated in a room with visual cues on 
the wall and on the pool edge above the water level. The acquisition trials were conducted 
on post-exposure days 20-28. Four acquisition trials were administered daily with an inter­
trial interval of approximately 30 min. For the acquisition trials, a platform was placed 1.5 
cm below the water surface in the North East (NE) quadrant of the pool. Mice that failed 
to find the hidden platform within 90 seconds (sec) were guided to the platform and 
required to remain there for 30 sec before being returned to the cage. A probe trial was 
conducted 24 hrs after the acquisition trial on post-exposure day 28, for which the platform 
was removed. During this trial, the latency to reach the location where the target platform 
was previously located and the time spent in the original target quadrant were recorded 
using the Ethovision software.
2.1.2.3. Statistical analyses for the neurobehavioral studies
Post-hoc power calculations were performed using the G-power software (Faul, & 
Erdfelder 2007) and a power of 80% was detected for the rotarod test, 65% for the OFT 
and 31% for the MWM (based on the differences for the probe trial) at alpha 0.05 for the 
sample size using the described statistical analyses. A mixed linear model (MLM) 
regression was employed to examine the independent effects of exposure, time and any 
potential interactions between them, on the neurobehavioral outcomes. The MLM-based 
regression analysis approach is generally considered superior to other ANOVA methods
36
due to its flexibility to accommodate both fixed and random effects of the independent 
variables (Katz 2011). For OFT, distance travelled and perimeter activity within the arena 
were used as the outcome measures where exposure and time (three 5 min-intervals over 
15 min) were used as fixed factors with each mouse as a random factor. For the rotarod 
test, latency to fall (sec) was examined as an outcome variable, each mouse as a random 
factor, and exposure and time (days) as fixed factors. Similarly, for the MWM, escape 
latency (sec) and amount of time spent in the target quadrant were considered outcome 
measures while time (days) and exposure were considered fixed factors and mouse as a 
random factor. All analyses were performed with SPSS 13.0 (IBM Corp. Armonk, NY) 
and the statistical significance was set at an alpha 0.05 level.
2.1.2.4. Histopathological analyses
Animals (n = 5 [3F, 2M] per exposure/control) were euthanized on post-exposure 
day 42 for the neuropathological study. All animals were transcardially perfused with PBS 
followed by an overnight fixation of brain samples in 4% paraformaldehyde and paraffin 
embedding. Six pm thick coronal sections were rehydrated in a gradient of ethanol before 
the immunohistochemical procedure. Nissl substance was stained with 0.25% Cresyl 
Violet to assess neuronal loss, described elsewhere (Bondolfi et al 2002). Antibodies for 
GFAP (1:10,000, Dako, Carpinteria, CA) and CD45 (1:50 Serotec, Raleigh, NC) were used 
to stain astrocytes and microglia, respectively. All primary antibodies were localized using 
Vectastain ABC kits (Vector Laboratories, Burlingame, CA). Both microscopy and 
quantification were performed with the operator blinded to the exposure assignment. 
Three stained sections from each mouse brain were visualized with an Olympus (BX60) 
light microscope and 2D images were acquired using an Olympus MagnaFire SP camera 
and analyzed using Image-Pro Plus software (Bethesda, MD). The dentate gyrus of the 
hippocampus and the cerebral cortex were examined. Within the cerebral cortex, 3
different locations were used for quantification and the same locations were examined
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from each mouse. For statistical analyses, the total area occupied by the stained material 
(consisting of both processes and cell bodies that were present in the field of view) was 
analyzed and compared using the Student’s t-test.
2.1.3. Results
2.1.3.1. Neurobehavioral testing
Mice were tested for anxiety and related behavior using the OFT. The time spent at 
the perimeter and the overall distance traveled within the arena were used as the outcome 
measures (Figure 2.2). For the time spent at the perimeter, there was a significant main 
effect of exposure (F(i, 50) = 4.15, p = 0.047) and a confounding effect of gender (F(i, so) =
13.22, p = 0.001). Figure 2.2A shows that female exposed mice spent more time at the
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Figure 2.2. The open field test: Mean ± SEM, n = 10 in each of the exposed and control 
groups. (A) An increase in perimeter activity was noted in exposed mice compared to 
controls on the OFT conducted on last exposure day (day 28) and a significant 
confounding effect of gender was also observed, p < 0.05 (based on MLM regression, a 
main effect was observed irrespective of time, which was also a fixed main factor in the 
regression model). Exposed female mice spent more time (s) at the perimeter than control 
female mice. Male exposed mice spent more time at the perimeter than control male mice, 
but only during the first 10 minutes. Female mice spent more time at the perimeter than 
male mice. (B) There was no main effect of exposure, p > 0.05 nor an interaction between 
time and exposure, p > 0.05. An interaction was observed between exposure and gender 
on the locomotor activity in the arena, p <0.05, (based on MLM regression as described in 
A above) indicated by a larger distance (cm) traveled by male exposed mice than control 
male mice. Female exposed mice traveled less distance within the arena than control 
female mice. Note: A version of this figure is published (Abdullah et al 2012).
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Figure 2.3. The rotarod test: Mean ± SEM, n = 10 in each of the exposed and the 
control group. Exposed animals had a shorter latency to fall compared to controls,
* denotes p < 0.05 for a main exposure effect (based on MLM regression where days and 
exposure were fixed main independent factors). This test was conducted on every 
alternate day during post-exposure days 1 to 7. Note: A version of this figure is published 
(Abdullah et al 2012).
perimeter than female control mice. Similarly, exposed male mice spent more time at the 
perimeter than control male mice. Overall, female mice spent more time at the perimeter 
than male mice. For the distance travelled, there was no main effect of exposure (F(i, 47) = 
1.092, p = 0.17), but an interaction between exposure and gender (F(i,44) = 7.42, p < 0.01) 
as well as a confounding effect of time (Fp, 39) = 30.57, p = < 0.01) was observed on this
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outcome. Figure 2.2B shows that compared to female control mice, exposed female mice 
travelled less distance over the three timepoints. Conversely, male exposed mice traveled 
more distance within the arena than control male mice.
Differences in sensorimotor coordination between exposed and control animals 
were assessed based on their ability to stay on an accelerating rotating rod. A shorter mean 
latency to fall was observed in the exposure group than the control group (F(i, 70) = 8.20, p 
= 0.006). Figure 2.3 shows that compared to their baseline values, exposed animals had 
approximately 13% lower latency to fall on day 1, 15% on day 3, 10% on day 5 and 11% 
on day 7, while control mice performed within 8% of their baseline performance, 
indicating a significant motor impairment in the exposed animals. There was a marginal 
confounding effect of gender (F(i, 70) = 3.17, p = 0.08) on this sensorimotor performance 
measure.
During post-exposure days 20-28, mice were evaluated on the spatial memory task 
using MWM. Throughout the acquisition trials (days 20-28), there was an effect of 
training days on the escape latencies (F(8,30) = 2.63, p = 0.03), but there was no difference 
between exposed and control mice on this outcome (F(8,150) = 0.48, p = 0.49, Figure 2.4a). 
There was a main exposure effect on the distance travelled (F(i, 151) = 10.88, p < 0.01, 
Figure 2.4B), and a confounding effect of both gender (F(i,-i5i) = 6.99, p < 0.01) and of 
training days (F(i, 147) = 5.10, p < 0.01) on the relationship between GW exposure and this 
outcome. There was also a significant exposure effect on the swim speed (F(i, 145) = 4.18, p 
= 0.04, Figure 2.4C) and a confounding effect of gender on this relationship (F(i, 145) = 
4.75, p = 0.03, figure 2.4D). On the final day 28, a single probe-test was conducted 24 
hours post-acquisition to evaluate long-term memory. Both the control and exposed groups 
displayed similar average escape latency (t-test(is) = 0.94, p = 0.36, figure 2.4D) and 
duration of time spent in the quadrant which previously contained the platform (t-test (is) = 
- 0.23, p = 0.82, figure 2.4E).
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Figure 2.4. The Morris water maze test: Mean ± SEM, n = 10 in each of the exposed and 
the control group. (A) There were no differences between the two groups on escape latency 
during the acquisition trials (post-exposure days 20-28), p > 0.05. (B) Significant differences 
on total distance travelled in the maze were observed between the two groups and a 
confounding effect of gender was noted, p < 0.05 (based on MLM regression where training 
days, gender and exposure were all fixed main independent factors). Within each gender, 
exposed mice performed worse than control mice. (C) For the swim velocity, there was a 
significant difference between the two groups and a main exposure effect was observed,
*p < 0.05 denotes a main exposure effect (based on MLM regression as described for B 
above). (D) Figure depicting a confounding effect of gender on the relationship between 
exposure and swim velocity, p < 0.05 (based on MLM regression as described above). 
Female exposed had lower swim velocity that control female mice. Male exposed mice also 
had lower swim velocity than male control mice but only on last two days of the acquisition 
trials. (E-F) During the probe trials conducted on day 28, there were no differences between 
the two groups on either the (E) latency to escape or the (F) duration of time in the target 
quadrant, p > 0.05 (based on the Student’s t-test) . Note: A version o f this figure is published 
(Abdullah et al 2012).
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Figure 2.5. GFAP staining: Mean ± SEM, n = 5 in each of the exposed and the control 
group. (A) Representative images of cerebral cortices after GFAP staining from mice exposed 
to GW agent and control mice, taken with a 20x objective providing a 200x magnification. 
The insert is an image of exposed mice taken with a 60x objective showing 600 x 
magnification. Arrows point to reactive astrocytes in the cerebral cortex of exposed mice. 
Note: A version o f this figure is published (Abdullah et al 2012). (B) Quantification depicting 
a nearly four-fold increase in GFAP reactivity in response to exposure. This increase was 
statistically significant based on the Student’s t-test, *p < 0.001.
Nissl staining 
Figure 2.6
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Figure 2.6 Nissl staining Mean ± SEM, n = 5 in each of the exposed and the control group. 
Representative images of Dentate Gyrus after Nissl staining from mice exposed to GW 
agent and control mice, taken with a 20x objective providing a 200x magnification. Visual 
inspection did not reveal any differences between the two groups. The scale bar represents 
50pm in each image.
2.1.3.2 Histopathological analyses
Astrogliosis was quantified using GFAP staining which showed a robust presence
of reactive astrocytes in the cerebral cortex of exposed animals as compared to controls (t-
test = -6.43 (df = 8), p < 0.01, Figure 2.5a and 2.5b). No differences were observed in the
hippocampus between the two groups. The results from Nissl staining do not show any
differential neuronal loss between the two groups in either the cortex or the hippocampus
(Figure 2.6). Microgliosis was measured using CD45 staining but no staining was detected
in neither controls nor exposed mice (data not shown).
2.1.4. Discussion
These studies indicate that the sensorimotor deficits and astrogliosis observed in 
rats exposed to PB, PER, and DEET with or without stress were also present in mice
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exposed to PB, PER, DEET and stress. In addition, these studies also provide novel data 
with respect to the evidence of anxiety-related behavior in mice administered this 
particular GW agent combination as compared to controls. The OFT has been in use for 
several decades to assess motor function, exploration and anxiety over a short-time period 
(Blanchard et al 2001; Aguilar et al 2002). Using this apparatus, anxiety-like features were 
observed in mice exposed to PB, PER, DEET and stress, as indicated by an increase in 
time spent at the periphery of the OFT arena. Several studies using rodents show altered 
OFT behavior in response to PB and PER, or to PER and DEET (Abdullah et al 2011; Hoy 
et al 1999).
Interestingly, gender differences were observed in this anxiety measure within the 
OFT arena, where female mice generally appeared more anxious than male mice. Cross- 
sectional analyses using a sample from UK Armed Forces showed much higher rates of 
psychological distress and chronic fatigue in women deployed to the 1990-1991 GW than 
men (Rona et al 2007). These studies support a potential influence of GW agents in 
producing the anxiety symptoms which may be different between male and female 
veterans with GWI and warrant further investigation.
Previous studies conducted by Abou-Donia and colleagues showed a presence of 
sensorimotor impairment in rats exposed to PB, PER and DEET (Abou-Donia et al 2001). 
Sensorimotor deficits were observed in mice exposed to PB, PER, DEET and stress 
compared to control mice in mouse model A. To date, there are only two reports showing 
cognitive impairment in animals exposed to combinations of PB and PER or PB and stress, 
in particular both showing a presence of delayed learning and/or cognitive impairment 
(Abdullah et al 2011; Lamproglou et al 2009). However, the GW exposure paradigm 
utilized in the current study produced considerable sensorimotor impairment, evident in the 
rotarod studies and MWM swim velocity. This confounded the cognitive testing
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performed using the MWM. A recent study by Patil and colleagues demonstrated that the 
mouse strain of C57BL6 utilized in the current study is prone to anxiety which affects 
performance on the MWM (Patil et al 2009). Perhaps an alternative cognitive testing 
method, such as novel object recognition test, which is less physically demanding for the 
animals, might be ideal under these circumstances.
Having demonstrated neurobehavioral outcomes, the next goal was to determine if 
some of the pathological features examined in the original rat model are also present in this 
mouse model. The observed presence of an increase in reactive astroglia is consistent with 
findings from Abdel-Rahman and colleagues (Abdel-Rahman et al 2004). A particular 
characteristic of reactive astrogliosis is an increase in GFAP (a member of the intermediate 
filament family), as observed here, which is thought to be an early marker of CNS injury 
(Zhang et al 2010). The literature suggests that microglial activation precedes astrogliosis 
and microglia can revert to its resting state if homeostasis is restored (Lue et al 2010). 
However, there was no presence of reactive microglia in neither exposed nor control mice. 
Given that a long time had elapsed between exposure and neuropathological examination 
(42 days), it is possible that reactive microglia were present at an earlier timepoint. It is 
also suggested by a recent astroglial imaging study that astrocytosis may be an early event 
in a neurodegenerative condition, which could explain why neuronal loss was not observed 
at this stage (Carter et al 2012).
In summary, translation of this GW agent combination from rats produced 
previously reported sensorimotor deficits and astrogliosis (Abdel-Rahman et al 2004; 
Abou-Donia et al 2001). However, cognitive impairment was not detected in model A due 
to the confounding effects of sensorimotor deficits, which is reported to be one of the top 
four complaints among veterans with GWI. Therefore, additional work (i.e. examination 
of a different exposure paradigm) was required to determine if a different combination of
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GW agents may produce cognitive impairment in a mouse model. The next section will 
describe work that was particularly focused on characterizing cognition after combined 
exposure to another GW agent combination.
2.2. GW agent exposure model consisting o f high dose PB and PER - 
model B
2.2.1. Introduction
At the time this work was undertaken, only one rat model of GW-agent exposure 
(stress and PB) had conclusively demonstrated significant memory impairment 
(Lamproglou et al 2009) while most other rat models had only reported sensorimotor 
deficits in response to PB, DEET and PER alone or in combination with each other (Abou- 
Donia et al 2001). In model A above, the presence of motor impairment confounded the 
MWM experiments and, as a consequence, cognitive data were uninterpretable. As one of 
the main goals of this thesis was to develop mouse models of GW-agent-induced 
phenotypes, particularly one that includes cognitive dysfunction, a combination of high 
dose PB and PER was administered and post-exposure neurobehavioral characterization 
was performed over an extended time period in order to maximize the likelihood of 
obtaining a cognitive outcome. The combined exposure of PB and PER was chosen based 
on earlier genomic work conducted at the Roskamp Institute, which showed a greater 
disruption of neuronal gene expression with PER exposure than with DEET (Kayihan et al 
2010). In addition, a recent case-control study conducted by Steele and colleagues 
demonstrated much higher risk of GWI among veterans who were exposed to PB and wore 
pesticide imbedded uniforms, which largely contained PER (Steele et al 2012).
For these studies, high doses of PB and PER were chosen in an attempt to mimic a 
high-level exposure likely to be experienced by GW veterans. For instance, daily
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consumption of 120 mg of PB (equivalent to 4 PB pills containing 30 mg each) for an 
average weight of 75kg per individual would approximate 1.6 mg/kg; 2 mg/kg PB 
exposure is shown to inhibit AChE and activate pathways involved in the formation of 
long-term memory (Friedman et al 1996). Permethrin was provided to the enlisted 
personnel as a 0.5% spray and according to the RAND survey, the PER spray use may 
have been as high as 360 times per month (Binns et al 2008). This PER usage far exceeded 
that stated on the PER label, which recommended that uniforms should have been sprayed 
only once every six weeks or after six launderings (Binns et al 2008). Given the paucity of 
information on doses and routes (e.g., inhaled, skin absorption) of PER delivery, there is no 
accurate way of estimating the exact dose of PER exposure to GW veterans. Thus, 200 
mg/kg of PER was administered to mimic a high-level exposure. Although maximum 
permitted intake in human is 3.75 mg for a 75 kg person, the dose of 200 mg/kg was 
chosen since it was used in mice by previous studies showing adverse behavioral or 
pathological outcomes (Dodd, & Klein 2009; Pittman et al 2003; permethrin information 
sheet). The doses for PB and PER used in this study are approximately half of the LD50 
dose in rodents for each chemical (4mg/kg for PB and 429mg/kg for PER via i.p. in mice, 
see Table 1.1 for more details), respectively (Chaney et al 2002). These studies will 
characterize some of the key neurobehavioral and neuropathological features associated 
with GWI and provide a mouse model of GW-agent exposure for further biochemical 
studies aimed at identifying biological pathways involved in GWI.
2.2.2. Materials and Methods
2.2.2.1. Chemicals
Reagents were obtained through Fisher scientific and Sigma Aldrich as described
above.
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2.2.22. Animals
Study animals were housed, maintained on standard diet and randomized using 
IACUC approved procedures described above. Pilot studies were performed to determine 
the upper limits of doses, survival and the maximum tolerated dose for PB and PER using 
apolipoprotein E (APOE) knockout mice which were available in our vivarium at that time. 
Death was observed at 4 mg/kg (as previously reported (Grauer et al 2001) for PB and 300 
mg/kg of PER also suggested lethality. Therefore, doses of PB and PER were further 
reduced to 2 mg/kg PB and 200 mg/kg PER for the following study with CD1 mice, an 
out-bred strain derived from in-bred swiss albino mice. Thirty-two CD1 mice (male, age 
10 weeks, weight 40.76 g ± 2.38 SD) were purchased (Harlan Animal Research 
Laboratories, FL) and allowed to acclimate for one week to the new environment at the 
Roskamp Institute in accordance with the American Association for Laboratory Animal 
Science guidelines. Mice were co-administered 2 mg/kg PB and 200mg/kg of PER in a 
single i.p. injection volume of 50pl of 100% dimethyl sulfoxide (DMSO) or the same 
volume of DMSO alone (vehicle control) daily for 10 consecutive days. This timepoint 
was chosen based on previous reports of minimal time of GW agent exposure experience 
by veterans. The choice of i.p. injection was chosen since PB has poor oral bioavailability 
(see Mestinon® drug insert for details) and PER has low solubility in certain aqueous 
solutions (Ray, & Fry 2006), which can potentially impact overall results by introducing 
variability due to inconsistent delivery.
2.2.2.3. Neurobehavioral testing
Neurobehavioral testing was performed during the light phase of the circadian 
cycle by two investigators who were blinded to the exposure assignment. A timeline of 
these studies is provided in Figure 2.7.
Motor coordination was assessed using the rotarod test during the exposure period
(days 5, 7 and 9) and on post-exposure days 1, 3, 5 and 7. On the first day of testing, mice
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Figure 2.7. Timeline of neurobehavioral experiments for mouse model B of GW agent 
exposure: Rotarod experiments were performed during both the exposure period and the 
post-exposure period. All other tests were performed on post-exposure days.
were allowed to acclimate to the experimental paradigm using 3 trials at 5 rpm fixed speed 
over 5 minutes per trial with 3-minute inter-trial rest intervals on the first testing day. 
Subsequently, 3 trials of 5 minutes each were conducted per day, during which the speed 
was accelerated from 5 to 50 rpm (with the same inter-trial interval) within each trial. The 
latency to fall was evaluated as the outcome measure. The OFT was performed using a im  
arena on post-exposure days 15 and 30 and a single trial lasting 15 minutes was conducted 
as described above for model A. Total distance travelled in the arena and perimeter activity 
were used as outcome measures.
The MWM test was conducted using a 2.5m2 pool filled with cloudy water, 
situated in a room with visual cues on the wall and on the pool above the water level. The 
acquisition trials were conducted on post-exposure days 43-51. Briefly, 4 acquisition trials 
were administered (each for 90 seconds) with an inter-trial interval of approximately 30 
minutes. Each probe trial was for 60 seconds. All procedures for acquisition trials and 
probe trials were conducted as described above for model A with the exception that after 
the first probe trial on post-exposure day 51, additional probe tests were performed 
(without repeating the acquisition trials) at approximately 30-day intervals (post-exposure 
days 86 and 115) to determine long-term memory retention (Lamproglou et al. 2009). The 
experimental conditions and the arena settings were kept consistent for each probe test
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with the aid of the Ethovision software. If a mouse did not reach the target platform 
location at the end of the session, each mouse was guided to the general location where the 
platform was originally placed and then retrieved from the pool. All OFT and MWM trials 
were recorded and analyzed with the Ethovision tracking system.
2.2.2.4. Statistical analyses for neurobehavioral studies
Post-hoc power calculations were performed using the G-power software (Faul, & 
Erdfelder 2007) to determine the adequacy of the study sample. For the sample size and 
the statistical analyses utilized in each neurobehavioral test, a power of 99% was detected 
for the rotarod test, 67% for the OFT and 100% for the MWM at alpha 0.05. All statistical 
analyses for the OFT, the rotarod and the MWM were performed as described above for 
model A. For the MWM test, one of the exposed mice developed a tumor growth on its ear 
and was therefore excluded from the studies. All analyses were performed with SPSS 13.0 
(IBM corp. Armonk, NY) and the statistical significance was set at the alpha 0.05 level.
2.2.2.5. Histopathological studies
A subset of animals were euthanized (n = 5 GW agent/control) on post-exposure 
day 8 (an acute post-exposure timepoint) after the rotarod test. The remaining mice were 
allowed to live up to post-exposure day 150 (a chronic post-exposure timepoint) and were 
then euthanized for neuropathological studies. All histopathological studies were 
performed as described above for model A with the exception that for post-exposure acute 
studies, a 1:1000 fold dilution of the GFAP antibody was used. For acute studies, presence 
of reactive microglia was also examined using ionized calcium binding adaptor molecule 1 
(Ibal) at a 1:1000 fold dilution and visualized as described above for neuropathology work 
on model A. For chronic 150 post-exposure timepoint, an Alzheimer’s disease (AD) mouse 
model (P SAPPswe mouse, see chapter 4 for more information on these mice) was used as a 
positive control.
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2.2.3. Results
2.2.3.1. Neurobehavioral studies
On post-exposure day 15, there were no differences between the GW agent exposed 
mice and control mice for psychomotor function, as measured by the distance traveled 
within the OFT arena (Figure 2.8A). For this outcome, a significant effect o f time was 
observed (F(2, 36) = 6.32, p = 0.004) but no significant interaction between time and 
exposure (F(2 , 36) = 0.10, p = 0.9) was seen. A decrease in the time spent at the perimeter
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Figure 2.8. The Open Field Test: Mean ± SEM, n = 10 in each of the exposed and the 
control group. (A) On post-exposure day 15, distance (cm) ± SEM traveled within the arena 
did not differ between GW agent exposed and control mice, p > 0.05. (B) On post-exposure 
day 15, duration of time (s) spent at the perimeter was shorter for exposed mice compared to 
control mice over 15 minutes displayed by 5 minute interval (average of 0-5 minute = 5, 
average of 6-10 minutes = 10 and average of 11-15 minutes = 15), p < 0.01, (based on MLM 
regression where time and exposure were fixed factors). (C) On post-exposure day 30, 
distance (cm) traveled in the OFT was significantly lower for GW agent exposed animals 
compared to controls over the 15 minutes testing period, p < 0.05 (based on MLM regression 
as described for B above). (D) On post-exposure day 30, mean time spent at the perimeter for 
exposed mice, as compared to control mice, was numerically higher during the last 11-15 
minute interval for exposed animals compared to controls, p > 0.05. Note: A version o f these 
figures is previously published (Abdullah et al 2011).
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Figure 2.9. The Rotarod Test: Mean ± SEM, n = 16 in each of the exposed and the control 
group (A) Mean ± SEM latency to fall (s) of exposed to PB and PER and control mice was 
similar during days 5 to 9 of the exposure period, p > 0.05. (B) Rotarod experiments were 
performed during the post-exposure period covering days 1-7, although mean was shorter in 
exposed mice on days 3 and 5 but there was no statistically significant difference between 
mice, p > 0.05 (based on MLM regression with post-exposure days and exposure were main 
fixed factors). Note: A version o f figure 2.8 is published (Abdullah et al 2011).
was observed in exposed mice compared to controls (F(i, 54)= 18.19, p < 0.001, Figure
2.8B). On post-exposure day 30, GW agent exposed mice traveled less distance than
control mice (F(i, 52) = 5.92, p = 0.018, Figure 2.8C) and there was no confounding effect of
the testing-period (F(2,37) = 3.07, p = 0.06) nor an interaction (F(2, 37) = 1.46, p > 0.05. At
this timepoint, GW agent exposed mice spent more time at the perimeter compared to
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Figure 2.10. The Morris Water Maze test: Mean ± SEM, n = 10 within the exposed group and 
n = 11 within the control group. (A) GW agents exposed mice showed a significantly lower 
latency to escape than control mice throughout the acquisition period (post-exposure days 43 to 
51), *denotes p < 0.05 for a main exposure effect (based on MLM with both training days and 
exposure were fixed main factors). (B) During probe trials, for escape latency, on post­
exposure days 51 and 86, exposed mice performed better than control mice but performed 
worse on day 115 and an interaction between post-exposure days and exposure itself was 
significant, p < 0.05 (based on MLM with exposure and post-exposure days as fixed main 
factors). (C) For the duration of time spent in the North East (NE) quadrant of the MWM, 
exposed mice performed similar to control mice on days 51 and 86. However, numerical value 
for control mice was larger than exposed mice on day 115, p > 0.05 (based on MLM regression 
as described above for B). Note, a black and white version o f these figures are published 
(Abdullah et al 2011).
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control mice during the 11-15 minute interval (Fq,52) = 3.31, p = 0.07, Figure 2.8D). There 
was no confounding effect of time (F(i, 35) = 0.19, p > 0.05) nor an interaction (F(2, 35) = 
0.92, p > 0.05) between time and exposure on this outcome measure.
On the rotarod test, there were no differences between the two groups on 
sensorimotor function during the exposure period (Figure 2.9A) and, although exposed 
mice had a shorter numerical value for latency to fall than control mice on post-exposure 
days 3 and 5, there were no statistically significant differences between the two groups (Fq, 
118) = 0.21, p > 0.05, Figure 2.9B).
For the MWM acquisition trials conducted on post-exposure days 43-51, a 
significant difference between control and exposed mice was observed for the latency to 
reach the escape platform (Fq, 141) = 7.97, p = 0.005, Figure 2.10A). Figure 2.10B-C 
illustrates that for the probe trials, exposed mice had shorter escape latency than control 
mice on post-exposure days 51 and 86 but control mice performed better than exposed on 
post-exposure day 115. For these probe trials, a significant interaction between GW agent 
exposure and post-exposure days (on which the probe trials were conducted) was observed 
(F(2,37)= 5.58, p = 0.008, Figure 2.9B). There was no independent effect of exposure (Fq, 
55) = 3.00, p = 0.09) or post-exposure days (F(2, 37) = 2.2, p = 0.12) for this outcome 
measure. Gulf War agent exposed mice spent a similar time searching the target quadrant 
as control mice on post-exposure days 51 and 86 but spent less time searching the target 
quadrant on post-exposure day 115. There was no effect of exposure (F(i, 53) = 0.19, p > 
0.05) nor of post-exposure days (F(2, 43) = 1.66, p > 0.05) and no interaction between 
exposure and post-exposure days (F(2, 43) = 3.84, p = 0.07, Figure 2.10C) was observed. 
There were no significant differences between the two groups on swim speed, as 
demonstrated by a lack of main exposure effect on the swim velocity (Fq, 57) = 1.74, p > 
0.05) and a lack of interaction between post-exposure day and GW agent exposure (Fq, 38) 
= 0.90, p > 0.05).
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Figure 2.11 GFAP staining: Mean ± SEM, n = 5 within each of the exposed group and the 
control group. Representative images of the cerebral cortex of a PB+PER exposed mouse 
and a control mouse, euthanized on post-exposure day 8. Images acquired with a 20x 
objective providing 200 x magnification. (B) Quantification shows no differences between 
the two groups.(C) Representative images of PB+PER exposed and control mice at 150 days 
post-exposure (n = 5 per group). The insert is an image of GW agent exposed mice taken 
with a 60x objective showing 600 x magnification. Arrows point to reactive astrocytes in 
the cortex of GW agent exposed mice. The scale bar represents 50pm. (D) Quantification 
shows a 350% increase in GFAP reactive astrocytes (at 150 days) in the cerebral cortex of 
GW agents exposed mice relative to control mice, p < 0.05 based on the Student’s t-test 
(Abdullah et al 2011).
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Figure 2.12. Nissl staining: Mean ± SEM, n = 5 within each of the exposed group 
and the control group. Representative images of the dentate gyrus of a PB+PER 
exposed mouse. (A) Exposed and control mice euthanized on post-exposure day 8 
and (B) at post-exposure 150 days (n = 5 per group) showing no differences 
between the two groups. The scale bar represents 50pm.
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Thai staining 8 days post-exposure
Control Figure 2.13 PB+PER
Figure 2.13. Ibal staining: Mean ± SEM, n = 5 within each of the exposed and the 
control group. An image acquired with a 20x objective from Ibal stained CA1 
hippocampal regions on post-exposure day 8. Microglia staining was detected but 
there were no differences between the two groups. The scale bar represents 50pm.
CD45 staining 150 days post-exposure 
Figure 2.14
PSAPPswe mouse model Mouse model B of GW agent exposure
Figure 2.14 CD45 staining: A representative image (taken with a 10x objective 
providing a 100* magnification), which depicts the presence of extensive microgliosis 
(quantified using CD45) in the hippocampal region of the AD mouse model (left 
image) but a complete lack of it in the mice exposed to PB+PER in the GWT mouse 
model (right image). The scale bar represents 50pm.
2.2.3.2. Histopathological studies
At an early timepoint (post-exposure day 8), within both the cortex and the 
hippocampus, there were no differences between the groups in astrogliosis (t = -0.15, d f  = 
7, p > 0.05, Figure 2.11A-B). Interestingly, at the later timepoint of 150 days post­
exposure, a significant increase in astrogliosis was observed in the cortex o f exposed mice
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compared to control mice (t-test = -6.10, df = 8, p = 0.04, Figure 2.11C-D), but there were 
no differences in the hippocampus between the two groups. There was no evidence of 
neuronal loss in response to GW agent exposure in either the cortex or the hippocampus at 
either early or late timepoints (Figures 2.12A and 2.12B). As we were unable to visualize 
any microglia with CD45 staining in model A, Ibal staining was used to detect total 
microglia. Figure 2.13 shows presence of microglia but there was no evidence of reactive 
microglia (as quantified using Ibal staining) at the early timepoint, as microglia appeared 
to be ramified in both the exposed and unexposed animals. CD45 staining was used to 
visualize reactive microglia on post-exposure day 150 but there was no evidence of 
microgliosis at this later timepoint, evident by a lack of CD45 staining compared to an 
image from the brain of an AD mouse (positive control) that shows significant microgliosis 
(Figure 2.14)
2.2.4. Discussion
To date, a study by Lamproglou et al. 2009 is the only one showing memory 
impairment, but the exposure paradigm in this study included stress, which is an inherent 
feature of most military combat, including the Persian GW (Lamproglou et al 2009). As a 
goal of studies described in this thesis was to focus on memory impairment associated with 
exposures that were directly relevant to the 1990-1991 GW conflict, combined exposure to 
PB and PER was used since this particular combination is shown to cause 
neuropathological changes that could potentially give rise to cognitive impairment (Abdel- 
Rahman et al 2004).
This is the first report showing delayed cognitive impairment after combined 
exposure to PB and PER in mice. GW agent exposed mice consistently performed better 
than unexposed mice over the 9 days of the MWM acquisition trials. The data from escape 
latency during the probe trials conducted on post-exposure days 51 and 86 show that
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exposed mice performed better than control mice, but on post-exposure day 115, control 
mice performed better than exposed mice. These data suggest that earlier on, exposed 
mice had better spatial memory than control mice for reaching the exact location where the 
escape platform was previously located, and this was subsequently impaired in exposed 
mice. Data from time spent in the target quadrant (a less precise measure of spatial 
memory than escape latency) suggest that there were no differences between the two 
groups in the earlier two probe trials, but the probe trial on post-exposure day 115 suggests 
that exposed mice spent less time in the target quadrant than control mice. Hence, data 
from 115 days post-exposure provide additional support for the escape latency data. As 
mice were retrieved from the previous location of the hidden target platform, data from 115 
post-exposure day suggest that additional learning had occurred in control mice but not in 
exposed mice. This may also suggest that delayed memory problems in exposed mice 
might be a consequence of impaired learning. However, this outcome is somewhat 
ambiguous as the difference between the two groups is largely driven by continual learning 
in controls and a lack thereof in exposed mice. As such, additional work, which may 
include examination of cognitive outcome after PB and PER exposure in a different strain 
of mice, is required to validate cognitive impairment in mice exposed to PB and PER.
Although the biochemical mechanism of this delayed cognitive impairment in 
response to PB and PER exposure is unknown, the mechanism may be similar to that 
proposed for exposure to other AChE inhibitors (Terry et al 2011). It is suggested that 
there might be a compensatory increase in AChE after prolonged exposure to AChE 
inhibitors, as observed in studies showing that after 30 days of AChE inhibitor exposure, 
there is an increase in AChE mRNA levels in the cortex (Bansal et al 2009). An 
electrophysiology study of insect larvae showed that combined exposure to PER and 
Propoxur (another carbamate AChE inhibitor), at a maximum tolerable concentration,
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resulted in a synergistic increase in membrane depolarization, which was evidenced by a 
reduction in the amplitude of the excitatory post-synaptic potential (EPSP) and is 
indicative of an increase in synaptic ACh (Corbel et al 2006). Studies also suggest that 
excessive synaptic ACh can self-regulate by binding to presynaptic muscarinic receptors 
(mAChR) subtypes 2 and 4, which activate negative feedback that inhibits further ACh 
release (Zhang et al 2002). Hence, these studies suggest that some of the effects of GW 
agents on memory may be impacted by ACh availability, but further investigation is 
required.
In response to PB exposure in rats, a dose-dependent increase in anxiety at 30 
minutes post-exposure has been reported (Hoy et al 1999). Habituation was reported in 
rats 24 hours after exposure to PB and PER (Hoy et al 2000). Habituation was observed on 
post-exposure day 15 in exposed mice. However, on post-exposure day 30, a weak 
association was observed between anxiety parameter and GW agent exposure where 
exposed mice spent more time at the perimeter than control mice, during the last 11-15 
minute timepoint. Increased mood and anxiety dysfunction were observed in deployed 
GW veterans compared to non-deployed veterans, which has persisted decades after the 
GW conflict (Toomey et al 2009; Gray et al 1999). Thus, the animal studies discussed 
above provide some support for an association of anxiety disorder with GWI, and warrants 
further investigation.
A decrease in motor function (distance traveled) in the OFT was observed on post­
exposure day 30 in the exposed mice compared to controls, but there was no evidence of 
motor coordination problems in the rotarod test. Sensorimotor deficits using beam-walk 
(balance) and grip strength tests have been observed in response to combined PB and PER 
exposure (Abou-Donia et al 2004). Examination of motor function in clinical studies 
suggested that veterans with GWI do not show any overt muscle damage or peripheral
nerve pathology. However, studies did show a dose-response for psychomotor impairment
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where veterans with the highest exposure to both pesticides and PB had worse performance 
in psychomotor tasks than those with low-level exposure (Binns et al 2008). These data 
support a psychomotor-related dysfunction rather than fine motor coordination problems, 
observations that are similar to that reported for another organophosphate (OP) AChE 
inhibitor pesticide, diisopropyl-fluorophosphate (Terry et al 2011). It is also possible that 
GW-agent induced neurobehavioral changes may be a consequence of circadian 
abnormalities, often reported by veterans with GWI (Haley et al 2004), and thus are likely 
to be a consequence of GW agent exposure. The observed delayed presentation of 
neurobehavioral symptoms in GW agent exposed mice is consistent with the observation of 
delayed manifestation of GWI in veterans, where 60% of GWI symptoms developed once 
veterans returned from the war and 40% of the symptoms emerged years later (Kroenke et 
al 1998). These neurobehavioral studies show delayed emergence of anxiety and cognitive 
impairment in mice exposed to PB and PER compared to control mice.
A significant increase in astrogliosis was detected in exposed mice compared to 
controls after a timepoint at which cognitive impairment was evident. This observed 
increase in astrogliosis is consistent with the observed modulation of immune/ 
inflammatory response and with a report showing increased astrocyte reactivity in response 
to PER exposure alone and PB and PER with DEET in rodent brain (Abdel-Rahman et al 
2004). At this acute timepoint, there was no difference between the two groups with 
respect to GFAP immunohistochemistry. As CD45 staining was undetectable in model A, 
Ibal stain was used since it can detect both the reactive and ramified microglia through 
morphological analyses. There were no differences in Ibal staining between the exposed 
and control animals, in both the hippocampi and the cortices. The morphology of Ibal 
stained microglia (ramified) appeared similar in both exposed and control mice. Since 
CD45 staining is considered to be more specific to reactive microglia, this stain was 
chosen for the post-exposure day 150 timepoint. A positive control was also used (brain
section from an 18-month old PSAPPswe mouse model of AD) which showed a presence 
of extensive microgliosis. As in mouse model A, there were no reactive microglia present 
in either the control or the exposed mice. Thus it can be presumed that after exposure to 
GW agents, there is no microgliosis. Similarly, there were no differences between exposed 
and control mice on measures of neuronal loss, assessed using Nissl staining.
Observations of astrogliosis at only the chronic timepoint suggests an association 
between GW-agent induced astrogliosis and behavioral changes, since these changes 
succeeded the emergence of the cognitive impairment phenotype. However, the presence 
of such pronounced astrogliosis in response to GW agent exposure merits further 
examination to determine a possible causal relationship between astrogliosis and 
behavioral outcomes after GW-agent exposure. Collectively, these studies demonstrate 
that exposure to GW agents used in mouse model B may produce neurobehavioral features 
that are similar to those suffered by veterans with GWI.
2.3. Validation o f cognitive studies for mouse model B o f GW agent
exposure
2.3.1. Introduction
It is anticipated that the future work at the Roskamp Institute will involve the 
C57BL6 strain, which is the most commonly used strain in laboratory research, particularly 
for research requiring genetic manipulations. Additional work for a DoD CDMRP award 
(PI: Ait-Ghezala) will require examination of cognitive dysfunction in response to GW 
agent exposure and to determine if cognitive dysfunction could be ameliorated by targeting 
inflammatory/immune pathways. Thus a main focus of GWI work at the Roskamp 
Institute will be to evaluate the cognitive component associated with GW agent exposure in 
genetically manipulated mice (i.e., CD40L deficient mice on C57BL6 background). 
Therefore, studies were performed to validate cognitive outcomes in C57BL6 mice.
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2.3.2. Material and Methods
2.3.2.1. Animals
For validation studies of cognitive neurobehavioral findings, the C57BL6 in-bred 
strain was used. Initial pilot studies were performed to ensure that doses of PB and PER 
administered to CD1 mice were suitable for this C57BL6 strain. However, a 2 mg/kg dose 
of PB was found to be lethal, which can be explained by the fact that C57BL6 is 
genetically predisposed to cholinergic deficiencies (Schwab 1990; Bentivoglio 1994). 
Subsequent pilot studies were performed to reduce PB dose through a serial dose reduction 
process. A dose of 0.7 mg/kg of PB was found to be tolerable in these mice and this dose 
was used to ensure survival in this strain over the experimental time-period. The dose of 
PER was kept constant at 200mg/kg. This combination was administered to mice daily for 
10 days, as described previously in section 2.2.above for the development of mouse model 
B. Animal work was performed in accordance with the animal welfare guidelines 
described above.
2.3.2.2. Barnes Maze
During the experiments conducted using the C57BL6 strain in mouse model A, it 
was observed that these mice performed poorly in the MWM. Patil and colleagues 
performed a comparison of CD1 mice and C57BL6 mice using the Barnes Maze (BM) and 
MWM (Patil et al 2009). These studies demonstrated that while CD1 mice performed 
better in the MWM than C57BL6 mice, C57BL6 mice performed much better than CD1 
mice in the BM. Therefore this test was chosen for cognitive validation studies in C57BL6 
mice. The BM protocol was based on work described elsewhere (Berta et al 2007). 
Briefly, each mouse was adapted to the maze and the escape hole on the first day of the 
acquisition trial, during which each mouse was separately placed in the middle of the maze 
and then guided to the escape hole where it remained for 2 min. Following that,
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acquisition trials were conducted over 4 days (days 10-13) for 180 seconds per trial and 4 
trials were administered per mouse with an inter-trial interval of 15 min. Each mouse was 
placed in the middle of the maze and the trial ended when the mouse entered the escape 
hole or after 180 seconds had elapsed. A rotating fan was on during the trials but was 
turned off when a mouse entered the target hole and escape into the escape box, where it 
was allowed to stay for 1 min. If the mouse did not reach the escape hole within 3 
minutes, the experimenter guided the mouse gently to the escape hole and left the mouse 
inside for 1 min. A probe trial was conducted on post-exposure day 14, 24 h after the last 
training day. The escape hole was removed for the probe trials. Each mouse was placed in 
the middle of the maze and allowed to explore the maze for a fixed interval of 90 seconds. 
The number of pokes in each hole and the latency and distance travelled to reach the 
virtual target hole were measured as outcome factors. To assess long-term retention, 
additional probe trials were administered approximately 30 days on post-exposure days 47 
and 77.
2.3.2.3. Statistical analyses:
For Barnes Maze, statistical analyses were conducted using a generalized linear 
model (GzLM) to accommodate non-normally distributed dependent variables. All 
analyses were performed with SPSS 13.0 (IBM corp. Armonk, NY) and the statistical 
significance was set at the alpha 0.05 level.
2.3.4. Results
For these validation studies, acquisition trials were conducted daily on post­
exposure days 10-13 to train mice to locate and enter the escape hole. Figure 2.15A shows 
that exposed mice learned this task better than control mice, as evidenced by a shorter 
duration of time spent in the arena over the 4 day training period (Wald = 12.08, p < 0.01). 
For probe trials, on post-exposure day 14, exposed mice more frequently visited the escape
hole location than control mice. On post-exposure day 47, there were no differences 
between the two groups. However, on post-exposure day 77, exposed mice less frequently 
visited the escape hole than control mice and these differences were statistically significant 
(Wald = 5.93, p = 0.05, Figure 2.15B). Examination of primary errors (represented by a 
comparison of percentage frequency of nose-poke in escape hole vs. other holes - not 
including two holes adjacent to the target hole) provided supporting data that on post­
exposure day 77, exposed mice had less accuracy than control mice in identifying the 
escape hole (Wald = 3.03, p = 0.08, Figure 2.15C).
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Figure 2.15. Barnes Maze: Mean ± SEM, n = 10 within each of the exposed group and the 
control group. (A) For the acquisition trials, duration of time in arena was lower for PB 
+PER exposed mice than controls and a significant interaction between training days and 
exposure was observed, *denotes p < 0.01 for a main exposure effect (based on GzLM 
where training days and exposure were incorporated as fixed main factors). (B) Data on the 
frequency of nose-pokes in the escape hole during the probe trials showed a significant 
interaction between exposure and post-exposure days on this outcome, where exposed mice 
performed better than control mice on day 14, but this pattern reversed on day 77, p < 0.05 
(based on GzLM with days and exposure were incorporated as fixed main factors). (C) 
Examination of primary error % (as measured by % frequency of correct nose-poke vs. those 
in other holes outside of target zone) showed that the error rate was numerically increased in 
PB+PER exposed mice compared to control mice on post-exposure day 77, p > 0.05.
2.3.4. Discussion
As described above, C57BL6 mice have cholinergic deficiencies; thus a much 
lower dose of PB was utilized in this strain. In addition, studies also show that these mice 
experience an elevated level of stress in the MWM and perform better in the BM (Patil et 
al 2009) and therefore the BM was utilized for cognitive validation studies of mouse model 
B of GW agent exposure. These data show that during the acquisition trials, all mice 
learned how to escape into the target box, where exposed mice learned the task more 
quickly than control mice during post-exposures days 10-13. During probe trials, the same 
pattern was evident on post-exposure day 14 as nose pokes in the target hole were higher in 
exposed vs. control mice. There were no differences between the two groups on post­
exposure day 47. On the contrary, by post-exposure day 77, a reverse pattern was seen 
where exposed mice performed worse than control mice, which is similar to the 
observations on post-exposure day 115 in CD1 mice experiments. These data clearly 
demonstrate that the cognitive impairment observed in this BM study is not an artifact of 
changes in control mice, as both exposed and control mice had lowered frequency of nose 
pokes in the escape hole and a concomitant increase in the frequency of incorrect nose- 
pokes when comparing post-exposure days 14 vs. 77.
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2.5. Summary of animal modeling of GW agent exposure
The animal modeling work described in this chapter suggests that different 
combinations and doses of GW agents may produce different neurobehavioral profiles, 
albeit with neuropathologically similar outcomes. For instance, GW agents administered 
to mouse model A included DEET and stress, along with PB and PER. In mouse model B, 
PB and PER were also utilized, although doses of PB and PER were much higher and 
administration time was different from that in mouse model A. Neurobehavioral studies in 
mouse model A suggest a significant motor impairment component along with anxiety. 
However, cognitive capabilities could not be ascertained due to marked motor problems in 
exposed mice, further complicated by the fact that the C57BL6 inbred strain is shown to 
perform poorly in the MWM due to its predisposition to anxiety (Patil et al 2009). 
Interestingly, earlier work conducted by Haley and colleagues aimed at sub-classification 
of veterans with GWI showed that Syndrome 3, which was associated with DEET 
exposure had a significant arthro-myo-neuropathy component consisting of symptoms such 
as pain, fatigue and numbness of extremities. One can then speculate that perhaps 
overexposure to DEET in combination with other GW agents may precipitate symptoms 
resembling those in veterans that were classified under Syndrome 3. On the other hand, 
while cognitive impairment was observed in mouse model B along with anxiety, there was 
no motor impairment, except perhaps psychomotor problems. This particular 
neurobehavioral profile may be similar to Syndrome 1 which also has a prominent 
cognitive component. Despite these clear differences in neurobehavioral presentations of 
the two mouse models of GW agent exposure, neuropathological findings were virtually 
identical where profound astrogliosis was noted in the cortex but not in the hippocampus. 
Similarly, in both mouse models of GW agent exposure, there was no neuronal loss or 
microgliosis in either the hippocampus or the cortex. Hence, GWI mouse modeling work
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based on the combinations of GW agents utilized in these studies may be extremely 
valuable in capturing different phenotypes of GWI symptomatology. It is anticipated that 
these mouse models of GW-agent exposure will be useful in molecular biology studies 
aimed at characterizing the underlying dysfunctional biomolecular pathways.
The next chapter describes molecular biology and proteomic studies performed on 
brain tissue and blood from these mouse models for identification of possible biological 
mechanisms associated with GW agent exposure.
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3.0. Chapter 3 Exploratory studies of brain and blood samples from 
mouse models of GW agent exposure
This Chapter presents exploratory work conducted on two mouse models of GW 
agent exposure characterized in Chapter 2 above. The western blot studies performed on 
the brain tissue from mouse model A of GW agent exposure (PB, PER, DEET and stress) 
to explore biological links with neurodegeneration, which was suggested to be an outcome 
from neuropathological studies conducted by Abdel-Rahman and colleagues (Abdel- 
Rahman et al 2004). Mouse model B of GW agent exposure used a combination of high 
doses of PB and PER. Unlike for mouse model A, there was no information available from 
the literature about potential biological mechanisms that might be affected in response this 
particular GW agent exposure. Consistent with the literature, genomic work performed at 
the Roskamp Institute using an in vitro model of GW agent exposure suggested that several 
different biological pathways are affected in response to a combined PB and PER 
exposure. Therefore, for mouse model B, proteomic studies were performed on the brain 
and blood samples in order to obtain information on several biological pathways in a single 
experiment.
3.1. Exploratory biochemical studies o f mouse model A o f  GW agent 
exposure
3.1.1. Introduction
As described in Chapter 1, the presence of memory impairment and reduced 
hippocampal volume observed in veterans with GWI suggests that hippocampal 
dysfunction may be associated with this illness (Menon et al 2004; Vythilingam et al 2005). 
Memory problems, along with hippocampal volume loss, are generally characteristic of 
Alzheimer’s disease (AD), a neurodegenerative disorder. Abdel-Rahman and colleagues 
observed degenerating neurons in several brain regions, including the hippocampi, of rats
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exposed to PB, PER, DEET and stress (Abdel-Rahman et al 2004). It was therefore 
hypothesized that biological pathways affected in response to GW agent exposure might 
overlap with those for AD. Support for this comes from studies showing modulation of 
mAChR activity after GW agent exposure. Downstream signaling pathways that are linked 
with mAChR activation include metabolism of the Amyloid Precursor Protein (APP), a key 
protein implicated in AD pathogenesis.
There is considerable support for modulation of mAChR activity after exposure to 
GW agents (Abdel-Rahman et al 2004; Mauck et al 2010). For example, an increase in 
mAChR subtype 2 (M2 AChR) ligand binding within the cortex was observed in rats 
exposed to PB, PER, and DEET (Abou-Donia et al 2001), although no findings have been 
reported for PB, PER and DEET in combination with stress for this particular brain region. 
It was also noted that the activity of M2 AChR was decreased after exposure to PB, PER, 
DEET and stress in the forebrain, midbrain and cerebellum (Abdel-Rahman et al 2004). 
Mauck and colleagues demonstrated that densities of M3 AChRs were decreased in the 
cortex after exposure to PB in rats (Mauck et al 2010). These studies suggest brain-region 
specific modulation of the cholinergic system in response to GW agents, particularly for 
the combination that was administered in mouse model A.
Muscarinic AChRs are widely known for their role in maintaining and regulating
synaptic ACh levels and differential activation of these receptors can also modulate
cascades of intracellular biological events that are implicated in AD pathogenesis (Isacson
et al 2002). The Amyloid Precursor Protein is a type I transmembrane protein, which is
processed via a-secretase (precluding the formation of the p-amyloid peptide and thus
termed non-amyloidogenic processing) or by (3- and y-secretases (amyloidogenic). The
latter pathway generates pathologic Ap fragments and is considered to play a key role in
AD pathobiology (Tandon et al 2000). Activation of M2 AChR is shown to lower
expression of the P-secretase APP converting enzyme (BACE) via adenylyl cyclase-
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coupled pathways (Zuchner et al 2004). Activation of the Ml AChR has consistently been 
shown to result in increased sAPPa release via protein kinase C (PKC) dependent 
pathways (Jones et al 2008; Slack et al 1995). Recent studies have shown that Ml AChR 
activation can reduce BACE expression and consequently Af3 levels (Fisher 2012). In two 
different transgenic mouse models of AD, Ml AChR deletion resulted in an increase of 
amyloid plaque burden and tangle formation (Medeiros et al 2011). However, stimulation 
of the Ml or M3 subtype with its agonists has also been shown to increase BACE 
expression by two-fold, also through PKC (Isacson et al 2002; Zuchner et al 2004). 
Although these are conflicting reports with respect to mAChR and BACE activation, they 
nevertheless suggest modulation of APP processing upon activation of mAChR signaling 
pathways.
Since evaluation of the present literature suggested that mAChR signaling 
pathways are modulated in response to the GW agent exposure utilized in mouse model A 
and may impact APP processing in neurodegenerative conditions, it can then be postulated 
that GW agent exposure might also affect APP levels. Therefore, studies were performed 
to evaluate APP levels for mouse model A. In addition, western blot studies were also 
performed to validate the histopathological findings of increased astrogliosis observed in 
mouse model A of GW agent exposure.
3.1.2. Materials and methods
Mice examined in model A were euthanized on post-exposure day 42 (after 28 days 
of PB, PER, DEET and stress exposure) via cardiac puncture followed by perfusion as 
described in Chapter 2 above. Extracted brains were homogenized in 1.5 ml of 
Mammalian Protein Extraction Buffer (MPER, Pierce) using a dounce homogenizer, 
followed by centrifugation at 21,000 x g for 15 minutes. Next, 150 pg of brain homogenate 
was combined with about 6pi of laemmli buffer (containing beta-mercaptoethanol) and this
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sample was loaded onto a Tris-HCL gel for electrophoresis. Proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane using a Biorad transblot apparatus overnight at 
90 mA. The membrane was blocked for 1 hour in 5% blocking milk (Biorad), then 
incubated with mouse primary antibody for full length APP, clone 22c 11 (Millipore) at 
1:1000 dilution for 2hrs followed by incubation with anti-mouse secondary antibody for 
lhr and then visualized using West-Femto substrate (Pierce). A band of 110 kd was 
detected, no other bands were detectable. Membrane was then stripped with Restore 
stripping buffer (Pierce) and re-probed with mouse primary GFAP antibody (Dako) at 
1:1000. The same procedure was followed for actin (Pierce) using conditions described 
above. Subsequently, PVDF membrane was stained with Coomassie blue stain to visualize 
transferred proteins and to ensure that the transfer in each well was consistent. All 
statistical analyses were performed using the Student’s t-test and p < 0.05 was considered 
statistically significant.
3.1.3. Results
There was a 1.25 fold increase in full length APP levels in exposed mice compared 
to controls but this difference did not reach statistical significance (t = -0.91, df = 8, P > 
0.05). Western blot analysis using the GFAP antibody validated the neuropathological 
findings of increased astrogliosis. Figure 3.1 A shows the images for APP, GFAP and actin 
western blots. Total proteins are visualized on the blot using Coomassie stained PVDF, 
(Figure 3.IB). Quantification is presented in Figure 3.1C and supports a limited increase in 
expression of APP and considerable increase of GFAP. Consistent with neuropathology 
findings, a statistically significant increase of 1.5 fold was observed for GFAP levels in 
exposed mice compared to control mice (t = -2.50, df = 8, p = 0.04).
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APP and GFAP western blot analyses
Figure 3.1A Figure 3.IB
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Figure 3.1. APP and GFAP western blot analyses: Mean ± SEM, n = 5 within each of the 
exposed group and the control group. (A) Western blot images of APP (llOkd), GFAP (50kd) 
and actin (42kd). (B) Membrane was stained with Coomassie blue which shows similar gel 
loading per well. (C) APP and GFAP densitometry values were normalized against actin for 
quantification. A 1.25 fold increase in APP expression was noted in exposed mice compared 
to control mice using western blot analyses but these differences did not reach statistical 
significance, p > 0.05. For GFAP, about 1.5 fold increase was noted and this difference was 
significant, *denotes p < 0.05 based on the Student’s t-test.
3.1.4. Discussion
The work conducted by Abdel-Rahman and colleagues suggested neuronal 
degeneration (characterized by dying neurons detected using H&E staining) in response to 
the GW agent exposure paradigm that was used in mouse model A. However, as described 
in Chapter 2 above, this work remains controversial since the method of detecting 
degenerative neurons by Abdel-Rahman and colleagues was considered to be an artifact o f
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sample handling (Jortner 2006) and has not yet been validated using another 
neuropathology technique.
The amyloid precursor protein
The limited exploratory biochemical studies of APP conducted here, along with the 
histopathological work presented in Chapter 2, do not indicate the presence of a 
neurodegenerative component in response to GW agent exposure. An examination of full- 
length APP alone is not fully informative of APP processing and more conclusive evidence 
would likely come from examination of fragments of APP, such as Ap40 and Ap42. 
However, other experiments conducted at the Roskamp Institute using Enzyme-Linked 
Immunosorbent Assay (ELISA) for endogenous mouse AP40 quantification did not 
accurately detect Ap levels in wild type mice as the endogenous levels of this peptide were 
very close to the lower detection limit of the ELISA. Hence, due to these limitations, 
additional work aimed at examining fragments of APP (i.e. AP) was not pursued further for 
this thesis. Future examination of tau and phosphotau levels may be useful for determining 
a possible presence of neurodegenerative response to GW agent exposure. Findings of an 
increase in GFAP stained astrocytes in exposed mice compared to controls in model A are 
similar to the findings originally reported by Abdel-Rahman and colleagues.
The Glial Fibrillary Acidic Protein
The neuropathological findings of astrogliosis in model A are confirmed by GFAP 
western blot studies. As described in Chapter 2 above, astroglia play a prominent role in 
modulating inflammatory responses in the CNS. Therefore, it appears that exposure to 
GW agents may have an inflammatory component, which is supported by observations of 
altered immune and inflammation profiles in veterans with GWI. As such, examination of 
inflammation related changes might be helpful in understanding the pathobiology of GWI.
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3.2. Exploratory biochemical studies o f  mouse model B o f GW agent
exposure
3.2.1. Introduction
The molecular biological work on model A described above, combined with the 
complicated clinical presentation in veterans with GWI, suggests that despite having a 
cognitive deficit component, veterans with GWI may not have a prominent 
neurodegenerative pathology at this stage of the illness. Current research on GWI 
pathology also suggests that several biological processes and functions are likely to be 
perturbed (Binns et al 2008). For example, clinical studies showed an abnormal 
suppression of adrenocorticotropic hormone (ACTH) levels in response to metyrapone 
challenge in symptomatic veterans who were deployed to GW compared to non-deployed 
asymptomatic GW veterans (Golier et al 2009). This suggests an impairment of the 
endocrine system in veterans with GWI. Similarly, several studies also suggest an increase 
in the production of inflammatory cytokine by lymphocytes obtained from veterans with 
GWI compared to asymptomatic GW veterans (Skowera et al 2004; Broderick et al 2011). 
Because of the indicated involvement of several biological systems, a comparative 
approach that can profile a large number of biological pathways in any given experiment 
may be useful in order to understand the biological dysfunction associated with GWI.
Over the last two decades, technological advances have allowed global examination 
of components of cellular networks and their interactions using Omics technology, which is 
coupled with similarly powerful computational tools (bioinformatics) that aid in the 
calculation and further interpretation of large datasets. Such an approach is now termed 
systems-biology, which encompasses genomics, proteomics, lipidomics and metabolomics 
techniques that quantify thousands of genes, proteins, lipids and metabolites, respectively, 
in a single experiment. These systems-biology approaches can potentially play an
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important role in identifying disease mechanisms in complex disorders (Filiou et al 2012; 
Bayes, & Grant 2009).
Advances in mass spectrometry (MS) have greatly facilitated protein identification 
and characterization. In the recent past, two dimensional gel electrophoresis (2DGE) was 
the primary tool used to visualize the proteome of a given biological sample and identify 
its components. However, this proteomic technique suffered from a limited range, as not 
all proteins (i.e., membrane proteins and proteins with extreme molecular weights and pH) 
were detectable using this gel-based system. Over the last decade, use of liquid 
chromatography with mass spectrometry (LC/MS) technique has gained widespread 
popularity due to its ability to identify and quantify a wider range of proteins than that 
visualized with 2DGE methods. As a consequence, numerous LC/MS-based quantitative 
techniques have emerged allowing accurate quantitation of proteins from a large variety of 
biological samples. For example, Isotopic Coded Affinity Tags (ICAT) uses chemical 
labeling strategies which allows addition of isotope-coded affinity tags that react with the 
cysteine residues on the proteins in a biological sample. Samples are then combined and 
analyzed using LC with tandem mass spectrometry (LC/MS/MS). However, this approach 
can be biased against proteins that do not contain this residue.
Another quantitative proteomic approach that enables accurate quantitation of 
proteins is called Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC), which 
allows direct in vitro metabolic labeling of proteins and peptides with isotope labels (i.e., 
180 , 13C, 15N). Recently, SILAC methodology has been modified to accommodate in vivo 
labeling of mammals (SILAM), such as mice and rats. However, these experiments are 
extremely costly and time consuming as they require metabolic labeling of cells/mammals 
and may introduce biologic or phenotypic changes due to unexpected and unpredictable 
biological responses to the isotopes (Ong 2012; Xie et al 2011; Filiou et al 2012; Zieske 
2006).
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While each technique listed above has provided a unique contribution to the 
proteomic field, there remained a need for a cost-effective technology that could examine 
proteins from samples where metabolic labeling is not feasible, label all peptides and allow 
simultaneous quantitation of proteins in multiple samples. These prerequisites have been 
addressed by the recently developed Isobaric Tagging for Relative and Absolute 
Quantification (iTRAQ)-based proteomic approach, which has gained widespread 
popularity due to its ability to simultaneously identify and quantify proteins from up to 8 
samples in a single experimental run (Zieske 2006). This technique allows incorporation 
of isobaric tags that maintain an overall atomic mass of 144, but upon fragmentation with 
MS/MS, give peptide peaks with unique reporter ions (i.e., m/z 114, 115). This allows for 
better quantitation by providing a strong ion signal. Furthermore, these tags react with all 
primary amines, and as such provide better peptide coverage than ICAT.
Hence, proteomic techniques (including iTRAQ), because of their ability to identify 
and quantify several thousand proteins in a given experiment, are well suited for examining 
complex illnesses, such as GWI. Furthermore, when proteomic technology is used in 
conjunction with a bioinformatics platform, it can provide a comprehensive view of 
disease-related changes (Bayes, & Grant 2009). Therefore, iTRAQ-based proteomics 
coupled with bioinformatic tools was applied to generate a proteomic dataset in order to 
characterize biomolecular pathways that were affected in GW exposed mice compared to 
control mice from model B. Given the paucity of reliable biomarkers of GWI, iTRAQ 
experiments were also performed on plasma samples from mouse model B to determine if 
such an approach can be used to discover objective biomarkers of chronic CNS changes 
associated GW agent exposure in this mouse model.
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3.2.2. Material and methods
3.2.2.1. Brain sample processing
Following exsanguination, animals were perfused with PBS. Whole brains were 
extracted, immediately frozen in liquid nitrogen and transferred to a -80°C freezer until 
further use. Four biological replicates were used for each group (n = 4 for each control and 
exposed) and each sample was individually prepared and processed. Using a dounce 
homogenizer, brains were homogenized in chilled lysis buffer (Membrane Protein 
Extraction Reagents, Pierce, Rockford, IL) containing protease (Roche, Indianapolis IN) 
and phosphatase inhibitor (Pierce) cocktails and centrifuged at 20,000 x g for 15 min at 
4°C. The supernatant was collected and quantified using the bicinchoninic acid assay 
([BCA], Pierce), and examined by SDS-PAGE. Aliquots equivalent to about lOOpg protein 
for each sample were precipitated in 4 volumes of acetone and pelleted by centrifugation. 
The pellets were reduced, alkylated and digested according to Masuda and colleagues with 
trypsin at a 1:200 enzyme to substrate ratio (Masuda et al 2008).
3.2.2.2. Plasma sample processing
Plasma samples from the same mice (on whom the brain samples were analyzed for 
iTRAQ) were prepared for iTRAQ experiments, as described elsewhere (Crawford et al 
2012) and briefly outlined here. Following exsanguination via cardiac puncture using a 18 
gauge wide-bore needle to prevent hemolysis of red blood cells (RBC) during blood 
collection. Blood samples were collected into a 1.5ml Eppendorf tube containing 10U of 
heparin and a protease inhibitor cocktail (PIC) (Roche) to a final concentration of IX. 
Samples were immediately centrifuged at 3,000 x g for 5 minutes and plasma was 
transferred to a new 1.5mL Eppendorf tube and snap frozen in liquid nitrogen. Plasma 
samples were subjected to a delipidation procedure using a non-denaturing biphasic 
solvent system according to previously published methods (Wong, & Ladisch 1983).
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Briefly, plasma was mixed with an equal volume of diisopropyl ether-butanol (3:2, v/v) 
and vortexed for 10 minutes at 4°C, followed by centrifugation at 15,000 x g for 5 minutes 
at 4°C to accomplish phase separation The lower phase was then transferred to a new tube 
and further diluted (5x) in chilled IX PBS (supplemented with protease inhibitor 
cocktails). Albumin was depleted using a solvent-based system (Fu et al 2005) where 
chilled ethanol was added to a final concentration of 42%. The samples were incubated for 
60 minutes at 4°C on an end-over shaker. The samples were again subjected to 
centrifugation at 15,000 x g for 5 minutes at 4°C. The albumin-depleted protein precipitate 
was quantified using the BCA assay and verified by SDS-PAGE. The pellet was reduced/ 
alkylated in 8M urea, then diluted 8-fold with 20mM HEPES, pH 8.0 to 20pl. Aliquots 
equivalent to about 100pg protein for each sample were subjected to tryptic digestion for 
iTRAQ studies described below.
3.2.2.3. Isobaric Tagging for Relative and Absolute Quantitation fiTRAO) labeling 
Following the sample processing and protein standardization steps above, as per
manufacturer’s instructions, tryptic peptides in each sample were individually labeled with 
iTRAQ reagents (4-plex labeling system from Applied Biosystems) at room temperature 
for 4 hours. Samples were pooled at this stage of the iTRAQ experiments (50pg of each) 
to allow simultaneous quantification. Each 4-plex group contained two control samples 
(114 and 116 mass tags) and two exposed samples (115 and 117 mass tags), for a total of 8 
samples divided into two 4-plex groups. For brain samples, an additional step was 
included following labeling and pooling to remove sodium deoxycholate was depleted as 
described elsewhere (Masuda et al 2008).
3.2.2.4. LC/MS/MS experiments
The peptide containing aqueous phase was transferred to a new tube, dried using
vacuum centrifugation and re-suspended in 20mM ammonium formate, pH 10. Samples
were fractionated using offline high-pH reversed phase chromatography using C l8 spin
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columns (Pierce) and eluted stepwise in an increasing concentration of acetonitrile (ACN) 
in 20mM ammonium formate, pH 10. This generated five fractions (flow-through, 10, 20, 
30, and 40%ACN fractions), which were dried in a vacuum centrifuge and then re­
suspended in mobile phase A (99.9% water, 0.1% FA) for LC-MS/MS analysis.
Samples were applied to a 100mm by 0.1mm C18 (3pm, 300A) column and 
infused into an LTQ-Orbitrap (Thermo Scientific) via an ADVANCE ion source (Michrom) 
over a 2.5 hr linear gradient of increasing amounts of mobile phase B (0.1% formic acid, 
99.9% acetonitrile) from 2-45% at a 300 nl/min flow rate using an Eksigent nano-2DLC 
system. Xcalibur 2.4 software (Thermo Scientific) was used to control MS instrument 
settings. Mass spectrometry data was collected in automated fashion in data-dependent 
acquisition (DDA) mode. Full scan MS spectra were acquired in Fourier transform mode, 
at resolution = 60,000 FWHM, between 300 and 1,200 m/z. Peptides were fragmented 
using pulsed-Q dissociation (PQD) in ion trap (IT) mode, at a relative collision energy 
(CE) setting of 31. Q (rf) settings and activation times were 0.55 and 0.4ms, respectively, 
with the number of ions for an MS/MS spectrum set at 40,000 and the maximum injection 
time at 200ms, with 2 microscans in MS/MS mode and repeat counts of 2. These settings 
were adapted from work by the Kuster group (Bantscheff et al 2008).
3.2.2.5. Proteomic data analysis
LC-MS/MS data files (*.raw) were transferred to Bioworks 3.3.1 (Thermo
Scientific) to identify peptides using the SEQUEST search algorithm. The spectra were
searched against the IPI.MOUSE.v3.59 database using the following search criteria:
maximum allowed missed cleavages for trypsin, 2; fixed modifications of +57.02146 for
iodoacetamide-modified cysteine residues; variable modifications of +144Da for iTRAQ-
labeled peptide N-termini and lysine side chains; and fixed modifications o f+15.99491 for
oxidized methionine. The resulting Bioworks. SRF files were converted to .OUT
and .DTA files to import the results into the Trans Proteomic Pipeline (TPP) v 4.2 software
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where peptides (and their corresponding proteins) were quantified using the Libra feature 
of the TPP software and reference ions were set as 114.1, 115.1, 116.1, and 117.1. The 
PeptideProphet feature of the TPP software was used to calculate a probability value for 
each peptide and these probabilities were used to set a false discovery rate (FDR) of 0.05. 
Peptides with a probability value equal to or lower than this cutoff value were exported to 
Excel. The Excel files were imported to JMP (SAS) 8.0.2 for data cleaning and statistical 
analysis as described below.
For data cleaning, reporter ion counts below 20 were assigned a value of zero;
peptides that did not yield any ion count for any of the iTRAQ labels were deleted.
Proteins identified with 2 or more peptides were used for the quantitative analysis and
those identified by a single peptide were only included in the analysis if the same peptide
was identified in multiple biological replications. All reporter ion peak intensities were In
transformed to make intensity data additive, and the loading bias was removed by mean
normalization on each replication and label. MS data were analyzed by Analysis of
Variance (ANOVA) using models adapted from Hill and colleagues (Hill et al 2008) that
were crafted specifically for iTRAQ experiments. Briefly, a linear mixed model was used
where mouse was treated as a random variable, whereas exposure was treated as a fixed
variable. ANOVA of the quantitative dataset identified proteins for which the variable
“exposure” was significant. All proteins that showed statistically significant (p < 0.05)
response to exposure to the GW agents were analyzed using the Ingenuity Pathways
Analysis (IPA, Ingenuity® Systems, www.ingenuitv.com) software. These analyses were
conducted as described elsewhere (Abdullah et al 2011). Briefly, the Ingenuity
knowledgebase comprises a repository of proteins/genes that are grouped based on
biological interactions and functional relationships. Once a dataset is uploaded to IPA (e.g.,
brain proteins demonstrating expression changes in response to GW agent exposure), the
proteins are mapped onto biological functions and pathways in IPA from which the
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biological relevance of the response can be inferred. Assignment of each uploaded protein 
to particular biofunctions and pathways is determined by the IPA using published literature 
and scientific databases. The IPA uses a right-tailed Fisher’s exact test to calculate a p- 
value to determine the probability of whether each biofunction and/or disease assigned to 
that dataset is due to chance alone.
3.2.3. Results
3.2.3.1. Quantitative proteomic studies of brain samples from GW agent exposure model B 
Proteomic studies conducted using iTRAQ LC/MS analyses at post-exposure day 
150 identified and quantified 1,089 proteins from 114,767 spectra. Figure 3.2 shows an 
example of MS data from an iTRAQ labeled peptide from a mouse brain lysate. 
Subsequent ANOVA showed that 31 proteins were differentially expressed in response to 
exposure, of which 8 were upregulated and 23 were downregulated (see
(A)
(B)
(C)
Images of MS spectra 
Figure 3.2
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Figure 3.2. Example of MS data from iTRAQ labeled peptide from mouse brain 
lysate reveals differential expression of FXYD protein. Pictured are (A) base peak 
LC/MS chromatogram, (B) full-scan MS spectrum in high resolution (Fourier 
Transform) mode and (C) the PQD MS/MS spectrum from the 976.82 m/z precursor ion 
(indicated by a red diamond). Expanded from the MS/MS spectrum are the iTRAQ 
reporter ion peaks (circled region and blown-up insert) from which the quantitative 
measurements were made, while the 200 -  2000 m/z range of the spectrum contains the 
amino acid sequence-informative fragment ions. Note: though the relative intensity of 
the reporter ions on the MS/MS spectrum is low (-1%) relative to those observed using 
beam-type fragmentation, these are typical for 2D trap fragmentation of iTRAQ labeled 
peptides. To ensure statistically-relevant ion counts of the reporter fragments for 
quantification and to account for the insufficient fragmentation efficiency observed in 
PQD MS/MS spectra, 40,000 precursor peptide ions were accumulated in the trap prior 
to fragmentation. Note, image already published (Abdullah et al 2011).
Table 3.1). Based on fold-change, the top five upregulated molecules were histidine triad 
nucleotide binding protein 2, vinculin, nucleophosmin, UBX domain protein 6 and 
propionyl CoA carboxylase. The top five downregulated molecules included isoleucyl- 
tRNA synthetase, growth hormone 1 (GH), proteasome subunit alpha type 2 and adaptor- 
related protein complex 1 sigma 1 subunit. Two of the 31 proteins were unnamed proteins 
and were not mapped in IPA; the remaining differentially-expressed named proteins (n = 
29) with a protein/gene ID were further examined using IPA. The biofunctions identified 
by IPA to be significantly associated with these molecules are presented in Figure 3.3. 
Lipid metabolism, molecular transport, the endocrine system and the nervous system were 
among the top five biofunctions.
3.2.3.2. Quantitative proteomic studies of plasma samples from GW agent exposure 
model B
Plasma samples were also analyzed from the mice euthanized at 150 days post-exposure.
A total of 198 proteins were identified from 18,034 spectra. Of these, 23 proteins (Table
3.2) were significantly different between GW agent exposed mice compared to controls. A
total of 9 proteins were downregulated and 14 were upregulated. Ingenuity Pathways
Analysis software was used to examine the functional relevance of differentially expressed
proteins. The top five molecules included CAS1 domain containing 1 (CASD1),
apolipoprotein A (APOA1), immunoglobulin heavy constant p (IGHM), Carboxylesterase
1G (Ceslg) and Igh-la Igh protein (Ighg2a). The proteins that were significantly
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Table 3.1. GW-agent induced differentially expressed proteins in the brain
IPI Accession 
No. Entrez Gene Name
P-
value
Fold
change Xype(s)
IPI00133034.3 Histidine triad nucleotide binding protein 2 0 .0 0 2 .2 1 Other
IPI00405227.3 Vinculin 0.04 1.97 Enzyme
IPI00127415.1 Nucleophosmin 1 0.03 1.82
Transcription
regulator
IPI00121151.1 UBX domain protein 6 0.04 1.71 Other
IPI00330523.1 Propionyl Coenzyme A carboxylase, a polypeptide 0.04 1.71 Enzyme
IPI00133224.1 FXYD domain containing ion transport regulator 6 0 .0 2 1.77 Ion channel
IPI00831256.1 Unc-13 homolog C 0.04 1.93 Other
IPI00415908.4 Protein phosphatase methylesterase 1 0 .0 1 1.64 Enzyme
IPI00115085.1 Inositol(myo)-l(or 4)-monophosphatase 1 0 .0 2 -1.03 Phosphatase
IPI00329927.4 Neurofascin homolog 0.04 -1.04 Other
IPI00230124.5 Fatty acid binding protein 3, muscle and heart 0.05 -1.04 Transporter
IPI00321919.1 G protein-coupled receptor 56 0.05 -1.04 GPCR
IPI00338094.6
Bone morphogenetic protein receptor, type II 
(serine/threonine kinase) 0 .0 2 -1.05 Kinase
IPI00857233.1 Glia maturation factor, beta 0.04 -1.05 Growth factor
IPI00331066.6 Calbindin 1, 28kDa 0.03 -1.05 Other
IPI00134191.3
Solute carrier family 2 (facilitated glucose 
transporter), member 3 0 .0 1 -1.05 Transporter
IPI00284505.1 Cadherin, EGF LAG seven-pass G-type receptor 3 0.03 -1.06 GPCR
IPI00471348.3 Not available 0 .0 2 -1.06 Other
IPI00319406.6 EF-hand domain (C-terminal) containing 1 0.05 -1.06 Other
IPI00762293.2 Chromobox homolog 7 0 .0 0 -1.06 Other
IPI00123223.2 Vlurinoglobulin 1 0 .0 1 -1.07 Transporter
IPI00755154.7 Leiomodin 3 (fetal) 0 .0 0 -1.07 Other
1PI00221615.5 ADP-ribosylation factor 5 0.05 -1.08 Transporter
IPI00114416.1 Godecenoyl-Coenzyme A delta isomerase 0.04 -1.08 Enzyme
IPI00314054.3 Solute carrier family 6 , member 6 0.03 -1.09 Transporter
IPI00127930.1 Guanine nucleotide binding protein, beta 5 0 .0 1 - 1.11 Enzyme
IPI00118026.1 Adaptor-related protein complex 1, sigma 1 subunit 0.03 - 1.11 Transporter
IPI00890001.1 3roteasome subunit, alpha type, 2 0 .0 2 -1.16 Peptidase
EPI00129161.1 Growth hormone 1 0 .0 1 -1.08 Hormone
IPI00271869.1
Glyceraldehyde-3 -phosphate dehydrogenase 
aseudogene 0.03 -1.03 Other
IPI00225201.5 soleucyl-tRNA synthetase 0.03 -1.89 Enzyme
Note: A list consisting of IPI accession numbers, names, types and p-values for proteins shown to be differentially 
expressed in response to GW agent exposure. A ratio of In-transformed value for each protein was calculated for 
GW agent exposure/control and the corresponding fold change is indicated using color, where red indicates up- 
regulation and blue indicates down-regulation.
modulated at 150 days post-exposure to PB+PER compared to control were associated 
with biofunctions (see Figure 3.4) that regulate immune parameters, such as immune cell 
trafficking, inflammatory responses, immunological disease, humoral immune response
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Ingenuity analyses based biofunctions 
Figure 3.3
Threshold
Figure 3.3. IPA based biofunctions: Brain proteins (n = 5 per group) that were 
differentially expressed in response to GW agent exposure were further interrogated using 
IPA and a "Core Analysis" was performed. Line designated by the term “threshold” 
indicates statistical significance cut-off of -log (p-value) of 1.5 or below. This figure 
represents biofunction categories differentially regulated in response to GW agent 
exposure at post-exposure day 150, a timepoint which immediately followed observations 
of cognitive impairment. Note: Image already published (Abdullah et al 2011).
and antigen presentation. Other related biofunctions included neurological diseases and 
lipid metabolism.
3.2.4. Discussion
Given the heterogeneity of GW exposures, symptom profiles vary with different 
exposures and produce a complex clinical presentation. As described in Chapter 2 above, 
mouse model B of GW agent exposure (PB+PER) demonstrates cognitive and 
psychomotor-based CNS symptoms; such symptoms are also observed in veterans with 
GWI (Binns et al 2008). Given the complexity of the clinical presentation observed in 
veterans with GWI, it is possible that biological changes that correlate with these 
symptoms are also complex. It is expected that the proteomic findings that are discussed 
below may provide a global view of the underlying biological disturbances associated with 
GW agent exposure.
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Table 3.2. GW-agent induced differentially expressed proteins in plasma
IPI accession 
number Entrez Gene Name p-value
Fold
Change Type(s)
IPI00222011.1 Chromosome 9 open reading frame 43 0.01 -1.71 Other
IPI00896683.1
Immunoglobulin heavy chain (gamma 
polypeptide) 0.01 -1.33 Other
IPI00457431.1 Ig heavy chain V-III region U61 0.04 -1.32 Other
IPI00109876.1
Growth Factor receptor(GRB)-bound protein 
2-related adaptor protein 0.01 -1.15 Other
IPI00473912.4 GRB10 interacting GYF protein 2 0.02 -1.11 Other
IPI00420972.2 Immunoglobulin heavy constant gamma 2A 0.00 -1.10 Other
IPI00227455.2
Potassium channel tetramerisation domain 
containing 8 0.04 -1.10 Other
IPI00128030.1
Antigen p97 (melanoma associated) 
identified by monoclonal antibodies 133.2 
and 96.5 0.05 -1.07 Other
IPI00128484.1 Hemopexin 0.00 -1.04 Transporter
IPI00308213.3
Immunoglobulin heavy constant gamma 1 
(Glm marker) 0.01 1.04 Other
IPI00123920.2
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 0.00 1.06 Other
IPI00131830.1
Serine (or cysteine) peptidase inhibitor, clade 
A, member 3K 0.00 1.08 Other
IPI00139788.2 Transferrin 0.00 1.09 Transporter
IPI00123223.2 Murinoglobulin 1 0.03 1.17 Transporter
IPI00114958.1 Kininogen 1 0.01 1.20 Other
IPI00121209.1 Apolipoprotein A-I 0.04 1.20 Transporter
IPI00624663.3 Pregnancy zone protein 0.00 1.21 Other
IPI00322463.3 Apolipoprotein H (beta-2-glycoprotein I) 0.02 1.22 Transporter
IPI00115867.4 Carboxylesterase 1G 0.02 1.30 Enzyme
IPI00177214.2 Immunoglobulin heavy constant mu 0.00 1.30
Transmembrane
receptor
IPI00556788.1 Immunoglobulin heavy constant gamma 2A 0.00 1.73 Other
IPI00856876.1 CAS1 domain containing 1 0.03 1.79 Enzyme
IPI00877236.1 Apolipoprotein A-I 0.00 1.91 Transporter
Note: A list consisting of IPI accession numbers, names, types and p-values for proteins shown to be differentially 
modulated in plasma in GW agent exposed mice compared to control mice. A ratio of ln-transformed value for each 
protein was calculated for GW agent exposure/control and the corresponding fold change is indicated using color, 
where red indicates up-regulation and blue indicates down-regulation.
Proteomic findings from brain and blood support a role of immune and 
inflammatory dysfunction in the pathogenesis of GWI and are also supported by 
neuropathology data presented in Chapter 2. For instance, in plasma APOA1 was 
increased by 1.6 fold and was associated with modulating immune responses after
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Figure 3.4
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Figure 3.4. IPA based biofunctions: Plasma proteins (n = 5 for each of the exposed and the 
control group) that were differentially expressed in response to GW agent exposure to mice in 
model B were further interrogated using IPA and a "Core Analysis" was performed. Line 
designated by the term “threshold” indicates statistical significance cut-off of -log(p-value) 1.5 
or below. The figure above represents biofimction categories modulated in response to GW 
agent exposure at post-exposure day 150, a timepoint that immediately followed observations 
of cognitive impairment. A number of humoral and cellular immunity related biofimctions 
were affected in response to GW agent exposure.
exposure to GW agents. As expected, the humoral immune response was only present in 
plasma but not in the brain. In both blood and brain, biofunctions that were modulated in 
response to GW agent exposure included immune cell trafficking and inflammatory 
response. A number of studies have shown that each PB and PER can modulate both the 
cell-mediated and humoral immunity (Peden-Adams et al 2004; Punareewattana et al; 
Prater et al 2005). Administration of PER to mice is shown to affect cell-mediated 
immunity by depressing splenic T-cell proliferative response and thymic cellularity, as well 
as affecting humoral responses by reducing splenic B lymphocyte-specific antibody 
production (Prater et al 2002; Prater et al 2003). Exposure to PB is shown to affect 
humoral immunity where responses to IgM antibody were dampened in mice after 14 days 
of PB exposure. These findings are in agreement with the evidence of immune dysfunction 
observed in veterans with GWI. Several studies report a persistent Thl immune response 
(pro-inflammatory cytokine production by Type-1 T-helper cells) that is accompanied by
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an increased expression of the pro-inflammatory cytokines on CD4 T-cells in veterans with 
GWI (Skowera et al 2004). Although Th2 immune response (reflected by production of 
anti-inflammatory cytokines by Type-2 T-helper cells) was observed in blood of veterans 
with GWI compared to well-veterans from GW era (Broderick et al 2011). Low CD3 T- 
cell and natural killer cell counts have been observed in ill veterans (Zhang et al 1999; 
Whistler et al 2009). These studies clearly support a role of immune/inflammation 
imbalance with respect to GW agent exposure and are currently being evaluated as a new 
line of investigation at the Roskamp Institute aimed at characterizing immune/ 
inflammation profiles associated with GW agent exposure (PI: Ait-Ghezala, CDMRP 
award).
Fatty acid binding proteins
Lipid metabolism was also one of the biofunctions shown to be affected in both the 
brain and blood of mice exposed to GW agents. Among the proteins associated with lipid 
metabolism, of particular interest is the observation of a reduction in fatty acid binding 
protein 3 (FABP3) in the brain of GW agent exposed mice. Fatty acid binding protein 3 is 
expressed in neurons within the hippocampus and cortex (Motohashi et al 2009). Clinical 
studies suggest that FABP3 levels are decreased in the brain but increased in the CSF and 
serum of patients with neurocognitive disorders (Chiasserini et al 2010; Wada-Isoe et al 
2008). FABP3-deficient mice show increased fear and anxiety, also observed in GW agent 
exposed mice. Therefore, the observed decrease in FABP3 provides evidence for a 
dysregulation of lipid metabolism in response to GW agent exposure. Furthermore, 
FABP3 is involved in the uptake of AA (Murphy et al 2005). Metabolites of AA have a 
well-defined role in propagating inflammation, and thus it can be hypothesized that 
changes in lipids and lipid metabolites may be of importance in understanding the 
pathobiology of GWI.
Apolipoproteins
In blood, lipid metabolism was also modulated in response to GW agent exposure. 
In particular, lipoproteins, APOH and APOA1, were associated with this biofunction and 
are highly relevant to lipid metabolism. For instance, APOA1 plays a critical role in 
cholesterol efflux by acting as a cofactor of lecithin-cholesterol acyltransferase (a 
phospholipase) and solubilizing phospholipids to facilitate cholesterol absorption (Phillips 
et al 1998). Apolipoprotein H, also known as beta2-glycoprotein 1, is shown to be an anti­
phospholipid antibody that is present in autoimmune diseases (Matsuura et al 2010; Yasuda 
et al 2000). Hence both brain and plasma proteomic profiling suggest that lipid metabolism 
may be affected in response to GW agent exposure.
Growth Hormone
Proteomic findings show lower GH levels in the brain of exposed mice compared 
to controls. Growth hormone (GH) is regulated by the neuroendocrine system and GH 
deficiency is associated with impaired cognition (Maruff, & Falleti 2005). Several studies 
suggest that the cholinergic system controls ghrelin induced GH release where a number of 
studies have shown that administration of pyridostigmine can increase circulating GH 
levels (Broglio et al 2004) (Ghigo et al 1990). Therefore, additional evaluation of the 
molecular pathways associated with GH may be helpful in providing an understanding of 
the pathobiology of GWI.
These exploratory proteomic studies provided a global view of the biological
changes and identified key areas of focus. However, additional validation of these studies
is required using alternative techniques, such as western blot or ELISA (where available).
Immune/inflammatory-based changes identified are consistent with current GWI research
and this aspect of GWI is being investigated as a separate project at the Roskamp Institute
which is geared towards discovery and validation of novel treatments against CNS
symptoms of GWI. Findings pertaining to lipid metabolism provide a novel avenue for
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exploration, particularly since lipid metabolites are upstream of many inflammatory 
cascades. Further evaluation of lipid changes using lipidomic approaches are presented in 
the next chapter of this thesis.
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4.0. Chapter 4 Application of lipidomics technology to lipid profiling of 
mice exposed to GW agents
The studies presented in this thesis reflect the lipidomics work performed as part of 
the implementation of the lipidomics platform at the Roskamp Institute and also provide 
data which will be helpful in increasing the awareness of the role that lipids play in the 
CNS disorders. Given that the proteomic findings in Chapter 3 suggested that lipid 
metabolism pathways may be affected in response to GW agent exposure, the primary 
focus of the lipidomics work was to understand lipid changes in relation to GW agent 
exposure. Therefore, lipidomics technology was applied to examine brain and blood 
samples from mouse models of GW agent exposure. Lipid profiling was performed on the 
brain and blood samples from mouse models of other neurological illnesses (in comparison 
to their respective control groups) to determine if phosphatidylcholine (PC) and 
sphingomyelin (SM) profiles of GW agent exposed mice were distinct from those observed 
in mouse models of other neurological conditions. Lipid profiles from mouse models of 
GW agent exposure were further interrogated to identify molecular pathways that may 
underlie the CNS symptoms associated with GW agent exposure and whether these 
pathways are targetable by therapies.
4.1. Introduction
4.1.1. Lipid characteristics
Glycerophospholipids and sphingomyelin together are defined as phospholipids 
(PLs) and represent 20-25% of the dry weight of the adult brain and nearly 60% of the 
neuronal membrane mass (Farooqui et al 2007). Phospholipids have side chains that are 
linked to a backbone composed of either a glycerol or a sphingosine (in the case of 
sphingomyelin only) and also contain a phosphoric acid and a polar head-group. 
Phospholipids are amphipathic molecules that have both polar and non-polar components
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and can be further divided into subclasses, such as PC, phosphatidylethanolamine (PE), 
SM, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA) and 
phosphatidylglycerol (PG). Each PL subclass has a unique polar head-group. For example, 
PC and SM both contain a choline moiety in their head-groups, while PE has 
ethanolamine, PS has serine and PI has an inositol group.
Within each PL class, there are a large number of distinct molecular species, which 
arise from a combination of different fatty acid side chains with various head-group 
structures. It is estimated that a mammalian lipidome may contain about 3000 distinct PL 
species (Brouwers 2011). The polar end is charged due to the presence of a phosphate and 
sometimes a nitrogenous base. In a lipid bilayer, the PLs are organized in a way where the 
polar head-groups of PLs face the intracellular and extracellular spaces of the lipid bilayer 
and the hydrophobic side chains are packed within the inter-membrane faces of the lipid 
bilayer. These hydrophobic chains are connected to glycerol of PL through acyl, alkenyl 
and alkyl bonds. In general, the first position of the glycerol backbone (snl) contains 
saturated fatty acid (e.g., palmitic or stearic acid) and the second position of the glycerol 
backbone (sn2) contains unsaturated fatty acids, such as AA and DHA (Farooqui et al
2007). Among other things, the degree of saturation of these lipids affects membrane 
fluidity where an increase in saturated lipids would make it more viscous but an increase in 
unsaturated lipids would increase membrane fluidity (Farooqui et al 2007). Figure 4.1 
shows examples of PL and ether PL (ePL) structures.
4.1.2. Lipid role in cellular function and signaling pathways:
Cellular PLs have a key role in maintaining structural function and integrity of the
membrane. The lipid bilayer, much of which is composed of PC and SM, maintains the
integrity of the cell membrane. Fluidity of this lipid bilayer is critical in allowing passage
of certain molecules and solutes in and out of the cells. Membrane permeability is affected
by an increase in saturation of fatty acid chains, making it more rigid and less fluid
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(Tymoczko et al 2012). Phospholipids also play an important role in membrane fusion, 
which is a critical requirement of many cellular processes including fertilization, cell 
division, exocytosis, endocytosis and intracellular membrane transport. Phospholipids also 
form specialized subcellular structures and are essential for proper functioning of 
membrane bound proteins (Adibhatla, & Hatcher 2008; Wenk 2005).
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Figure 4.1. Images of phospholipids: (A) An image of diacyl PL containing ester linked 
fatty acid side chains connected to a glycerol backbone and a phosphate group that 
combines with different polar head-groups (R). Each fatty acid side chain can vary in 
carbon numbers, generally even numbers from 14-22 carbons with various double bonds. 
Fatty acid side chain 1 (Cl6:0 - containing 16 carbons and no double-bond) is connected 
to the first carbon in the glycerol backbone and fatty acid side chain 2 (Cl8:2 - containing 
18 carbons and 2 double bonds) is connected to the second carbon in the glycerol 
backbone. (B) Examples of different polar head-groups include glycerol, inositol, 
choline, serine and ethanolamine. (C) A cross-section of plasma membrane. Polar 
headgroups are present in the intracellular and extracellular sides where fatty acid side 
chains are sandwiched between them in the hydrophobic region of the lipid bilayer. (D) 
An example of ether PC that contains O-alkyl linked ether bonds at the sn-1 and ester 
linkage at the sn2 position. (E) An example of plasmalogen PC which contains a vinyl 
ether at the snl and an ester linkage at the sn2 position.
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Over the last few decades, fundamental discoveries have been made with regard to 
the role that PLs and their metabolites play in a variety of biological functions and cellular 
signaling pathways. One of the most important discoveries pertains to arachidonic acid 
(AA - an omega-6 fatty acid/fatty akyl where the final carbon-carbon double bond is at the 
6th carbon position from the terminal methyl group), which is liberated from PL by 
phospholipase A2 (PLA2). Subsequent metabolism of AA to prostaglandins and 
leukotrienes (collectively referred to as eicosanoids) is facilitated by the enzymatic activity 
of cyclooxygenase (COX) and lipooxygenase (LOX), respectively. The eicosanoids are 
upstream of pro-inflammatory pathways and have been widely targeted for therapeutic 
modulation of inflammation, including the use of COX inhibitors (Adibhatla, & Hatcher
2008). More recently, similar enzymatic pathways for DHA, an omega-3 fatty acid (where 
the final carbon-carbon double bond is at the 3rd carbon position from the terminal methyl 
group), have been shown to generate anti-inflammatory mediators, such as resolvins and 
protectins. These bioactive DHA metabolites can resolve inflammation at low nanomolar 
concentrations (Serhan et al 2008). See Figure 4.2 for a schematic presentation of PL 
metabolism pathways.
Lysophopholipids (LPL) are generated by the action of phospholipases on PLs and 
a number of these are novel mediators of inflammatory and immune responses. Among 
these, LPC is the most abundant LPL and is shown to affect immune cell functioning. 
There is a high concentration of LPC in blood but most of it is found bound to serum 
albumin and lipoproteins (Kabarowski 2009). A review of the literature suggests that LPC 
is capable of eliciting both pro- and anti-inflammatory (mixed inflammatory) responses 
where acyl LPCs (LPC16:0 and LPC18:0) have been shown to increase expression of 
CD40 (which belongs to the TNF-a super family) in mature dendritic cells and cause an 
upregulation of inflammatory and/or anti-inflammatory cytokines (Bach et al 2010).
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Figure 4.2. Image of phospholipid metabolic pathways: (A) This image shows that PL can be 
metabolized by PLA2 which can generate AA, DHA and LPCs. Arachidonic acid can be further 
metabolized by COX and LOX to generate prostaglandins and leukotrienes. Prostaglandins and 
leukotrienes are further metabolized to produce thromboxanes and lipoxin, respectively. 
Docosahexaenoic acid can be enzymatically converted to protectins or to resolvins via the LOX 
pathway. Upon action of PLA2 on PC, certain LPC products are converted to PAF.
Treatment with LPC16:0 and LPC18:0 in vitro resulted in an increase in IFN-y, a pro- 
inflammatoiy cytokine (Thl), and an increase in IL-13 (Type Th2) and IL-5 (Type Th2), 
both of which are considered anti-inflammatory cytokines. In vivo, an increase in the 
production of IL-6 (Thl/Th2) and IL-5 was reported in response to LPC16:0 and LPC18:0 
exposure (Bach et al 2010). In addition, LPC16:0 or LPC20:2 can cause secretion of GM- 
CSF from natural killer cells (Fox et al 2009). Collectively, these studies suggest that 
metabolites of PC can modulate both immune and inflammatory responses and may 
represent upstream targets of these biological functions.
There are two varieties of PLs, those that contain acyl chains at both the sn-1 and 
sn-2 positions and those that are ether lipids which contain either O-alkyl or O-alk-l-enyl, 
specifically at the snl position (Vance, & Vance 2008). In general, ether PLs are abundant
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in PC and PE and the presence of ether bonds allows for a tighter packaging of these lipids 
in cell membranes. Ether PLs are thought to play a role in membrane reorganization and 
vesicle formation. Among ether PLs, plasmalogens are those that contain O-alk-l-enyl at 
snl, generally contain more polyunstaturated fatty acids (PUFA) and play a role in 
cholesterol esterification and maintenance of myelin covered axonal nodes (Mankidy et al 
2010; Gorgas et al 2006). A deficiency of the plasmalogen content within PL is considered 
to be a prominent feature of several CNS disorders, including Niemann Pick type C disease 
(NPCD), Zellweger’s disease (ZD) and AD (Gorgas et al 2006).
Another lipid metabolite, PAF, was originally named due to the initial discoveries 
showing that it was released from Immunoglobulin E (IgE) stimulated basophils and 
caused aggregation of platelets. This bioactive lipid is now shown to be present in a 
number of cells and can be produced in the brain via de novo synthesis or remodeling 
pathways which consist of biochemical reactions involving PLA2 and acetyltransferase 
(MAclennan KM et al 1996). Studies have shown that PAF can affect a number of 
physiological and biological functions, such as BBB permeability, inflammation and ACh 
release (MAclennan KM et al 1996).
In summary, cellular signaling mediated by these lipids and their metabolites is 
upstream of several key intracellular cascades in biological functions, which include 
modulation of inflammatory and immune responses. Therefore, examination of PLs and 
their metabolites represents a highly relevant area for further examination of 
neurobehavioral and neuropathological features of GW agent exposure.
4.1.3. Lipidomics technology
The advances in lipid research have been greatly facilitated by recent developments
in MS instrumentation and techniques that allow accurate identification and quantification
of several thousands of lipids and their molecular subspecies in complex biological
samples with relative ease. MS-based lipidomic approaches have largely displaced other
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methods for lipid analysis because of their higher sensitivity, information content and 
efficiency (Brouwers 2011).
Individual PLs and their molecular species can be identified and quantified using 
LC/MS (Brouwers 2011). A number of approaches are available that rely solely on mass 
spectrometry, but use of LC/MS is particularly advantageous since it allows for the 
separation and quantification of PLs in much higher detail than that achievable by using 
MS alone (Brouwers 2011). While an LC-free shot-gun lipidomics approach is quicker, ion 
suppression, particularly for shot-gun methods that employ direct infusion of crude 
extracts, can become troublesome and reduce accurate detection of molecules that don’t 
compete well for the charge during the ionization process. In these shot-gun methods, ion 
suppression by other molecules in the biological matrix that can carry the charge better 
than PLs is also a problem for accurate detection and quantification of PL. On the other 
hand, use of normal phase LC in conjunction with MS separates PL subclasses based on 
the polarity of their head-group which is tremendously useful in resolving issues pertaining 
to ion suppression. Many of the commonly used chromatographic procedures published 
today are based on work from the early 1990s, which applied a binary gradient using a 
combination of hexane, 2-propanol and water as mobile phase with increasing water 
amounts to achieve separation of major PLs within 20 minutes. However, these studies 
were limited by poor run-to-run reproducibility, which was possibly due to the absence of 
chemicals to prevent column degradation (Brouwers 2011). In recent years, a number of 
these difficulties have been overcome by the use of varying combinations of chloroform, 
methanol and buffered ammonium hydroxide to improve separation, and with the use of 
diol-modified silica to achieve greater stability and quicker regeneration of the stationary 
phase (Brouwers 2011).
The experiments detailed in this thesis not only take advantage of these advances in
LC/MS methods, but also use a novel approach of applying in-source collision induced
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dissociation (SCID) to generate partial fragmentation of lipids to obtain structural 
information during the full scan mode of data acquisition. This method is tremendously 
useful in (1) the quantification of molecular species with overlapping mass-to-charge ratios 
(m/z) across different classes of PL and (2) reducing the number of LC/MS/MS runs 
required for the identification of individual molecular species. With this SCID LC/MS 
approach, separation, identification, and quantification of the seven major PL classes and 
SM can be accomplished in a single experiment. In addition, identification and 
quantification of dozens of molecular species over a 1,000 fold concentration range can be 
obtained within each class of PL.
Given that the chemicals that were used to develop mouse models of GW agent 
exposure affect ACh turnover and ACh-related signaling pathways, PLs that contain 
choline represent relevant targets to explore in the pathobiology of GWI. 
Phosphatidylcholine and SM (both containing choline in their head-groups) were 
characterized using this novel SCID LC/MS approach. Studies described in this Chapter 
include comparisons of brain and blood from mouse models of GW agent exposure with 
their respective control groups. Phosphatidylcholine and SM in brain and blood samples 
from mouse models of other CNS illnesses (AD and Traumatic Brain Injury [TBI]) were 
also examined in order to understand how lipid changes may overlap or differ between 
these mouse models and models of GW agent exposure. Based on this lipidomic-based 
target identification approach, a pilot study was conducted to determine if lipid 
abnormalities can be normalized with treatments that affect lipid metabolism and whether 
such treatments can normalize lipid metabolism dysfunction associated with GW agent 
exposure.
4.2. Materials and methods
4.2.1. Mouse models
Whole brain homogenates from mouse models A (n = 5 per exposure/control) and B 
(n = 4 per exposure/control) of GW agent exposure were prepared as described above in 
Chapter 3. Brain extracts were from the same mice on which exploratory biomolecular 
(mouse model A) and proteomic studies (mouse model B) were conducted. The post­
exposure interval for mouse model A was 42 days (approximate age 4 months) and for 
mouse model B (CD1 mice) it was 150 days (approximate age 7 months). Both brain and 
plasma samples were analyzed for mouse model A and mouse model B of GW agent 
exposure. A mouse model of AD (PSAPPswe mice containing both the Swedish mutation 
K595N/M596L in APP and the M146L Presenilin [PS] mutation) was used for comparing 
AD-dependent lipidomics changes against GW agent dependent lipidomic changes. Six- 
month old PSAPPswe mice were compared to B6SJL/F1 wild-type mice (n = 5 per group), 
a timepoint at which the PSAPPswe mice have high brain levels of soluble and insoluble 
Ap levels and show Thioflavin S positive plaques and astrocytosis (Kumar-Singh et al 
2005; McGowan et al 1999). Only brain samples were available for lipidomics analyses 
from this AD mouse model.
The other comparison groups included two mouse models of Traumatic Brain 
Injury (TBI), one that received controlled cortical impact (CCI) and another which 
received a closed head injury (CHI) which mimics mild TBI (mTBI). Administration of 
CCI TBI to mice is described in detail elsewhere (Crawford et al 2012). Briefly, mice were 
administered anesthesia at lL/min O2 mixed with 3% isoflurane. Once each mouse was 
deeply anesthetized, it was individually mounted in a stereotaxic frame and the 
temperature was monitored throughout the surgery. A midline incision was made, followed 
by a 5-mm craniectomy that was adjacent to the central suture, midway between lambda
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and bregma, with the dura kept intact over the cortex. A single severe injury was 
administered as reported (Crawford et al 2012) using an electromagnetic device and an 
injury was delivered to the right cortex with a 3-mm diameter tip at a rate of 5 m/sec and 
depth of 1.8mm. Sham mice for the CCI procedure received anesthesia and craniectomy 
without receiving an injury. For the lipidomic studies described below, 8 mice were 
utilized (n = 4 per group), the injury was administered at 3-months of age and a post-injury 
timepoint of 3-months was examined (approximate age 6 months). Lipidomic studies were 
performed on both brain and plasma samples.
For mTBI studies, the same equipment was used but injury was delivered as a 
closed head injury on the midline at a lesser force than CCI to avoid skull fracture 
(Mouzon et al 2012). The injury was administered to the head using a strike velocity of 
5m/s, a strike depth of 1.0mm and dwell time of 200ms. Animals either received a single 
mTBI (s-m-TBI) or repeated mTBI (r-mTBI) for which additional injuries were 
administered at days 3, 5, 7 and 9 after the original injury. A control group for each injury 
was used where single anesthesia (s-sham) and repetitive anesthesia (r-sham) was 
administered to derive matching groups for comparison. This mTBI injury was 
administered to 10-week old C57BL6 male mice (n = 3/4 per injury/sham). Mice were 
euthanized after the 24hrs post-injury timepoint and only plasma samples were used for the 
lipidomic studies described below.
Based on the findings from lipidomics work aimed at pathway identification, pilot 
treatment studies were performed. A dihydropyridine calcium channel blocker (DHP- 
CCB), nilvadipine, was chosen based on the support from the literature showing an impact 
of this drug on opposing LPC induced adverse biological affects (Takayama et al 2009). 
As described in Chapter 2, it is anticipated that C57BL6 mice will be used for subsequent 
GWI work to be conducted at the Roskamp Institute, and thus this strain was chosen for
100
these studies. Included in the aims was the need to determine if the brain and plasma PL 
and SM changes observed in CD1 mice from mouse model B can be observed in this 
C57BL6 strain and whether nilvadipine treatment can normalize PL abnormalities (if 
observed in this strain) associated with GW agent exposure. Briefly, 0.7mg/kg of PB and 
200mg/kg of PER were administered to C57BL6 mice for 10 days while unexposed 
animals received vehicle (DMSO) only. At 3-months post-exposure (approximate age 6 
months), a subset of unexposed (n = 5) and exposed mice (n = 5) received i.p. nilvadipine 2 
mg/kg in 70% DMSO for 10 days while the control group received vehicle only (n = 4 
exposed, n = 5 unexposed). This dose of nilvadipine was chosen based on work conducted 
at the Roskamp Institute showing efficacy in AD mouse models without any toxic side- 
effects (unpublished work). Mice were immediately euthanized after 10 days of treatment 
and both brain and blood samples were analyzed for lipidomic analyses.
All animal procedures were approved by the Roskamp Institute IACUC and were 
conducted in accordance with the guidelines described in Chapter 2.
4.2.2. Lipidomic analyses
The Folch method (Folch et al 1957) was used to extract lipids from 50pl of crude
mouse brain homogenate in mammalian protein extraction reagent (Pierce, IL) for mouse
models A and B of GW agent exposure. For these two mouse models of GW agent
exposure, only the insoluble fractions were examined for lipidomic studies. One whole left
hemisphere was used for the PSAPPswe mouse model studies. For the CCI TBI mouse
model, lipids were extracted from each ipsilateral cortex, hippocampus and cerebellum
separately for injured mice and the corresponding hemisphere from sham mice. Each brain
region was homogenized separately in PBS and then lipids were extracted from 50pi of
homogenate from each region for each mouse. For plasma lipidomic studies, 50pl of
plasma was used for all mouse models. The Folch extraction was performed following an
addition of di-14:0 fatty acid PC and 14:0-LPC (Avanti Polar Lipids) as the internal
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standards (IS), at lpg/5pl concentration. The Folch lower (organic) phase was evaporated 
and redissolved in 2:1 chloroform-methanol for LC/MS analysis. For mouse model A and 
B and for PSAPPswe mice, each sample was analyzed by LC/MS in duplicate. All other 
samples (brain samples of mouse models of CCI TBI and plasma samples of mTBI and 
C57BL6 mouse model B of GW agent exposure) were analyzed in triplicate. Brain lipids 
from PSAPPswe and models A and B of GW agent exposure were eluted isocratically with 
hexane:2-propanol:water:formic acid-ammonium hydroxide (30:60:9:1:0.12, v/v) at a flow 
rate of 50pl/min using a 1mm x 10cm column packed with 3 pm Pinnacle II silica particles 
(Restek) maintained at 25°C. Additional methodological developments were subsequently 
performed to obtain a better separation of PLs. Subsequent to that, lipidomic analyses 
were performed for the experiments pertaining to brain and plasma samples from TBI 
mouse models and C57BL6 mouse model of GW agent exposure B. For these 
experiments, a solvent gradient was run from 10% solvent B (80% methanol, 10 mM 
formic acid, 5 mM ammonium hydroxide) in solvent A (chloroform-acetonitrile, 2:1) to 
60% B in 13 min with a 4 min hold at the final conditions. The flow rate and column 
specifics were same as above. Full scan MS analyses were performed using a Thermo LTQ 
linear ion trap mass spectrometer, which was equipped with a Thermo Surveyor pumping 
system and Micro AS autosampler. Alternate positive (40% relative energy) and negative 
(90% relative energy) ion spectra were acquired from m/z 70 to 1,200 with SCID. All 
spectra were obtained with a 200 msec maximum ion time and 5 microscans. The fatty acid 
composition of individual lipid molecular species was determined by separate DDA LC/ 
MS/MS analyses (1 full scan followed by 3 DDA scans of the most intense ions from the 
full scan, ions sampled were excluded from further analysis for 1 min, 30% relative CID 
energy, 3 microscans, 500 msec max injection time) under the above LC conditions. 
Spectra of PC and SM molecular species were located on the chromatogram using
retention time (RT) and m/z 184 ion plots to locate the fragment ion of the phosphocholine
head-group. These mass spectra were summed over the peak for each lipid class,
converted to listings with a threshold of 0.01% base ion intensity, exported to Microsoft
EXCEL and then analyzed using LipidomeDB on-line (Zhou et al 201 l)(http://
lipidome.bcf.ku.edu:9000/Lipidomics/I to identify and quantify (with reference to the
added internal standards) each lipid molecular species. Dimension reduction and multi-
collinearity issues were resolved using principal component analysis (PCA), which is
routinely used to evaluate lipidomic data (Graessler et al 2009). Variables with
eigenvalues of > 1 were retained and PCA was used for extracting components (a
composite variable that contains original lipid variables that are grouped based on
correlations of the original lipid outcome variables with each other and variance explained
in the dataset). The Anderson-Rubin method was used for exporting uncorrelated scores in
order to perform MLM regression analyses on each component (the outcome measure)
while adjusting for fixed (exposure and replication) and random (mouse) factors.
Additional analyses were also performed by grouping individual PC molecular species
based on the saturation status, where PC species containing saturated fatty acids (SFA),
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) were each
grouped as separate variables. Statistical analyses were performed using MLM as
described above for these outcome variables.
4.2.3. Free fatty acid and 2-arachidonylglycerol quantification
Total brain homogenate from mouse model B of GW agent exposure was used for
quantification of free fatty acids (FFA) and 2-arachidonylglycerol (2AG) using reverse
phase LC (RPLC)/MS procedures. Brain homogenate (60pl) was diluted with 240pi of
PBS, followed by an addition of 700pl of ethanol. To this, lOOpg of 15-(S)HETE-ds
(Cayman Chemicals) was added as an IS. We used this IS as the goal was to expand the
RPLC method to include examination of FFA metabolites (i.e., prostaglandins, leukotrienes
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and resolvins). Next, the samples were vortexed for 1 min and heated at 80°C for 2 min, 
followed by centrifugation at 21,000 x g for 10 minutes. The supernatant was transferred 
to a new tube, mixed with 2 ml of hexane and then vortexed again for 1 min. This mixture 
was left to stand for 1 min to allow the phases to separate. The upper phase (hexane) was 
discarded and lower phase was taken to dryness using a speed vac. The dried lower phase 
was then resuspended in lOOpl of 75% methanol and 25% lOmM ammonium acetate 
(NHUOAc). For LC/MS analyses, free fatty acids were eluted using a solvent gradient of 
100% solvent A (lOmM NHUOAc) in pH 4.5 in 40% of 33% methanol (MeOH) in 
acetonitrile (ACN) and solvent B (33% MeOH in ACN) at 200pl/min using a 2.1mm x 
3pM Kinetix column packed with 2.6 pm C l8 particles (Phenomenex) maintained at 25°C. 
The gradient was maintained at 100% solvent A for 2 min. From 2-12.5 min a linear 
gradient was run to 70% B and then to 82% B from 12.5 min to 18 min. A reverse gradient 
to initial conditions was then run over the next 6 min. As above, LC/MS analyses were 
performed using a Thermo LTQ linear ion trap mass spectrometer. Full scan negative ion 
mode was used to quantify FFA. LC/MS/MS was performed for monitoring 2AG, where 
the m/z 379 MH+ precursor ion was isolated using an isolation width of 2.7 with CE of 
25V applied. The m/z 287.3 product ion was used to monitor 2AG. Similarly, LC/MS/MS 
was performed for monitoring the 15-(S)HETE-ds internal standard; m/z 327 was used for 
isolating product ion 227 using the same isolation width and CE as above. The total peak 
area of each analyte of interest was divided by the peak area for the IS for quantification. 
MLM regression was used for statistical analyses as described above for LC/MS.
4.3. Results
4.3.1. General lipidomics strategy
Figure 4.3 displays a chromatogram from an LC/MS run showing individual peaks 
for each PC, SM, PI, PE, LPE, and LPC subclasses of PL. As described in the methods
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section, m/z values corresponding to the fragment ions from each head-group were used to 
locate peaks for each PL class on the chromatogram. Use of m/z 184 (the phosphocholine 
fragment ion produced by SCID) in the positive ion mode assisted with identifying the PC, 
SM and LPC peaks. Similarly, PE and LPE were located on the chromatogram using m/z 
140 for phosphoethanolamine fragment ion. Phosphatidylinositols were identified using 
the m/z 241 phosphoinositol fragment ion. Figure 4.4A shows a spectrum of PC in the 
positive ion mode. This figure demonstrates that all PC molecular species in a run can be 
visualized on the chromatogram using m/z 184. Figure 4.4B shows that the use of SCID in 
the negative ionization mode yields a m/z 168 for the head-group of PC and provides 
additional information about the fatty acid composition of individual PC molecular species. 
This strategy facilitates localization of each PL class peak on the chromatogram and assists
SCID LC/MS lipidomic analysis
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Figure 4.3. Schematics of LC/MS lipidomics approach: A chromatogram of a LC/MS 
run showing PL identified in both the negative and positive ionization mode. In the top 
panel, all three phosphocholine moiety containing lipids, PC, SM, and LPC, were localized 
with m/z 184 on the chromatogram in the positive ionization mode. Similarly, PE and LPE 
peaks (3rd panel from the top) were localized using m/z 140 in the negative ionization 
mode. In the last panel, the PI peak was localized on the chromatogram using m/z 241 in 
the negative ionization mode.
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Figure 4.4. Schematics of LC/MS lipidomics approach: (A) MS spectra summed over 
the chromatogram in positive ionization scanning mode. Detection of PC and SM was 
facilitated using SCID to generate fragment ion m/z 184, corresponding to the 
phosphocholine head-group. The m/z 678.5 is the [M+H]+ ion for di-14:0 PC. (B) Summed 
MS spectra in negative ionization mode shows that SCID fragmentation can help 
distinguish between different subspecies of PC. The ePC(34:2) molecular species with 
[M-15]- m/z 742.6 contains a fatty acid (FA) C l8:2 corresponding to m/z 279.4 and FA 
C16:0 with [M-15]- m/z 255.4.
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with the identification of individual molecular species prior to performing an in-depth 
characterization using LC/MS/MS approach.
4.3.2. Profiling o f brain PC and SM from model A o f GW agent exposure:
Brain lipids from mouse model A exposed (n = 5 [3F, 2M]) and control (n = 5 [3F, 
2M]) were analyzed using a multivariate approach of PCA, which isolated 7 components, 
of which component 1 accounted for 41% of the total variance in the dataset and 
component 2 accounted for 23% of the variance. Based on MLM regression analyses, 
component 2 was significantly associated with GW agent exposure (F(i,i7) = 7.8, p = 0.01). 
Among 18 PC and SM molecular species in component 2, 11 were diacyl PC molecular 
species, 2 were very-long chain fatty acid (VLCFA > 22 carbons) containing SM and 5 
were ePC, of which 1 contained SFA and the remaining 4 contained MUFA. Figure 4.5 
shows all PC and SM species detected and those that were specific to component 2. 
Additional univariate analyses were performed, focusing on molecular species that were in 
component 2. Univariate analyses support PCA analysis as ePC(34:0), ePC(36:2), 
ePC(36:l), one diacyl PC(36:0) and PC(40:4), all factors of component 2, were 
significantly elevated in exposed compared to control mice. Figure 4.4 also shows an 
increase of a 24:0 dihydro sphingomyelin (DSM) in exposed mice compared to control 
mice. Figure 4.6 shows that among significantly modulated PC species, those containing 
MUFA were more abundant compared to those with SFA or PUFA. Identifications of PC 
molecular species associated with GW agent exposure for this model is presented in Table 
4.1 on page 143.
4.3.3. Profiling o f brain PC and SMfrom model B o f GW agent exposure
In mouse model B of GW agent exposure (n = 4 GW agent exposed and n = 4
controls), a different PC and SM profile was observed from that seen in model A. Total PC
(F(i,i3) = 7.87, p = 0.02) and total SM (F(i,i3) = 7.57, p = 0.02) were significantly increased
in the brain of exposed mice compared to control mice, see Figures 4.7A and B.
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Figure 4.5. Brain phospholipid changes for mouse model A of GW agent exposure: Mean ± 
SEM (n = 5 per group) of all of the PC and SM molecular species identified during the LC/MS 
analysis and those denoted by $ were associated with component 2. Within component 2, 
univariate MLM analyses showed that ether PC: ePC(34:0), ePC(36:2), ePC(36:l) were 
significantly higher in the exposed mice than in the controls. Species with LCFA, PC(38:1) and 
PC(40:4) were also elevated in exposed mice compared to controls, ^denotes p < 0.05 for a 
main exposure effect. PC(38:4) was marginally elevated in exposed vs. control, p = 0.08. A 
VLCFA containing DSM (24:0) was also significantly elevated in exposed mice vs. controls, 
^denotes p < 0.05 for the main exposure effect. Inserts contain lipids with different 
concentrations than those shown in the main image.
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Degree of unsaturation of brain PC for mouse model A of GW agent exposure
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■  Control
■  PB+PER+DEET+Stress
400
SFA MUFA PUFA
Figure 4.6. Degree of unsaturation of brain PC molecular species for mouse model 
A of GW agent exposure: Mean ± SEM (n = 5 per group) presented as percentage of 
control. Figure shows that among significantly modulated PC molecular species, MUFA 
containing PC were nearly 300% relative to controls, SFA containing species were 170% 
and PUFA were 143% in exposed relative to control animals, *denotes p < 0.05 for a 
main exposure effect (based on MLM where exposure was included as a fixed main 
factor).
Multivariate PCA showed that component 1 explained 44% of the variance, component 2 
explained 21% of the variance and component 3 explained 14% of the variance. 
Collectively, these three components explained the largest total variance within the data. 
Of these, component 3 was significantly associated with the exposure (F(i,io) = 16.2 p = 
0.002). Figure 4.8 shows the individual molecular species and demonstrates that most PC 
molecular species were increased in GW agent exposed mice compared to control mice. 
For component 3, although both diacyl and ePC were increased in exposed mice compared 
to controls, those with diacyl side chains were greatly affected, where 9 diacyl PCs were 
elevated but only 1 ePC was elevated. In addition, PC molecular species with long chain 
fatty acids (LCFA; 14-20 carbons) appeared to be affected. Figure 4.8 shows distribution
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of individual SM molecular species; none of the SM species were part of component 3. 
Examination of degree of unsaturation status of PC molecular species showed that 
molecular species containing SFA (F(i,i3) = 4.5 p = 0.06), MUFA (F(i,io) = 7.4 p = 0.02) and 
PUFA (F(i,12) = 16.2 p = 0.002) were all similarly increased in exposed animals relative to 
controls (Figure 4.9).
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Figure 4.7. Total brain PC and SM for mouse model B of GW agent exposure: Mean 
± SEM of PC and SM in exposed (n = 4) and control mice (n = 4) for mouse model B of 
GW agent exposure. Individual molecular species of PC and SM identified by LC/MS 
were summed after lipidome DB analyses to generate total PC and total SM levels, 
respectively. (A) A nearly 1.20 fold increase in total PC was noted in exposed mice in 
model B compared to control mice, *denotes p < 0.05 for a main exposure effect (based 
on MLM where exposure was included as a fixed main factor). (B) For total SM, a 1.22 
fold increase was observed in exposed animals compared to controls, *denotes p < 0.05 
(based on MLM analyses as described above for A).
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Figure 4.8. Brain phospholipid changes for mouse model B of GW agent exposure:
Mean ± SEM (n = 4 per group) of all of the PC and SM molecular species identified by 
LC/MS analysis; those denoted by $ were associated with component 3. (A) Univariate 
analyses show that all molecular species in component 3 (indicated using asterisks) were 
significantly different between exposed and control animals, *denotes p < 0.05 for a 
main exposure effect (based on MLM where exposure was included as a fixed main 
factor). (B) Although SM(18:0) and SM(24:1) were also increased in response to GW 
agent exposure, none of the SM species were associated with component 3. Insert 
contains lipids with different concentrations than those shown in the main image.
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Figure 4.9. Degree of unsaturation of brain PC molecular species for mouse 
model B of GW agent exposure: Mean ± SEM (n = 4 per group) presented as 
percentage of control. The figure represents percent SFA, MUFA and PUFA containing 
PC molecular species exposed relative to control. Phosphatidylcholine containing SFA 
and MUFA were nearly 117% relative to controls and PUFA containing PC molecular 
species were 123% relative to controls in exposed mice compared to controls in mouse 
model B. *denotes p < 0.05 for a main exposure effect (based on MLM where exposure 
was a fixed main factor).
4.3.4. Profiling o f brain PC and SM from the PSAPPswe mouse model
Brain lipid extracts from 6-month old PSAPPswe mice (n = 5, [3F, 2M]) and wild-
type mice (n = 5, [2M, 3F]) were examined to compare PC and SM profiles in order to
determine if detected changes are similar to those observed in mouse models of GW agent
exposure. Total PC levels were decreased in PSAPPswe mice compared to wild-type mice,
but the differences were not significant (F(i,24) = 2.8, p = 0.1, Figure 4.10A). Similarly,
total SM levels were lower in PSAPPswe mice compared to wild-type mice (F(i,24) = 2.6, p
= 0.1, Figure 4.10B). Figures 4.11 and 4.12 show individual PC and SM molecular
species. Univariate analyses showed that a number of PC and SM molecular species were
lower but PCA analyses did not reveal a particular underlying pattern in the dataset that
was associated with PSAPPswe status. Examination of degree of unsaturation showed that
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compared to control mice, PC molecular species with SFA were reduced by 16% (F(i,25) =
6.3, p = 0.02), MUFA (F(i,24) = 3.3, p = 0.08) were marginally reduced and PUFA (F(i,23) = 
2.7, p = 0.1) were generally similar (Figure 4.13).
4.3.5. Pro filing o f  brain PC and SM from  the CCI TBI mouse model
For these studies, lipid extracts from cortex, hippocampus and cerebellum were 
examined separately at the 3-months post-injury timepoint. For total PC, a significant main 
injury effect was observed (F(i,33) = 9.3, p = 0.004) and an effect of brain regions (F(i, 33) = 
150, p <0.001) and an interaction between injury and brain regions (F(i, 29) = 24.2, p < 
0.001) were observed as well. Similarly, for total SM, there was a main effect o f injury (F(i, 
34) = 8.4, p = 0.007), a brain region effect (F(i, 32) = 124, p < 0.001) and an interaction 
between injuiy and brain regions (Fp, 32) = 20.7, p < 0.001). Figure 4.14 shows that total 
PC and SM species are modulated in response to CCI TBI at this 3-month post-exposure 
timepoint, where PC and SM levels are lower in the hippocampi and cerebella and are 
elevated in the cortices of injured mice compared to sham mice. Figure 4.15 shows an 
example of a subset of individual molecular species changes with a similar pattern for each
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Figure 4.10. Brain total PC and SM for PSAPPswe mouse model of AD: Mean ± SEM of 
in PSAPPswe (n = 5) and control mice (n = 5). (A) Individual molecular species of PC and 
identified by LC/MS analyses were summed after lipidome DB analyses to generate total PC 
and total SM levels, respectively. A nearly 1.08 fold decease in total PC was noted in 
PSAPPswe compared to control mice. (B) For total SM, a 1.12 fold decrease was observed 
in PSAPPswe compared to controls, p > 0.05.
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Figure 4.11. Brain phospholipid changes for the PSAPPswe mouse model of AD:
Mean ± SEM (n = 5 per group) of all of the lipids identified by LC/MS analyses. 
ePC32:0, ePC(36:l), ePC(36:0) and ePC(34:0) were significantly lower in PSAPPswe 
mice compared to control mice, ^denotes p < 0.05 for a main exposure effect (based on 
MLM where exposure was a fixed main factor). Insert contains lipids with different 
concentration than those shown in the main image.
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Figure 4.12. Brain phospholipid changes for the PSAPPswe mouse model of AD:
Mean ± SEM (n = 5 per group) of all of the lipids identified by LC/MS analyses. (A) 
PC(32:0) and PC(42:10) and (B) SM(16:0), DSM(16:0), and SM(18:1) were all 
significantly lower in PSAPPswe mice compared to control mice, *denotes p < 0.05 for 
a main exposure effect (based on MLM where exposure was a fixed main factor). Insert 
contains lipids with different concentration than those shown in the main image.
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Figure 4.13. Degree of unsaturation status of brain PC for PSAPPswe mouse model
of AD: Mean ± SEM (n = 5 per group) presented as percentage of control. Figure shows 
that SFA, MUFA and PUFA containing species did not differ from wild-type control 
mice and were generally similar to each other, p > 0.05.
CCI TBI mouse model
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Figure 4.14. Brain total PC and SM for CCI TBI mouse model: Mean ± SEM of in CCI
TBI (n = 4) and sham mice (n = 4). Individual PC molecular species identified by LC/MS 
were summed after lipidome DB analyses to generate total PC and total SM levels, 
respectively. (A) In the hippocampus and cerebellum, a nearly 2.3 and 1.5 fold decrease, 
respectively, in total PC was noted in CCI injured mice compared to control mice, p < 0.05. In 
the cortex, a 1.7 fold increase was noted in injured mice compared to sham mice, p < 0.05. (B) 
Similar observations were made for SM, a decrease of about 1.5 and 1.4 was noted 
respectively in the hippocampi and cerebella of injured mice compared to sham mice, p < 
0.05. A 1.7 fold increase was again noted for SM in the cortices of injured mice compared to 
sham mice, *denotes p < 0.05 for a main injury effect (based on MLM with injury and region 
were fixed main factors).
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Figure 4.15. A representative image of some of the brain PC and SM molecular species
for CCI TBI model: Mean ± SEM (n = 4 per group). (A-C) As in total PC and SM graphs, 
region specific differences are observed where in the hippocampus, lipid levels are 
decreased in the TBI group compared to sham mice. However, in the cortex, PC and SM 
levels are increased in TBI compared to controls. Note, figure is a representative image only 
and no statistical analyses were performed on individual species given that total PC and SM 
levels were significant and each species appeared to behave in exactly the same pattern.
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Figure 4.16. Degree of unsaturation of brain PC for the CCI TBI mouse model:
Mean ± SEM (n = 4 per group) presented as percentage in CCI injured mice relative to 
sham mice. Within the hippocampus SFA were 45%, MUFA were 45% and PUFA were 
39% in injured mice relative to controls. Within the cortex, SFA were 176%, MUFA 
were 170% and PUFA were 170% in injured mice relative to controls. In the cerebellum, 
SFA were 67%, MUFA were 67% and PUFA were 63% in injured mice relative to 
controls, *denotes p < 0.05 for a main injury effect (based on MLM with exposure and 
brain regions were fixed main factors).
lipid species within each brain region as that observed for total PC and SM. Examination 
of the degree of unsaturation of PC molecular species did not show any differential 
changes after injury where SFA, MUFA and PUFA were equally lowered in the hippocampi 
and the cerebella but were increased in the cortices of injured mice compared to sham 
mice, see Figure 4.16.
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4.3.6. Profiling ofplasma PC and SMfrom mouse model A o f GW agent exposure:
Plasma PC and SM from model A were examined to determine if changes in their levels 
could serve as biomarkers of GW agent exposure (n = 4 exposed and n = 4 controls). As 
was observed in the brain tissue samples, total PC levels did not differ between exposed 
and control animals (Fp, 22) = 2.5, = 0.1). Total levels of SM individual molecular species 
were elevated in exposed animals compared to controls (F(i,i9) = 7.92, p = 0.01). Figure
Plasma lipidomics of mouse model A of GW agent exposure
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Figure 4.17. Plasma PC and SM changes for mouse model A of GW agent exposure: Mean 
± SEM (n =4 per group) of all of the PC and SM identified by LC/MS analyses. Note, $ denotes 
those species that were associated with component 1 from PCA. Univariate analyses of species 
from component 1 show that PC(32:0), PC(34:0), ePC(36:2), SM(22:1), PC(36:0), ePC(38:5), 
ePC(38:2), ePC(38:0), and PC(38:5) were significantly different between PB+PER+DEET 
+Stress and control mice, *denotes p < 0.05 for a main exposure effect (based on MLM where 
exposure was a fixed main factor). Insert contains lipids with different concentration than those 
shown in the main image. 119
4.17 shows all individual PC and SM molecular species that were identified in this 
experiment. A data reduction strategy using PCA suggested that component 1 explained 
the largest variance, 39% and was associated with GW agent exposure in model A ( F ( i ,  21) = 
5.0, p = 0.04). Examination of the degree of unsaturation of individual PC molecular 
species revealed that SFA (F(i,20) = 20.7, p < 0.001) containing PC molecular species were 
significantly elevated but MUFA ( F ( i ,  23) =1.05, p = 0.32) and PUFA ( F ( i ,  22) = 2.1, p = 0.2) 
containing PC species were similar between exposed and control animals, see Figure 4.18.
Degree of unsaturation of plasm a PC for mouse model A of GW
agent exposure
Figure 4.18
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Figure 4.18. Degree of unsaturation status of plasma PC for mouse model A of 
GW agent exposure: Mean ± SEM (n = 4 per group) presented as percentage in 
exposed relative to control showing that SFA containing species were 120% MUFA 
were 108% and PUFA containing species were 105% in plasma of exposed mice 
relative to controls, * denotes p < 0.05 for a main exposure effect (based on MLM 
where exposure was a fixed main factor).
4.3.7. Profiling ofplasm a PC and SM from  mouse model B o f  GW  agent exposure
As in model A o f GW agent exposure above, lipidomic profiling was perfonned to 
detennine if  plasma PC and SM changes can serve as biomarkers of GW agent exposure (n 
= 4 GW agent, n = 4 control). There were no significant differences between exposed and
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Plasma lipidomics of mouse model B of GW agent exposure
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Figure 4.19. Plasma PC and SM changes for mouse model B of GW agent exposure:
Mean ± SEM (n = 4 per group) of all of the PC and SM identified by LC/MS analyses. Note, 
symbol $ denote those species that were associated with component 1 from PCA. Univariate 
analyses of species from component 1 show that ePC(32:l), ePC(34:3), ePC(36:l), ePC(36:0), 
ePC(38:2), ePC(38:l), PC(38:4), ePC(40:5), ePC(40:4), ePC(40:3), PC(42:11), PC(42:2) and 
PC(44:8) were significantly different between PB+PER and control mice, * denotes p < 0.05 
for a main exposure effect (based on MLM where exposure was a fixed main factor). Inserts 
contain lipids that have different concentration than that in the main figure.
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Degree of unsaturation of plasma PC of mouse model B
for GW agent exposure
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Figure 4.20. Degree o f unsaturation o f plasma PC for mouse model B o f 
GW agent exposure: Mean ± SEM (n = 4 per group) presented as percentage in 
exposed relative to control showing that molecular species containing SFA were 
109%, MUFA were 101% and PUFA were 93% in exposed mice relative to 
controls, p > 0.05.
control mice either for total PC (F(i, 15) = 0.026, p = 0.9) or total SM levels (F(i, 16) = 1.13, p 
= 0.3). The multivariate approach of using PCA showed that component 1 explained 30.1 
% of variance in the dataset and was associated with GW agent exposure in this model (F(i, 
13) = 7.25, p = 0.02). Figure 4.19 shows individual PC and SM species and those that were 
specific to PCA component 1. There was also a marginal effect of degree of unsaturation, 
where SFA containing PC molecular species were marginally increased in exposed mice 
compared to controls (F(i, 14) = 3.9, p = 0.07). However, MUFA (F(i, 14) = 0.4, p = 0.5) and 
PUFA (F(i, 13) =0.3, p = 0.6) did not differ between exposed and control animals, see Figure 
4.20.
4.3.8. Profiling ofplasma PC and SM from CCI TBI mouse model
In the CCI mouse model of TBI (n = 4 CCI, n = 4 sham), there were no differences 
between injured and sham mice for the total PC (F(i,20) = 1.17, p = 0.3) and SM levels (F(i,
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Plasma lipidomics of CCT TBT mouse model
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Figure 4.21. Plasma PC and SM changes for the CCI TBI mouse model: Mean ± SEM 
(n = 4 per group) of all of the lipids identified during the LC/MS run. The symbol $ denote 
those species that were associated with component 1 from PCA. (A-B) Univariate analyses 
of species from component 1 show that ePC(32:3) and PC(34:0),were significantly 
different with injury compared to controls, ^denotes p < 0.05 for a main injury effect 
(based on MLM with exposure as a fixed main factor).
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Figure 4.22. Plasma PC and SM changes for the CCI TBI mouse model: Mean ± SEM 
(n = 4 per group) of all of the lipids identified during the LC/MS run. The symbol $ denote 
those species that were associated with component 1 from PCA. (A-B) Univariate analyses 
of species from component 1 show that SM(18:0) and PC(34:1), PC(38:5), PC(40:5), 
PC(40:6), PC(40:7) were significantly different with injury compared to controls, *denotes 
p < 0.05 for a main injury effect (based on MLM with exposure as a fixed main factor). 
Insert contains lipids that have different concentration than that in the main figure.
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Figure 4.23 Degree of unsaturation of plasma PC for the CCI TBI mouse 
model: Mean ± SEM (n = 4 per group) presented as percentage of sham showing 
that MUFA containing PC molecular species were decreased in injured animals 87% 
relative to sham injured mice and that SFA (91%) and PUFA (88%) were also 
slightly decreased in injured animals relative to sham but these differences were not 
significant, p > 0.05.
20) = 0.3, p = 0.6). Figure 4.21 and 4.22 show individual molecular species o f PC and SM.
As above, PCA was performed but for PC species only which showed that component 1
explained the largest variance (44%) and was significantly associated with injury (F(i, 5) =
16.3, p = 0.01). Figure 4.23 shows an effect on the degree of unsaturation, where SFA 
levels were similar between injured and sham mice (F(i, 20) = 1.1, p = 0.3). However, 
MUFA containing PC molecular species were marginally decreased in injured mice
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compared to controls (F(i, 15) = 4.2, p = 0.06) but with no significant difference in PUFA 
containing PC species between injured and sham animals (Fp, 17) = 0.9, p = 0.3).
4.3.9. Pro filing o f  plasma PC and SM from  mTBI mouse model:
Total PC and SM from plasma samples from single and repetitive mTBI mouse model 
(n = 4 s-sham, n = 4 s-m-TBI, n = 3 r-sham and n = 4 r-m-TBI) are presented in Figure 
4.24. For total PC levels, a significant main effect of injury was observed (F(i,28) = 38.5, p
< 0.001) and post-hoc analyses showed significant differences between s-sham and s-mTBI 
(p < 0.001) as well as differences between r-sham and r-mTBI (p < 0.001) (Figure 4.24A). 
For total SM levels, a significant main effect of injury was observed (Fp, 34) = 4.7, p = 
0.01) and post-hoc analyses showed significant differences between s-sham and s-mTBI (p
< 0.001) and between r-sham and r-mTBI (p < 0.05), see Figure 4.24B. Examination of the
degree o f unsaturation in PC provided evidence that PC molecular species that contained 
Plasm a lipidomics of mTBI mouse model
Figure 4.24A Figure 4.24B
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Figure 4.24. Plasma PC and SM for the mTBI mouse model: Mean ± SEM of in s-m­
TBI (n = 4), s-sham (n = 4), r-m-TBI (n = 4) and r-sham (n = 3). (A) Individual molecular 
species of PC and identified during the LC/MS were summed after lipidome DB analyses 
to generate total PC and total SM levels. A significant decrease in s-m-TBI mice was 
observed compared to s-sham mice and an increase in r-sham and r-m-TBI mice for total 
PC, *p < 0.05 denotes a main injury effect (based on MLM where exposure was included as 
a fixed main factor). (B) For total SM, a decrease was observed in s-mTBI compared to s- 
sham and an increase in r-sham and r-mTBI animals compared to shams, * p< 0.05 (based 
on MLM where exposure was included as a fixed main factor).
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SFA did not differ by injury (F(i, 35) = 1.1, p = 0.4). On the other hand, those that contained 
MUFA (F(i, 35) = 25.3, p < 0.001) or PUFA (F(i,29) = 38.8, p < 0.001) were decreased in 
injured compared to uninjured mice. Post-hoc analyses revealed that there were significant 
differences between s-sham and s-mTBI (p < 0.001) in MUFA containing PC species and 
for PUFA containing molecular species (p < 0.001). These differences were not significant 
for r-sham compared to r-mTBI (Figure 4.25).
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Figure 4.25. Degree of unsaturation of plasma PC for the mTBI mouse model: Mean ± 
SEM (n = 3/4 per group) presented as percentage in s-m-TBI relative to s-sham and r-m- 
TBI relative to r-sham. PC species containing MUFA were decreased in s-mTBI, 73% 
relative to s-sham mice. There were no differences for SFA between the four groups. For 
PUFA, s-mTBI mice showed a decrease, 83% relative to control, ^denotes p < 0.05 for a 
main injury effect (based on MLM where injury was included as a fixed main factor). There 
were no significant differences between r-sham and r-mTBI mice, p > 0.05.
4.3.9. Lipidomic approaches for target identification for mouse model B o f  GW  aoent 
exposure
Since one of the main goals of this project was to determine if lipidomic technology 
can be useful in identifying molecular targets for therapeutic interventions, additional
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analyses were focused on mouse model B of GW agent exposure. From brain tissue, FFAs, 
C16:0 (palmitic acid [PA]), C l8:2 (linoleic acid [LA]), 18:1 omega-9 (oleic acid [OA]), 
C20:4 omega-6 (arachidonic acid, [AA]), and C22:6 omega-3 (docosahexaenoic acid, 
[DHA]) and a bioactive lipid 2-arachidonoylglycerol (2AG) were examined using the 
RPLC/MS and the RPLC/MS/MS. There were significant increases in PA (F(i, 16) = 4.5, p = 
0.05), OA(F(i, 19) = 6.8, p = 0.02), AA (F(i, i6) = 9.1, p = 0.01), DHA (F(i, 20) = 18.7, p < 
0.001) and 2AG (F(i,20) = 8.0, p = 0.01) in exposed mice compared to controls. There were 
no differences between the two groups for LA (Fp, 19) = 2.5, p = 0.13). Figure 4.26 shows 
an increase in several FFA and 2AG in the brains of exposed animals expressed as a 
percentage of control levels. Examination of the PC/SM ratio showed a small but 
significant decrease (F(i,9) = 5.7, p = 0.04) in exposed animals (mean ratio = 12.79, SE ±
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Figure 4.26. Brain free fatty acids and 2AG for mouse model B of GW agent exposure:
Mean ± SEM (n = 4 per group) presented as percentage of control. Brain PA levels were 117%, 
OA levels were 130% LA levels were 116%, AA levels were 128% and DHA levels were 
140% in PB+PER exposed mice relative to control mice from mouse model B. Brain 2AG 
levels were 153% relative to controls, * denotes p < 0.05 for a main exposure effect (based on 
MLM with exposure as a fixed main factor.
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Additional plasma lipids from mouse model B of GW agent exposure
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Figure 4.27. Plasma ePC, PE and LPC comparisons for mouse model B of the GW agent 
exposure: Mean ± SEM in exposed (n = 4) and control (n = 4). There was (A) 1.44 decrease in 
ePC and (B) 1.13 fold increase for LPC. (C) There was no differences in total PE levels 
between exposed animals compared to controls, * denotes p < 0.05 for a main exposure effect 
(based on MLM where exposure was included as a fixed main factor).
Plasm a LPC and free fatty acids from mouse model B of 
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Figure 4.28. Plasma FFA and LPC molecular species comparisons for mouse model B of 
GW agent exposure: Mean ± SEM in exposed (n = 4) and control (n = 4). (A), LPC(16:0) was 
only marginally increased in exposed compared to controls (p = 0.07). (B-C) LPC(18:1), 
LPC(18:2) LPC(20:5), LPC(20:2), LPC(22:6) and LPC(22:5) were significantly increased in 
exposed mice compared to controls, *denotes p < 0.05 for a main exposure effect (based on 
MLM where exposure was included as a fixed main factor). (D) A number of FFA, AA and 
DHA showed a trend for an increase in exposed animal compared to controls, p > 0.05.
0.29) compared to controls (mean ratio = 13.20, SE ± 0.21).
In plasma, FFA as well as ePC, PE and LPC were examined using the lipidomic 
LC/MS approach employed above for PC and SM quantification. Total ePCs were further 
examined since the profiling data suggested that several ether PC molecular species were 
decreased in exposed animals compared to controls. Total ePC levels were significantly 
lower in exposed animals compared to controls (F(i, 15) = 5.3, p = 0.04). Total PE levels did 
not differ between exposed and control mice (F(i, 17) = 2.4, p = 0.14). Total LPC levels 
were significantly elevated in exposed mice compared to controls (F(i, 19) = 5.5, p = 0.03, 
Figure 4.27). However, LPC molecular species that contained PUFA were significantly 
elevated in exposed mice compared to controls (F(i, 19) = 6.8, p = 0.02, see Figure 4.28). 
Examination of FFA from plasma showed a significant increase in OA (F(i, 12) = 4.6, p = 
0.05), and a marginal increase in DHA (F(i, 18) = 4.2, p = 0.06) and in AA (F(i, 16) = 3.6, p = 
0.08) in exposed animals compared to controls, see Figure 4.28.
4.3.10. Pilot studies o f the effects o f a potential treatment on recovery o f normal lipid 
profiles in mouse model B o f GW agent exposure
There were 4 comparison groups in this study, those treated with nilvadipine (n = 5 
exposed and n = 5 unexposed) and those that received vehicle only (n = 4 exposed, n = 5 
unexposed). For plasma lipid profiles, there was a main effect of GW agent exposure on 
PC levels (F(i,42) = 21.09 p < 0.001), no main effect of nilvadipine treatment (F(i,42) = 0.6, 
p = 0.4) and an interaction between GW agent exposure and nilvadipine treatment (F(i,42) = 
29.15, p < 0.001). Figure 4.29A shows that PC in unexposed controls were similar to 
unexposed nilvadipine treated mice. GW agent exposed mice had higher PC levels than
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Lipidomics data from pilot nilvadipine treatm ent studies in mouse 
model B of GW  agent exposure
Figure 4.29A Figure 4.29B Figure 4.29C
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Figure 4.29. Plasma PC, LPC and SM comparisons from nilvadipine treatment 
studies for mouse model B of the GW agent exposure: Mean ± SEM in PB+PER 
(n = 5), control DMSO (n = 4), PB+PER+Nilvadipine (n =5), and Nilvadipine (n = 
5). (A-B) Total PC and LPC levels were increased in PB+PER exposed mice 
compared to controls and Nilvadipine treatment significantly reduced LPC and PC 
levels in PB+PER exposed mice compared to controls, ^denotes p < 0.05 (based on 
MLM with PB+PER and nilvadipine treatment as fixed main factors). (C) There was 
an effect of PB+PER exposure on SM levels (*p < 0.05) but no treatment affect of 
nilvadipine in GW agent exposed mice.
Table 4.1. Lipid Identifications obtained from lipid map for PC molecular species 
that were significantly different in mouse model A of GW agent exposure
Lipid (M+H)+
m/z
ID M-snl
m/z
M-sn2
m/z
Snl FA Sn2 FA
*ePC(34:0) 748.6 PC (0-16:0/18:0) - 480 - 283
PC(0-18:0/16:0) - 508 - 255
ePC(36:2) 772.6 PC(P-16:0/20:1) - 478 - 309
PC(O-18:0/18:2) - 508 - 279
PC(P-18:0/18:1) - 506 - 281
*ePC(36:l) 774.6 PC(O-18:0/18:l) - 508 - 281
*PC(36:0) 790.6 PC( 18:0/18:0) 522 522 283 283
*PC(38:4) 810.6 PC(18:0/20:4) 542 522 283 303
PC(16:0/22:4) 570 552 255 331
*PC(38:1) 816.6 PC( 16:0/22:1) 576 494 255 337
*PC(40:4) 838.6 PC(18:0/22:4) 570 522 283 331
PC(40:2) 842.7 PC(20:1/20:1) 548 548 309 309
PC(22:0/18:2) 518 578 339 279
PC(18:1/22:1) 576 520 281 337
Note: indicates molecular species for which product ions were observed to confirm identification using 
LC/MS/MS in data dependent analysis that was performed in conjunction with LC/MS SCID in negative 
ion mode. [M+HJ+ indicates m/z value + 1 hydrogen in positive ion. (M-snl) indicates lyso fragment ion 
corresponding to the loss at the first glycerol position. (M-sn2) indicates lyso fragment ion 
corresponding to the loss at the second glycerol position. Snl FA (fatty acid at the snl position and Sn2 
FA (fatty acid at the sn2 position.
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Table 4.2. Summary table showing fold-change of 
individual PC and SM molecular species identified 
from brain samples using SCID LC/MS
Model A Model B PSAPPswe
SM(16:0) 1.03 ND -1.17
PC(30:1) 1.90 ND 1.39
PC(30:0) 1.11 1.43 -1.03
ePC(32:l) 7.33 ND -1.08
ePC(32:0) 1.16 ND - 1 .1 2
SM(18:1) -1.06 ND -1.16
SM(18:0) 1 .1 2 1.26 - 1 .1 2
PC(32:1) 1.10 1.18 - 1.01
DSM(18:0) ND 2 .0 0 -1.54
PC(32:0) 1.11 1.16 -1.13
ePC(34:2) -1.31 ND - 1 .1 0
ePC(34:l) 1.31 1.15 -1.09
ePC(34:0) 1.45 1.18 -1.13
PC(34:3) 1.08 1.13 1 .0 0
PC(34:2) 1 .1 2 1.18 1.06
PC(34:1) 1.14 1.15 -1.08
PC(34:0) 1.13 1.16 -1.05
ePC(36:2) 2.70 1.21 -1.06
ePC(36:l) 2.71 1.11 -1.09
ePC(36:0) ND 2 .0 0 -1.18
PC(36:4) 1 .10 1.18 -1.05
PC(36:3) 1.13 1.17 - 1 .0 2
SM(22:1) 1.13 1.19 -1.07
PC(36:2) 1.08 1.18 -1.09
SM(22:0) 1.35 1.12 -1.16
PC(36:1) 1.11 1.25 -1.09
DSM(22:0) ND -1.32 -1.14
PC(36:0) 2 .0 2 1.26 - 1 .1 2
ePC(38:6) ND 1.27 -1.09
ePC(38:5) ND 1.24 -1.06
ePC(38:4) ND 1.25 -1.05
ePC(38:2) ND 1.25 -1.07
ePC(38:l) 1 .0 0 -1.17 -1.13
PC(38:6) 1.14 1.17 -1.05
PC(38:5) - 1.11 1.25 -1.07
PC(38:4) 1.37 1.27 -1.04
PC(38:3) 1.13 1 .2 2 -1.05
SM(24:1) 1 .12 1 .2 2 - 1 .1 0
PC(38:2) 1.43 1.24 -1.07
SM(24:0) 1.18 1.11 -1.15
PC(38:1) 2.90 1.31 -1.06
DSM(24:0) 2.82 1.06 - 1.21
PC(38:0) ND 2.15 -1.08
PC(40:7) 1 .2 2 1.24 - 1 .1 2
PC(40:6) 1.27 1.24 -1.07
PC(40:5) ND 1.30 - 1.01
PC(40:4) 2.71 1.30 -1.06
PC(40:3) ND 1.26 -1.03
PC(40:2) 1.50 ND - 1 .1 0
Note: Fold-change (exposed over controls, PSAPPswe over wild-type 
and injured over sham) values are displayed for each molecular species. 
Those indicated with ND (Not Detected) and were not detected in the 
SCID LC/MS run. (-) downregulated (+) upregulated
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Table 4.3. Summary table showing fold-change of individual PC and SM 
molecular species identified from plasma samples using SCID LC/MS
Model A Model B CCI TBI s-m-TBI r-m-TBI
SM(16:1) ND -1.17 1.04 -1.14 3.10
SM(16:0) ND -1.16 -1.13 1.07 1.30
PC(30:1) ND - 1 .00 1.28 ND ND
DSM(16:0) ND - 1.11 -1.06 1.06 1.64
PC(30:0) ND - 1 .0 0 -1.05 1.05 1.13
ePC(32:3) ND ND -1.03 ND ND
ePC(32:2) ND -1.85 -1.04 -1.43 1.06
ePC(32:l) ND -1.91 1.03 -1.32 1.32
ePC(32:0) ND - 1 .0 0 1.05 1 .0 2 1.57
SM(18:1) ND -1.06 -1.07 1.06 1.04
PC(32:2) ND 1 .1 2 1.01 -1.56 -1.29
SM(18:0) ND - 1.01 - 1 .1 2 -1 .0 0 1.01
PC(32:1) 1.23 1 .0 0 -1.09 -1.71 -1.23
DSM(18:0) 1.35 1 .1 2 -1.23 -2.40 1.05
PC(32:0) 1.17 1.15 -1.19 -1.03 -1.05
ePC(34:3) ND -5.00 -1.04 -1.33 1 .6 6
ePC(34:2) ND -1.04 -1.03 1.11 1.16
ePC(34:l) ND -1.08 1.02 -1 .1 0 1.17
PC(34:4) ND - 1 .00 1.06 ND 2.67
PC(34:3) 1.08 1.05 1.05 -1.62 -1.13
PC(34:2) 1.11 -1 .0 2 - 1.01 1.01 1.08
PC(34:1) 1.08 1.04 -1.16 -1.40 - 1 .1 2
PC(34:0) 1.09 1.08 -1.14 -1.26 1.07
ePC(36:5) ND - 1 .0 0 -1.01 1.53 2.18
ePC(36:4) ND - 1.11 -1.03 1.19 1 .1 2
ePC(36:3) ND -1.23 1.08 -1.09 1.18
ePC(36:2) 1.25 -1 .1 2 -1.08 -1.01 1.24
ePC(36:l) ND -1.23 1.01 -1.13 1.15
ePC(36:0) ND -3.00 -1 .0 2 -1.18 2 . 0 0
PC(36:6) ND 2.40 1.15 1.16 1.85
PC(36:5) 1.09 1.04 1.04 -1.09 - 1 .0 0
PC(36:4) 1.04 -1.08 -1.07 -1.25 -1.05
PC(36:3) 1.09 1.03 - 1 .1 2 1.04 - 1 .0 2
SM(22:1) 1.17 - 1.01 -1.09 -1.06 -1.04
PC(36:2) 1.09 -1.03 -1.14 -1.07 1.24
SM(22:0) 1.40 -1.11 1 .02 -1.26 -1.06
PC(36:1) 1.04 - 1.01 -1.29 -1.28 1 .1 0
DSM(22:0) 1.24 - 1.12 -1.05 -1.14 1.31
PC(36:0) 1.21 1.01 -1.03 -1.03 1 .01
ePC(38:6) ND -1.05 - 1 .0 2 1.38 1.21
ePC(38:5) 1.21 -1.08 -1.06 1.16 1.23
ePC(38:4) 1.43 - 1 .6 6 1.04 -1.36 1.18
ePC(38:3) ND -1.69 - 1 .1 0 -1.45 1.08
ePC(38:2) 1.90 -1.16 -1.04 1.04 1.14
ePC(38:l) ND -1.35 - 1 .0 2 1.01 1.25
ePC(38:0) 1.10 1.06 - 1.01 -1.33 -1.18
PC(38:6) 1.04 - 1.01 - 1.11 -1.15 -1.05
PC(38:5) 1.06 1.05 -1.18 -1.27 -1.09
PC(38:4) - 1.01 -1.14 -1.30 -1.38 1.09
PC(38:3) 1.04 -1.06 -1.27 -1.15 1.06
SM(24:1) 1.53 -1.14 1 .0 0 -1.06 1.11
PC(38:2) 1 .2 0 1.07 -1.05 -1.14 -1 .0 0
SM(24:0) ND -1.28 1 .1 2 -1.28 1 .2 2
PC(38:1) ND 1.53 - 1.11 1 .22 -1.45
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Table 4.3 continued
DSM(24:0) - 1 .10 1.27 -1.03 2 . 0 0
PC(38:0) 1.99 1 .0 2 -1.07 1.21 1.07
ePC(40:6) 2.18 -1.70 -1.01 -1.32 1.09
ePC(40:5) ND -1.83 -1.07 -1.15 1 .1 0
ePC(40:4) 7.62 -1.74 -1.08 -1.39 1.32
ePC(40:3) ND -1.71 -1.06 -1.42 1.29
ePC(40:2) ND 1.63 1.05 -1.09 1.08
PC(40:8) 1 .0 2 1.15 -1.09 -1.33 -1.23
PC(40:7) 1.03 1.18 -1.23 -1.08 - 1.11
PC(40:6) -1.00 -1.05 -1.28 -1.07 1.31
PC(40:5) 1.08 -1.04 -1.25 -1.35 1.04
PC(40:4) 1 .2 0 -1.16 -1.08 -1.64 1.03
PC(40:3) ND -1.45 -1.00 -1.26 1.55
PC(40:2) ND -2 . 0 0 1.06 -1.27 2.16
PC(42:11) ND -3.00 - 1 .0 2 - 1.21 1.30
PC(42:10) -1.08 1.30 -1.14 -1.87 -1.17
PC(42:9) -3.70 1.24 -1.15 -1.37 - 1.01
PC(42:8) ND 1.23 -1.04 1 .0 0 1 .2 2
PC(42:7) ND 1.04 -1.19 1.05 -1.07
PC(42:6) ND -1.32 -1.07 -1.31 1.08
PC(42:5) ND -2.17 1.04 -1.62 1.64
PC(42:4) ND -1.75 1 .2 0 -1.29 1.54
PC(42:2) ND -6.33 -1.08 -1.47 1 .2 2
PC(44:8) ND -2.75 -1.15 - 1 .20 2.38
Note: Fold-change (exposed over control, injured over sham) values are displayed 
for each molecular species. Those indicated with ND (Not Detected) and were not 
detected in the SCID LC/MS run. (-) downregulated (+) upregulated
unexposed mice and nilvadipine treated GW agent exposed mice. For LPC (see Figure 
4.29B), there was a main exposure effect (F(i, 50) = 6.82, p = 0.01), no main effect of 
nilvadipine treatment (F(i, 50) = 0.7, p = 0.4) and an interaction between GW agent exposure 
and nilvadipine treatment (F(i, 50) = 9.8, p = 0.003). Similar to PC findings, Figure 4.29 
also shows that LPC levels were elevated in GW agent exposed mice compared to 
unexposed control mice. LPC levels were lower in nilvadipine treated GW agent exposed 
mice compared to untreated GW agent exposed mice. For SM levels (see Figure 4.29C), 
there was a main effect of GW agent exposure (F(i, 51) = 17.14, p < 0.01), no main effect of 
nilvadipine treatment (F(i, 51) = 0.00, p = 0.9) and no interaction between nilvadipine 
treatment and GW agent exposure (F(i, 51) = 0.25, p = 0.62). Total PC and SM levels from 
one whole brain hemisphere were also examined but there were no differences between
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GW agent exposed mice compared to controls, no main effect of nilvadipine and no 
interaction between GW agent exposure and nilvadipine treatment.
Tables 4.2 and 4.3 provide fold-change and the direction of change information on 
each individual PC and SM molecular species for brain and plasma, respectively.
4.4. Discussion
Lipidomic analyses were performed on phosphocholine-containing lipids, PC and 
SM, since metabolism of these lipids is linked to ACh production and turnover as well as 
to activation of the ACh receptor signaling system, which is altered in response to various 
combinations of GW agent exposure. For example, Abou-Donia and colleagues have 
shown an increase in mAChR and nAChR ligand binding in the cortices of rats that 
received combined exposure to PB, PER and DEET (Abou-Donia et al 2004). Studies also 
suggest that after chronic exposure to AChE inhibitors there is a compensatory increase in 
AChE mRNA levels (Bansal et al 2009). Lamproglou and colleagues showed a decrease in 
phosphocholine levels in rats exposed to PB and stress compared to non-stressed rats 
(Lamproglou et al 2009). Interestingly, a number of studies have shown that early-life 
exposure to PER in rats increased membrane fluidity of heart cells, which was 
accompanied by an increase in plasma cholesterol levels as well as an increase in the 
production of inflammatory cytokines, such as IL-1(3, IL-12, IFN-y and IL-10 (Vadhana et 
al 2011). These studies suggest that the GW agent utilized may affect cellular membrane 
PL levels and their metabolism.
4.4.1. Relevance o f lipids and lipid mediated pathways to GWI:
As described in Chapter 3, impaired peripheral immune and inflammatory responses 
are among key biological features of GWI. While initial hypotheses by Rook and Zumla 
proposed a Th2 shift in the immune system (Rook and Zumla 1997), clinical 
studies so far show a mixed profile with both pro-inflammatory and anti-inflammatory
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cytokines being increased after stimulation of lymphocytes from veterans with GWI 
compared to control (Broderick et al 2011; Skowera et al 2004).
Phospholipids and their metabolites are involved in mediating a number of immune 
and inflammatory responses and are capable of eliciting both Thl and Th2 type immune 
responses. As described above, LPC can stimulate production of both pro- and anti­
inflammatory cytokines (Bach et al 2010). While prostaglandins that are AA metabolites 
initiate pro-inflammatory events, DHA metabolites are generally associated with anti­
inflammatory events. Findings presented in this Chapter support the hypothesis that lipid 
metabolites (that are downstream of AA and DHA) could contribute to the immune and 
inflammatory imbalance observed in veterans with GWI. Therefore, a future examination 
of lipids and their metabolites is expected to be useful for identifying biological processes 
that are upstream of the aberrant immune and inflammatory changes observed in veterans 
with GWI. An in-depth discussion of the lipid changes that were observed in each mouse 
model follows.
4.4.2. Brain lipid profiling
4.4.2.1. Brain lipid profile o f mouse model A o f GW agent exposure
In this study, we observed that among PC and SM molecular species quantified in
this experiment, several ePC and PC containing LCFA and SM containing VLCFA were
increased in the brains of exposed animals compared to controls. Among the myriad of
potential mechanisms for these lipid changes, (such as altered transport, uptake, storage,
synthesis and turnover), alterations in peroxisomal function best explain these observations
(Wenk 2005; Farooqui et al 2007). Changes in ePC and SM containing VLCFA are
generally indicative of peroxisome malfunction (Singh et al 2009). This is supported by
genomic work performed at the Roskamp Institute showing a decrease in message RNA for
peroxisomal biogenesis factor 10 (PEX-10) by nearly two-fold in response to PB, PER,
and DEET exposure of SH-SY5Y neuronal cells (Crynen et al 2012). A study in mice
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showed that exposure to PB and stress resulted in an increase in lipid peroxidation, further
supporting the hypothesis that peroxisomal dysfunction may be associated with GW agent
exposure (Somani et al., 2000). In exposed animals, while SFA and PUFA were also
increased compared to controls, MUFA containing PC species were nearly 300% relative to
control. This could be through an increase in Stearoyl-CoA desaturase (SCD) enzyme
activity, a lipogenic enzyme catalyzing the synthesis of MUFA. This is also supported by
the genomic studies conducted at the Roskamp Institute showing downregulation of the
SCD mRNA levels by nearly two-fold (Crynen et al 2012) - possibly a consequence of
negative feedback inhibition (this requires further examination). Collectively, these studies
suggest that peroxisome malfunction and SCD activity might be an interesting target for
further investigation in GW agent exposure associated with mouse model A.
4.4.2.2. Brain lipid profile o f mouse model B o f GW aeent exposure:
Brain lipid examination of mouse model B of GW agent exposure shows an increase
in total PC and SM levels in the brains of exposed mice compared to control mice. PC and
SM are generally found in the outer plasma membrane leaflet and changes in total PC
levels may affect membrane fluidity of the outer plasma membrane (Vance, & Vance 2008;
Farooqui et al 2007). A more detailed examination of membrane fractions as well as other
PLs may help determine if membrane integrity is affected in response to GW agent
exposure. These studies will be informative since the literature suggests that PER can
affect membrane fluidity. Lipid data analysis using PCA showed that PC molecular species
significantly associated with exposure included a large number of diacyl PC that contained
PUFA. This is consistent with the examination of degree of unsaturation status of PC
showing that PUFA containing species were increased by 123% in exposed animals
relative to controls. Given that both A A (associated with downstream pro-inflammatory
conditions) and DHA (anti-inflammatory conditions) can influence inflammation,
additional investigation is required to determine if these PUFA containing PC molecular
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species may be associated with the mixed inflammation profiles observed in veterans with 
GWI.
A review of the literature suggested that a ratio of PC/SM may be a useful index of 
membrane fluidity, where an increase in this ratio would indicate an increase in membrane 
fluidity. Examination of this index in mouse model B suggests a decrease in membrane 
fluidity. This is consistent with previous reports on PER’s effect on cellular membranes. 
For instance, following neonatal exposure to PER, Vadhana and colleagues reported a 
decrease in membrane fluidity of heart cell membrane (and concomitant heart disease) in 
adult rats (Vadhana et al 2011).
4.4.2.3. Brain lipid profiles o f other models o f neurological illnesses:
The main objective of these studies was to determine if the changes observed in PC 
and SM in the brains of mouse models A and B were distinct from other models of 
neurological illness. A decrease was observed in several brain PC and SM molecular 
species in PSAPPswe mice compared to wild-type mice. A close examination suggested 
that ePC species or SM molecular species containing C l6:0 and C l8:0 were decreased in 
PSAPPswe mice compared to controls. However, there was an increase in PC and SM in 
exposed mice compared to controls for both mouse models of GW agent exposure. Among 
these, several ePC were increased in exposed animals compared to unexposed. Although 
these studies suggest that peroxisomal dysfunction may be present in both GW agent 
exposure models and in the AD mouse model, the direction of change in each models 
suggests that in this AD mouse model, there may be a decrease in peroxisomal function, 
while in the GW agent exposed mice there appears to be an increase in perxoisomal 
function. Furthermore, unlike mouse models of GW agent exposure, there were no 
differences between PSAPPswe mice and control mice with regard to the degree of 
unsaturation of PC.
A direct comparison cannot be made with the CCI TBI mouse model since brain
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regions (cortex, hippocampus and cerebellum) were separately examined in this study. 
These data show brain region specific differences in PC and SM levels and brain region 
specific responses to the injury. Given that PC and SM levels were much higher in the 
cortex than in the hippocampus or the cerebellum, it would be expected that the net effect 
would be an increase in PC and SM given the size of the cortex in comparison to the 
hippocampus and the cerebellum. This would be similar to the findings observed in the 
CD1 mice from mouse model B of GW agent exposure. Nevertheless, these data suggest 
that future studies in the GW models should incorporate brain region specific lipid 
profiling to gain a more thorough understanding of the biochemical pathways that might be 
affected in response to GW agents. In particular, matrix assisted laser desorption/ 
ionization (MALDI)-MS imaging may be extremely valuable for identifying the 
underlying structural changes in response to GW agent exposure and other CNS injuries 
(Jackson, & Woods 2009).
4.4.3. Plasma lipid profiling
Diagnosis of GWI largely relies on clinical presentation of symptoms, and as yet, 
there are no objective biomarkers available for diagnosing GWI. Furthermore, nearly 
50,000 veterans continuing to suffer from unexplained symptoms have had their disability 
claims denied or are still pending due to the challenges associated with providing an 
objective and accurate diagnosis of GWI. It is anticipated that availability of biomarkers 
would be useful in objectively diagnosing GWI and would also be extremely useful in 
correctly classifying veterans with GWI so that appropriate care and therapies could be 
provided. The main goal of these studies was to determine if differences in plasma PC and 
SM could be used to differentiate GW agent exposed mice from controls and whether these 
changes were specific to GWI, with the ultimate goal of translating these findings to 
human studies.
4.4.3.1. Lipid profiling o f plasma PC and SM in mouse models A and B o f GW agent 
exposure:
For mouse model A of GW agent exposure, changes in PC and SM molecular species 
observed in the plasma of exposed mice compared to control mice showed that ePC and 
diacyl PC containing LCFA were increased in GW agent exposed mice compared to 
control mice. For both mouse models, particularly mouse model B, PC changes show that a 
large number of ePC and PUFA containing PC molecular species were affected in exposed 
animals compared to controls. In the plasma of GW agent exposed mice from both models, 
PC molecular species that contained SFA were affected more than MUFA and PUFA 
containing species. In mouse model A, SFA were increased in exposed animals compared 
to controls. In mouse model B, a non-significant increase in SFA was observed in exposed 
animals compared to controls. There are a number of limitations associated with 
comparison of mouse model A to mouse model B given the differences in post-exposure 
time period, age and gender composition. Nevertheless, these studies provide evidence that 
plasma PC levels are affected by GW agent exposure in both mouse models of GW agent 
exposure. Future examination of biological pathways associated with peripheral synthesis 
of these lipids and brain transport may be useful in understanding possible inter­
relationships between plasma and brain lipid changes in response to GW agent exposure.
4.4.3.2. Lipid profiling o f plasma PC and SM from mouse models o f other neurological 
illnesses
These studies show that plasma PC and SM changes observed in CCI and mTBI are 
distinct from those observed in mouse models A and B of GW agent exposure. For CCI 
TBI, a significant number of individual molecular species were lower in CCI injured mice 
compared to control mice. For s-mTBI, there was an increase in the levels of SM but a 
decrease in the levels of PC among injured mice compared to control mice. However, for
r-mTBI, injured mice had an increase in PC and SM levels compared to uninjured mice.
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Although a direct comparison of mTBI with CCI TBI is not possible given the post-injury
time difference between the two studies, if time was not a factor, it can be postulated that
different head injuries produce different profiles, particularly for PC since all three types of
injury produced distinct effects on total PC levels. In addition, these lipid profiles are
distinct from those in mouse model A of GW agent exposure where only an increase in
certain PC species was observed in exposed animals and there was no change in total PC
and SM in GW agent exposed animals compared to controls. Mouse model B showed a
decrease in a number of PC and SM molecular species but no change in total PC and SM
levels. All SFA, MUFA and PUFA containing species were decreased in CCI injured
compared to control mice. Interestingly, despite the differences in total PC profiles
between s-mTBI and r-mTBI, for both injuries, there was a tendency for a decrease in
MUFA containing PC compared to respective controls. In addition, there was a decrease in
PUFA containing PC molecular species in s-mTBI compared to s-sham. For both models of
GW agent exposure, there was a tendency towards SFA containing PC species being
increased in exposed animals compared to controls. Thus, it can be hypothesized that
different CNS insults produce distinct changes in plasma lipid profiles, which may be
useful in differential diagnoses, particularly since the veteran population may include
individuals with TBI and GWI. Further studies are required to determine the potential of
such an approach in the discovery of biomarkers for CNS illnesses.
4.4.4. Use of lipidomics for pathway identification and target validation
Lipid profiling of mouse model B of GW agent exposure was also performed to
determine the downstream consequences of PC changes in the brain and plasma in order to
identify potential treatment targets. In the brain, FFA profiling showed that both AA and
DHA were increased in mice exposed to GW agents compared to controls. Since
downstream metabolites of AA include prostaglandins, which have pro-inflammatory
actions, and DHA metabolites, which are considered anti-inflammatory, these studies
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support the observed mixed inflammatory profile in veterans with GWI. Also of interest is 
2AG, which is a monoacylglycerol (MAG) that contains esterified AA at the sn2 position 
of glycerol. The action of MAG lipase (MAGL) liberates AA from 2AG. 2- 
arachidonylglycerol is a major endogenous ligand of cannabinoid receptors and the 
downstream pathways controlled by these receptors mediate anti-inflammatory processes 
in the brain (Ueda et al 2001). Collectively, these studies show that lipid metabolites that 
are upstream of both pro- and anti-inflammatory biological pathways may be affected in 
mouse model B of GW agent exposure which is consistent with findings of increased 
production of both pro- and anti-inflammatory cytokines (mixed inflammation) in veterans 
suffering from GWI (Skowera et al 2004). Examination of bioactive lipid metabolites of 
AA and DHA as well as Thl and Th2 cytokines may help in understanding the 
consequence of changes in these lipids.
Examination of the plasma FFA and LPC results also supports a mixed inflammation 
profile in the periphery, since LPC molecular species (e.g., LPC (18:1)) are directly shown 
to cause pro-inflammatory changes. Furthermore, AA and DHA were increased in exposed 
mice compared to controls, also supporting a concept of a mixed inflammatory response. 
A decrease in a number of PC molecular species, particularly those that contain AA, DHA 
and ePC together with a net increase in LPC levels suggests an increase in the PLA2 
activity in the periphery. Based on these changes, it can be predicted that drugs that affect 
LPC levels and/or PLA2 activity may be useful for treating lipid abnormalities associated 
with GW agent exposure.
The literature suggests that a number of DHP-CCB can block LPC induced
endothelial dysfunction, oxidative stress, AA release and increased plasma membrane
fluidity (Golfman et al 1999) (Takayama et al 2009; Matsubara et al 2006). Given these
reports, nilvadipine, a DHP-CCB, was used to conduct pilot treatment studies in a mouse
model of GW agent exposure. One of the main goals of these studies was to determine if
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PC and SM changes observed in the brain, and PC and LPC changes observed in plasma 
from CD1 mouse model B at about the 4 month post-exposure timepoint, were also 
observed at the 3-month post-exposure in C57BL6 mouse model B. Each of these 
timepoints shortly followed the timepoint at which cognitive impairment was observed in 
exposed mice compare to controls in each CD1 and C57BL6 strain. The second objective 
was to test whether the increase in LPC observed in plasma of GW agent exposed mice 
(from CD1 strain) can be normalized by nilvadipine. Our results support the effectiveness 
of such an approach. These studies show that the elevated PC and LPC levels in the plasma 
of GW agent exposed mice (C57BL6 stain) were reduced after treatment with nilvadipine 
and levels of these lipids were normalized to being similar to those from unexposed mice, 
which did not receive GW agents or nilvadipine treatment. However, for this C57BL6 
strain, there were no differences between GW agent exposed mice compared to control 
mice in the brain PC and SM levels. Hence findings of elevated PC and SM in mouse 
model B from the CD1 strain were not observed in the C57BL6 strain. Also, there was no 
effect of nilvadipine treatment on PC and SM levels in the brain. As indicated in Chapter 
2, C57BL6 mice have cholinergic and PLA2 deficiencies, it is possible that the pathological 
trajectory in this strain is different, particularly since a lower PB dose was utilized than that 
employed for the original studies conducted using the CD1 mouse strain. Nevertheless, 
plasma data do support partial translation of lipidomics findings from the CD1 strain to the 
C57BL6 strain and do support a potential usefulness of such an approach in identifying 
treatment targets for GWI.
The lipidomic studies described in this chapter, although preliminary, show that
examination of PLs may be useful in profiling biological changes in brain and plasma after
exposure to GW agents. These studies also show that such an approach can identify
profiles that are unique in each mouse model of GW agent exposure. These studies also
identify a number of tractable lipid-metabolism related biological pathways as potential
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targets for therapeutic intervention. Further investigation is warranted to fully understand 
the biological mechanisms that underlie these lipid changes and the treatment responses 
observed in this mouse model of GW agent exposure.
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Chapter 5 - General discussion
Now nearly twenty years since the first Persian Gulf War conflict, veterans with GWI 
continue to suffer from this persistent and debilitating illness, which is characterized by the 
presence of widespread pain, headaches and cognitive difficulties (Binns et al 2008). 
Previously, GWI was thought to be a primarily somatic disorder; however, a number of 
recent findings show a prominent CNS component to this illness. In fact, it would appear 
that GWI has distinct CNS subtypes, which seem to differ from each other based on the 
presence of cognitive problems or motor related symptoms. Although a number of 
treatment approaches are being evaluated, currently there are no approved treatments 
available for GWI that can either provide symptomatic relief or target the underlying 
pathology. Similarly, there are no biomarkers available to assist with the diagnosis of 
GWI, as additional 50,000 GW veterans continue to suffer from unexplained illnesses but 
have not received a formal diagnosis of GWI. In addition, biomarkers are also needed to 
objectively diagnose GWI as the current diagnostic criteria rely heavily on self-report of 
symptoms which can be subject to reporting bias given that a long time has now elapsed 
since the original GW agent exposure and disease onset. Availability of a biomarker panel 
for diagnosing GWI may also be useful in developing and providing personalized care 
where the level of care and interventions provided to veterans could be tailored based on 
their diagnostic classification and severity of illness. Biomarkers of GWI may also be 
helpful in monitoring treatment response in future clinical trials for testing therapies 
against GWI.
According to a DoD report, in 1993, the Deputy Under Secretary of Defense 
introduced pest management initiatives which have resulted in improved standards and 
practices whereby there is now a 50% reduction of pesticides use on military installations,
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improved training of pesticide applicators and an increased awareness among military 
personnel of pesticide use. For instance, only a 20-33% DEET formulation is now 
provided to military personnel involved in Operation Iraqi Freedom compare to the 75% 
DEET that was issued during the first Gulf War. However, troops in current deployments 
have had access to uniforms that were pretreated with PER (Binns et al 2008).
In the civilian population, use of pesticides is of concern and has been implicated in a 
number of neurological illnesses. For instance, findings from a prospective longitudinal 
study of a Cache county (Utah, USA) cohort provide evidence that the use of 
organophosphate AChE inhibitors can increase the risk of AD and related disorders 
(Hayden et al 2010). Results from a 4-year prospective study conducted on agriculture 
workers in the Bordeaux region of France provide compelling evidence for an increased 
risk of neurocognitive decline among individuals with direct exposure to pesticides in 
midlife (Baldi et al 2011). In recent years, the Environmental Protection Agency (EPA) 
has initiated a phaseout of urban uses of organophosphates (OP) (2002). This has 
consequently resulted in a switch to other easily available pesticides and nearly 100 million 
applications of PER are made each year in US homes (Power, & Sudakin 2007; Coxl998). 
Data from the American Association of Poison Control Centers Toxic Exposure 
Surveillance System (TESS) show an increase in reporting of pyrethroid exposure related 
adverse events correlating with a decline in reporting of OP related incidences (Power, & 
Sudakin 2007). As such, exposure to these chemicals may further increase the incidence 
of neurological disorders. Therefore, understanding the molecular mechanisms of such 
exposures may help identify pesticide-related neurocognitive dysfunction so that 
appropriate corrective measures may be taken to reduce the CNS complications associated 
with pesticide use. Although the current work is performed within the context of GWI, 
these findings provide novel insights into the neurotoxic mechanisms associated with these 
chemicals.
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A series of well-conducted epidemiological studies provide excellent support for the 
theory that a combined exposure to PB, pesticides and an insect repellent (DEET) may be 
one of the main causative factors in this illness. The current scientific consensus is that an 
increased risk of GWI is associated with combined exposure, to PB and pesticides/insect 
repellents (Binns et al 2008). Studies by Haley and colleagues suggest that perhaps 
exposure to different combinations of these GW agents may have produced different sub­
syndromes of GWI; one that is generally characterized by cognitive impairment and 
associated with combined PB and PER exposure, and the other characterized by confusion, 
ataxia and motor type impairment and associated with PB and DEET (Haley et al 1997). 
Hence, a complicated symptom presentation and the heterogeneity of the original 
exposures are two major challenges for studies that are aimed at elucidating the pathogenic 
mechanisms and the discovery of suitable treatments.
A considerable time has elapsed since the original exposure and therefore it is
imperative that studies focus on long-term outcomes associated with GWI. The work
performed as part of this thesis presents a systematic attempt to identify the underlying
chronic pathological features of GWI by examining chronic timepoints in rodents after
GW agent exposure. Data presented in Chapter 2 show that various combinations and
doses of PB, PER, DEET and stress, when given to mice, can produce a number of
neurobehavioral changes that are similar to the symptoms observed in veterans with GWI.
For example, in mouse model A of GW agent exposure, combined exposure to PB, PER,
DEET and stress produced significant motor and anxiety-like symptoms that are consistent
with symptoms observed in veterans with GWI. These studies also provide novel insight
into gender differences in the presentation of neurobehavioral symptoms after GW agent
exposure. However, no cognitive deficits were evident in this model. This profile appears
similar to GW Syndrome 3 associated with PB and DEET and includes symptoms such as
confusion, ataxia and motor related problems (Haley et al 1997). In order to determine if
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GW agent exposure can produce cognitive neurobehavioral deficits, mouse model B was 
developed, in which mice were exposed to high doses of PB and PER. In this model, 
neurobehavioral testing showed a delayed appearance of cognitive symptoms, at 115 days 
post-exposure. Also, there was some evidence for psychomotor and anxiety related 
problems. However, no sensorimotor deficits were observed in mouse model B of GW 
agent exposure. This symptom profile and exposure combination appears similar to GW 
Syndrome 1 that was associated with PB and PER exposure and included cognitive 
impairment as a symptom (Haley et al 1997). Pathological examination revealed a 
presence of astrogliosis but no overt neuronal death or microgliosis. Collectively, these 
studies show that exposure to different combinations of GW agents produces distinct CNS 
symptom profiles but may share most of the same underlying pathology. This is evident by 
neuropathological studies showing profound astrogliosis in both mouse models of GW 
agent exposure but no neuronal loss or microgliosis.
In Chapter 3, exploratory proteomic approaches were found to be extremely useful in 
identifying global biological changes. This approach was particularly useful in these GWI 
research studies given the complexity of clinical presentation and the diversity of 
etiological exposures, and an unknown course of the disease progression. Examination of 
several biological pathways using proteomics provided a comprehensive view of the 
pathological mechanisms in a single experiment. Proteomic studies coupled with 
bioinformatic analyses suggested that in mouse model B, a number of immune and 
inflammatory related changes may be present in the brain and blood of exposed mice 
compared to control mice. These findings are supported by studies conducted on blood 
cells from veterans with GWI that show an increased presence of both pro- and anti­
inflammatory cytokines in ill veterans compared to controls.
These studies resulted in additional support to the Institute (PI: Ait-Ghezala) from the
DoD to explore immune and inflammation related dysfunction associated with GW agent
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exposure. Proteomic findings from mouse model B also support endocrine dsyfunction, 
which is already being evaluated as an avenue for identifying potential treatments and 
biomarkers for GWI by Dr. Golier at the Bronx Veterans’ Administration (VA) Hospital.
The data in Chapter 4 of this thesis presented lipidomic studies that were undertaken 
to examine biological pathways that may be upstream of ACh-related biological changes. 
As a number of lipid metabolites are upstream of immune and inflammation pathways, 
examination of phospholipids (particularly those containing choline) may also be helpful in 
understanding mixed inflammation (both pro- and anti-inflammatory) and related changes 
that are observed in veterans with GWI. Lipid profiling showed that changes in PC and SM 
from mouse models of GW agent exposure were distinct from those observed in other 
neurological illnesses. In general, compared to their respective control groups, both 
models of GW agent exposure showed an increase in PC and SM levels where the 
PSAPPswe mouse model of AD showed a decrease in PC and SM levels. Brain region 
dependent lipidomic studies showed considerable differences in total PC and SM levels 
and a differential response to head injury within these brain regions. These studies 
highlight that future examination of lipidomic profiles by brain region in may provide 
some important information on the pathological consequences of GW agent exposure.
From the aspect of biomarker discovery, plasma lipidomic work was undertaken as a
follow-up to proteomic studies from mouse model B of GW agent exposure, which had
detected a number of immune, inflammatory and lipid metabolism related changes in the
plasma of GW agent exposed animals. Lipidomic studies conducted using plasma samples
of mouse models of GW agent exposure showed that although ePC, diacyl PC containing
PUFA and SM containing VLCFA were affected in both mouse models of GW agent
exposure, the profiles were distinct for each mouse model with respect to the direction of
changes in PC and SM and specific molecular species that were altered. These studies
highlight a potential usefulness of lipidomics in classification of different sub-syndromes
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of GWI. Major efforts are now underway at the Roskamp Institute geared towards 
translating biomarker discovery work from preclinical to clinical stage, where a direct 
examination of blood samples from veterans with GWI will be undertaken in the near 
future. This work, aimed at using Omics technology for the discovery and validation of 
biomarkers of GWI, is proposed as part of a collaborative multi-center application (PI: 
Fiona Crawford) and involves collection of samples from GWI patients at the James J 
Peters VA Medical center in Bronx, NY and the Boston VA Medical Center, Boston MA.
Chapter 4 also included pilot lipidomic work aimed at determining if the biological
pathways that metabolize PC to LPC may be involved in the neurobehavioral and
neuropathological abnormalities observed in mouse models of GW agent exposure. For
mouse model A of GW agent exposure, examination of the brain PC and SM suggested
dysfunction of the peroxisomal pathways and examination of the degree of unsaturation of
PC suggested an abnormal increase in SCD activity in response to this GW agent exposure.
For mouse model B, data from the brain and blood samples suggested that perhaps PLA2
activity (or enzymes that have similar action to PLA2) might be affected in response to
GW agents. Recently, neuropathy target esterase (NTE), a major target of OP pesticide
AChE inhibitors, was shown to have similar activity for hydrolyzing brain PC and LPC
(Casida et al 2008). A number of studies show that inhibition of NTE by OP pesticides can
lead to an abnormal accumulation of PC in the brain (Read et al 2009). It is therefore
reasonable to propose that phospholipases involved in PC metabolism might be affected in
response to GW agents. Since studies suggested that DHP-CCB can mitigate the adverse
effects of LPC, nilvadipine was chosen for pilot treatment studies, since extensive
preclinical safety and pharmacokinetics profiling of this drug has already been conducted
at the Roskamp Institute. Pilot studies using nilvadipine showed that PC and LPC levels in
plasma are amenable to targeting and that nilvadipine can “normalize” the GW agent
induced lipid changes. Future studies in this area may be of value in discovering
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treatments for GWI. Another interesting aspect of OP pesticide exposure that appears 
similar to GW agent exposure is the observation that levels of 2AG appear to increase after 
exposure to OP (Casida et al 2008) and after GW agent exposure (as observed here). 
Studies show that OP could directly inhibit activities of MAGL, leading to an increase in 
2AG levels (Casida et al 2008). These findings suggest that perhaps examination of 
MAGL might also be an avenue worth exploring in future studies aimed at identifying 
GWI treatments.
Conclusion and future direction
The work described in this thesis has made significant advances towards 
developing well-characterized mouse models of GW agent exposure, in which the 
complexity of biological responses to exposures was captured using global proteomic 
approaches. Lipidomic approaches were used to fully characterize phosphocholine 
containing lipids in order to perform comprehensive evaluation of the brain and blood 
changes to identify biomolecular pathways that might be affected in response to GW agent 
exposure. These studies will help identify potential targets for therapeutic interventions in 
work that is already underway at the Roskamp Institute as well as future work aimed at 
identifying diagnostic biomarkers of GWI. As described above, the findings reported here 
have opened several novel avenues of investigation which are now part of planned projects 
that are now funded by the department of defense or the Veteran’s Administration. It is 
anticipated that the future work based on these findings will provide tangible treatment 
targets and possibly lead to the discovery and validation of objective biomarkers of GWI.
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